Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
Targeted nucleic acid nanocarriers provide a selective and efficient method for transient gene expression in hematopoietic stem cells, overcoming sustained expression decline and eliminating the need for cell selection, thus enhancing gene therapy efficacy.
Patent Information
- Application Number
- JP2024140719
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-01-05
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-26
AI Technical Summary
Current gene therapy methods, such as viral systems and electroporation, are non-selective, expensive, and face challenges with sustained therapeutic protein expression decline and require cell selection/purification steps, limiting their effectiveness and availability.
The use of targeted nucleic acid nanocarriers for transient expression of nucleic acids in hematopoietic stem cells, achieving a 'hit-and-run' effect that permanently modifies cell phenotype without the need for cell selection or purification, using TALENs, megaTALs, CRISPR-Cas, and other gene editing agents.
This approach enables rapid, selective, and efficient genetic modification of cells, ensuring sustained therapeutic effects with minimal cell manipulation and maintaining cell viability, allowing for in vivo and ex vivo applications.
Smart Images

Figure 2024164142000004 
Figure 2024164142000005 
Figure 2024164142000006
Abstract
Description
[Technical field]
[0001] The present disclosure provides compositions and methods for rapidly and selectively modifying hematopoietic stem cells (or cells derived therefrom) for therapeutic purposes by achieving transient expression of a nucleic acid that results in a permanent therapeutic change in the modified cells (referred to herein as a "hit-and-run" effect). The methods can be performed in cultured cells or in situ. [Background technology]
[0002] Successful gene therapy depends on the success of the gene delivery mechanism to the selected target cells. Currently, the most common method for successful long-term gene therapy is viral systems, such as those that utilize lentiviral vectors. These gene therapies rely on the continuous intracellular expression of therapeutically useful proteins. Although such viral systems can effectively deliver genes for gene therapy, they are non-selective, expensive, and not widely available. Furthermore, sustained therapeutic protein expression may decline over time due to intracellular events that occur over time.
[0003] Electroporation has also been developed as a mechanism for delivering genes into cells for gene therapy. However, electroporation relies on mechanical disruption and permeabilization of cell membranes, which reduces cell viability and makes it less than ideal for therapeutic use. Furthermore, like virus-based methods, electroporation does not selectively deliver genes to specific cell types within a heterogeneous pool, so prior cell selection and purification steps are required. Summary of the Invention [Problem to be solved by the invention]
[0004] The present disclosure provides compositions and methods for rapid and selective modification of hematopoietic stem cells (or cells derived therefrom) to serve therapeutic purposes by achieving transient expression of nucleic acids. Transient expression results in a permanent therapeutic change in the modified cells (referred to herein as a "hit-and-run" effect). Because only transient expression is required to achieve a sustained therapeutic effect, problems related to the decline of therapeutic protein expression over time are eliminated. Furthermore, these compositions and methods selectively modify selected cell types, and therefore do not require cell selection or purification steps prior to modification. This allows for rapid ex vivo production of therapeutic cells as well as targeted in vivo genetic modification of cells. [Means for solving the problem]
[0005] The hit-and-run effect described in this application is made possible by utilizing the transient expression of nucleic acid that causes gene editing or the transient expression of protein that permanently changes the phenotype of cells. Examples of nucleic acid that causes gene editing include TALEN, megaTAL, zinc finger nuclease and CRISPR-Cas system. Examples of proteins that change phenotype include transcription factors, kinases and cell surface receptors. Effect of the Invention
[0006] The compositions and methods disclosed herein have numerous applications. Examples in cultured cells include editing the genome of hematopoietic cells (including hematopoietic stem cells) with targeted nucleases, imprinting adoptively transferred cells with therapeutically desirable phenotypes by transient expression of specific transcription factors, suppressing cellular senescence in adoptively transferred cells by expression of telomerase reverse transcriptase or anti-apoptotic genes, or altering intrinsic cell tropism by expression of chemokine receptors. Examples in situ include co-injection of nucleic acids on carriers that selectively transfect dendritic cells to enhance the antigen-presenting capacity of the cells and thus enhance vaccine potency, or transfecting vaccine-primed T cells to induce long-lasting memory phenotypes.
[0007] Many of the drawings accompanying this application are easier to understand if viewed in color, but they will not appear in color in the published patent application as filed. Applicants reserve the right to submit color images of such drawings at any later time during the prosecution process, with color versions of such drawings deemed to be part of the original filing of the application. [Brief description of the drawings]
[0008] [Figure 1A] Figures 1A-1C. Fabrication of mRNA nanocarriers to genetically program therapeutic T cells. Figure 1A: Schematic illustrating how cultured T cells can be programmed to express therapeutically relevant transgenes loaded onto polymeric nanoparticles. These particles are coated with ligands that target these particles to specific cell types, allowing the transfer of their mRNA cargo and expression of a selected protein (such as a transcription factor or genome editing agent) in the targeted cells. [Figure 1B] Figures 1A-1C. Fabrication of mRNA nanocarriers for genetically programming therapeutic T cells. Figure 1B: Design of targeted nanoparticles loaded with mRNA. The inset shows a transmission electron micrograph of a representative nanoparticle (scale bar = 50 nm). Also shown is synthetic mRNA encapsulated in the nanoparticles. [Figure 1C] 1A-1C. Fabrication of mRNA nanocarriers for genetically programming therapeutic T cells. FIG. 1C: Examples of gene editing agents, phenotype-altering proteins, target genes and their uses that can be used in the embodiments disclosed herein. [Diagram 2] Antibodies used for flow cytometry. [Figure 3A] Figures 3A-3C. Physical properties of mRNA-loaded nanoparticles. Figure 3A: Finite track-length adjusted size distribution of individual particles. [Figure 3B] Figures 3A-3C. Physical properties of mRNA-loaded nanoparticles. Figure 3B: Transmission electron micrographs of a single nanoparticle (left, scale bar = 100 nm) and a nanoparticle ensemble (right, scale bar = 2 μm). [Figure 3C] Figures 3A-3C. Physical properties of nanoparticles loaded with mRNA. Figure 3C: Zeta potentials of control nanoparticles (-PGA-Ab) and nanoparticles coated with PGA and conjugated with antibody (+PGA-Ab) were measured and compared after 40-fold dilution in PBS (pH 7.4) (n=5). [Figure 4A] Figures 4A-4D. mRNA nanoparticle transfection requires minimal cell manipulation and achieves robust transgene expression by lymphocytes without affecting cell viability. Figure 4A: CD3-targeted polymeric nanoparticles were loaded with Cy5-labeled mRNA and mixed with primary T cells. Confocal microscopy reveals that these particles are rapidly internalized from the cell surface. Images represent 15 randomly selected areas. [Figure 4B] Figures 4A-4D. mRNA nanoparticle transfection requires minimal cell manipulation and achieves robust transgene expression by lymphocytes without affecting cell viability. Figure 4B: Flow cytometry of T cells 24 hours after incubation with CD3-targeted nanoparticles loaded with mRNA encoding eGFP. [Figure 4C]Figures 4A-4D. mRNA nanoparticle transfection requires minimal cell manipulation and achieves robust transgene expression by lymphocytes without affecting cell viability. Figures 4C, 4D: Comparison of the effects of electroporation and nanoparticle gene delivery on cell expansion cultures. The left panel shows the workflow of nanoparticle transfection (top) and electroporation (bottom). The right panel shows the fold expansion of PBMC cultures from three separate donors treated with stimulatory beads on days 0 and 12. Cultures from each donor were matched and either left untreated or treated by CD3 / CD28-targeted nanoparticle transfection (Figure 4C, right) or electroporation (Figure 4D, right) on days 5 and 12. Each line represents one donor and each point reflects the fold expansion of T cells. Paired differences between groups were analyzed by Student's t-test (ns, non-significant; *, significant, n=3). [Figure 4D] Figures 4A-4D. mRNA nanoparticle transfection requires minimal cell manipulation and achieves robust transgene expression by lymphocytes without affecting cell viability. Figures 4C, 4D: Comparison of the effects of electroporation and nanoparticle gene delivery on cell expansion cultures. The left panel shows the workflow of nanoparticle transfection (top) and electroporation (bottom). The right panel shows the magnification of expansion of PBMC cultures derived from three separate donors treated with stimulatory beads on days 0 and 12. Cultures from each donor were matched and either left untreated or treated by CD3 / CD28-targeted nanoparticle transfection (Figure 4C, right) or electroporation (Figure 4D, right) on days 5 and 12. Each line represents one donor and each point reflects the magnification of T cell expansion. Paired differences between groups were analyzed by Student's t-test (ns, non-significant; *, significant, n=3). [Figure 5A]Figures 5A, 5B. Nanoparticle transfection is rapid and is not exacerbated by lyophilization. Figure 5A: eGFP expression in 106 activated T cells measured 5 hours after addition of naive activated T cells or anti-CD3-targeted eGFP-encoding NPs. [Figure 5B] Figures 5A, 5B. Nanoparticle transfection is rapid and is not compromised by lyophilization. Figure 5B: NP transfection efficiency is maintained after freezing and resuspension. Freshly prepared NPs or NPs lyophilized and stored at -80°C and then resuspended to the original volume (targeted with anti-CD3 or anti-CD8 antibodies) were transfected into 106 activated T cells per condition. [Figure 6] Relative viability of T cells treated with nanoparticle transfection and electroporation. Samples of 2x106 activated T cells per condition were left untreated or treated with NP transfection or electroporation as described in Figure 2C. 18 hours after treatment, cells were labeled with fluorescent dye and viability was assessed. Results shown in this figure are representative of three separate experiments. [Figure 7A] Figures 7A-7H. Nanocarriers loaded with mRNA encoding megaTAL nuclease targeting TCRα are able to knock out T cell receptors in CAR-programmed lymphocytes. Figure 7A: Integration of nanoparticle transfection into standard manufacturing of CAR-T cells. After stimulation with anti-CD3 / CD28 coated beads (day 0), CD8-targeting mRNA NPs were delivered on days 1 and 2, followed by lentiviral delivery of a vector encoding the leukemia-specific 19-41BBζ CAR on day 3. NPs loaded with mRNA encoding megaTAL nuclease and eGFP or control particles loaded with eGFP mRNA alone were added. [Figure 7B]Figures 7A-7H. Nanocarriers loaded with mRNA encoding megaTAL nuclease targeting TCRα can knock out T cell receptor in CAR-programmed lymphocytes. Figure 7B: Flow cytometry of NP transfection efficiency (based on eGFP signal) correlated with the surface expression level of TCR by T cells (based on CD3 signal) after NP treatment. [Figure 7C] Figures 7A-7H. Nanocarriers loaded with mRNA encoding megaTAL nuclease targeting TCRα can knock out the T cell receptor in CAR-programmed lymphocytes. Figure 7C: Summary plot showing editing efficiency as assessed by reduction in CD3 surface expression at day 14 (n=5). [Figure 7D] Figures 7A-7H. Nanocarriers loaded with mRNA encoding megaTAL nuclease targeting TCRα can knock out T cell receptor in CAR-programmed lymphocytes. Figure 7D: Surveyor assay confirming TCRα chain locus disruption. [Figure 7E] Figures 7A-7H. Nanocarriers loaded with mRNA encoding megaTAL nuclease targeting TCRα can knock out the T cell receptor in CAR-programmed lymphocytes. Figure 7E: Flow cytometry of lentiviral transduction in genome-edited T cells compared to control T cells. [Figure 7F] Figures 7A-7H. Nanocarriers loaded with mRNA encoding megaTAL nuclease targeting TCRα can knock out T cell receptor in CAR-programmed lymphocytes. Figure 7F: Proliferation of TCR+ (control) and TCR- (treated with mTAL NPs) CAR-T cells co-cultured with irradiated TM-LCL leukemia cells. [Figure 7G]Figures 7A-7H. Nanocarriers loaded with mRNA encoding megaTAL nuclease targeting TCRα can knock out T cell receptors in CAR-programmed lymphocytes. Figure 7G: Cytotoxicity assay of lysis of CD19-K562 target cells by CAR-T cells. [Figure 7H] Figures 7A-7H. Nanocarriers loaded with mRNA encoding megaTAL nuclease targeting TCRα can knock out the T cell receptor in CAR-programmed lymphocytes. Figure 7H: Intracellular cytokine expression of IL-2 and IFN-γ after stimulation with PMA and ionomycin (P / I). [Figure 8A] Figures 8A-8F. Nanocarriers loaded with mRNA encoding the Foxo13A transcription factor induce surface markers and transcriptional patterns characteristic of CD8+ central memory T cells. Figure 8A: Total Foxo1 protein expression measured by intracellular labeling in Jurkat T cells and primary T cells treated with control (GFP+) or Foxo13A-GFP NPs targeting CD3. [Figure 8B] Figures 8A-8F. Nanocarriers loaded with mRNA encoding the Foxo13A transcription factor induce surface markers and transcriptional patterns characteristic of CD8+ central memory T cells. Figure 8B: Time course qPCR measurement of relative Foxo13A mRNA expression after exposure of cells to Foxo13A-eGFP NPs. [Figure 8C] Figures 8A-8F. Nanocarriers loaded with mRNA encoding the Foxo13A transcription factor induce surface markers and transcriptional patterns characteristic of CD8+ central memory T cells. Effect of CD8-targeted Foxo13A-GFP NPs on CD62L expression 24 hours after particle treatment. [Figure 8D]Figures 8A-8F. Nanocarriers loaded with mRNA encoding Foxo13A transcription factor induce surface markers and transcriptional patterns characteristic of CD8+ central memory T cells. Figure 8D: Percentage of CD62L+ cells measured in sorted CD8+eGFP+ cells treated with CD8-targeting control or Foxo13A / eGFP-encoding NPs at 1, 8, and 20 days of culture post particle transduction. Results are from three independent donors. *P<0.05; **P<0.01 between indicated conditions calculated from paired t-test of ratios. [Figure 8E] Figures 8A-8F. Nanocarriers loaded with mRNA encoding the Foxo13A transcription factor induce surface markers and transcriptional patterns characteristic of CD8+ central memory T cells. Figure 8E: Heatmap of TCM signature gene expression in TCM, naive, and control cells after 8 days of treatment. [Figure 8F] Figures 8A-8F. Nanocarriers loaded with mRNA encoding the Foxo13A transcription factor induce surface markers and transcriptional patterns characteristic of CD8+ central memory T cells. Figure 8F: Volcano plot of differential gene expression in cells treated with Foxo13ANP after 8 days. TCM signature genes and selected memory phenotype genes are shown. P-values for overlap of Foxo13A and the TCM signature gene set were determined by GSEA (analysis shown in Figure 9B). [Figure 9A] Figures 9A, 9B. Gene set enrichment results reveal a strong correlation between TCM cells and cells treated with Foxo13A nanoparticles. Figure 9A: Heatmap of TCM down-signature gene expression in TCM, naive and control cells after 8 days of treatment. [Figure 9B]Figures 9A, 9B. Gene set enrichment results reveal a strong correlation between TCM cells and cells treated with Foxo13A nanoparticles. Figure 9B: Gene set enrichment analysis of genes differentially expressed in Foxo13A NP-treated cells and control NP-treated cells when tested against TCM-up and TCM-down signature gene sets. [Figure 10A] Figures 10A-10D. mRNA nanocarriers allow specific transfection of CD34+ human hematopoietic stem cells with minimal effects on expansion or phenotype. Figure 10A: Targeting CD105 allows specific transfection of HSC CD34+ cells derived from mobilized PBSCs. These cells were left untreated or transfected with PGA-coated NPs carrying mRNA encoding eGFP and conjugated with a nonspecific control antibody (Control Ab-eGFP NP) or anti-CD105 (α-CD105 NP). Transfection efficiency was assayed by flow cytometry 24 hours after NP exposure. [Figure 10B] Figures 10A-10D. mRNA nanocarriers allow specific transfection of CD34+ human hematopoietic stem cells with minimal impact on expansion or phenotype. Figure 10B: NP transfection efficiency in CD34+ samples from three separate donors. [Figure 10C] Figures 10A-10D. mRNA nanocarriers allow specific transfection of CD34+ human hematopoietic stem cells with minimal effects on expansion or phenotype. Figure 10C: In vitro expansion of CD34+ HSCs following addition of control or CD105-targeted NPs. After transfection of cells as in Figure 10A, total cell numbers were assessed 0, 4, and 8 days after particle exposure. [Figure 10D]Figures 10A-10D. mRNA nanocarriers allow specific transfection of CD34+ human hematopoietic stem cells with minimal effect on expansion or phenotype. Figure 10D: Flow cytometry analysis of HSC markers CD34, CD133 and CD49f after 8 days of culture in untransfected cells (dashed line) or cells treated with anti-CD105 mRNA (solid line). This indicates that the addition of NPs does not affect the surface expression of key stem cell markers. [Figure 11-1] Representative related sequences. [Figure 11-2] Representative related sequences. [Figure 11-3] Representative related sequences. [Figure 11-4] Representative related sequences. [Figure 11-5] Representative related sequences. [Figure 11-6] Representative related sequences. [Figure 11-7] Representative related sequences. [Figure 11-8] Representative related sequences. [Figure 11-9] Representative related sequences. [Figure 11-10] Representative related sequences. [Figure 11-11] Representative related sequences. [Figure 11-12] Representative related sequences. [Figure 11-13] Representative related sequences. [Figure 11-14] Representative related sequences. [Figure 11-15] Representative related sequences. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] Successful gene therapy depends on the success of the gene delivery mechanism to the selected target cells. Currently, the most common method for successful long-term gene therapy is viral systems, such as those that utilize lentiviral vectors. These gene therapies rely on the continuous intracellular expression of therapeutically useful proteins. Although such viral systems can effectively deliver genes for gene therapy, they are non-selective, expensive, and not widely available. Furthermore, sustained therapeutic protein expression may decline over time due to intracellular events that occur over time.
[0010] Electroporation has also been developed as a mechanism for delivering genes into cells for gene therapy. However, electroporation relies on mechanical disruption and permeabilization of cell membranes, which reduces cell viability and makes it less than ideal for therapeutic use. Furthermore, like virus-based methods, electroporation does not selectively deliver genes to specific cell types within a heterogeneous pool, and therefore requires prior cell selection and purification procedures.
[0011] The present disclosure provides compositions and methods for rapid and selective modification of cells to serve therapeutic purposes by achieving transient expression of nucleic acids. Transient expression results in a permanent therapeutic change in the modified cells (referred to herein as a "hit-and-run" effect). Since only transient expression is required to achieve a sustained therapeutic effect, problems associated with the decline of therapeutic protein expression over time are eliminated. Furthermore, these compositions and methods selectively modify selected cell types, and therefore do not require cell selection or purification steps prior to modification. This allows for rapid ex vivo production of therapeutic cells as well as targeted in vivo genetic modification of cells.
[0012] The hit-and-run effect described herein is made possible by utilizing transient expression of nucleic acids that cause gene editing or transient expression of proteins that permanently change the phenotype of a cell. Examples of nucleic acids that cause gene editing include TALEN, megaTAL, zinc finger nucleases, and CRISPR-Cas systems. Examples of proteins that change the phenotype include transcription factors, kinases, and cell surface receptors. Transient expression refers to the production of a recombinant gene product for a short period of time after introduction of a nucleic acid into a cell. In certain embodiments, the transient expression lasts for 12 hours to 20 days, 18 hours to 18 days, 24 hours to 14 days, or 36 hours to 10 days. The phenotype of a cell refers to its phenotypic characteristics and / or its location in the organism.
[0013] The compositions and methods disclosed herein have numerous applications, including editing the genome of lymphocytes (e.g., hematopoietic stem cells (HSCs)) with targeted nucleases, co-injection of nucleic acids onto carriers that transfect dendritic cells to enhance the antigen-presenting capacity of the cells and thereby increase vaccine potency, or transfecting vaccine-primed T cells to induce a long-lasting memory phenotype.
[0014] Certain embodiments include nanocarriers that can target specific selected cells and allow for controlled dose delivery of nucleic acid by simply mixing the nanocarriers with cultured cells ex vivo or with cells in a subject's body in vivo. In certain embodiments, the nanocarriers include (1) a selected cell targeting ligand, (2) a carrier, and (3) a nucleic acid encapsulated inside the carrier. Certain embodiments include nanocarriers that include (1) a selected cell targeting ligand, (2) a carrier, (3) a nucleic acid encapsulated inside the carrier, and (4) a coating.
[0015] In certain embodiments, the selected cell targeting ligand can include a surface-tethered targeting ligand that selectively binds the nanocarrier to the selected cell and initiates rapid receptor-induced endocytosis to internalize the nanocarrier. As disclosed in more detail elsewhere in this application, the selected cell targeting ligand can include antibodies, scFv proteins, DART molecules, peptides, and / or aptamers. Certain embodiments utilize anti-CD8 antibodies to transfect human T cells and antibodies that recognize CD34, CD133, or CD46 to target HSCs.
[0016] In certain embodiments, the carrier comprises a carrier molecule that compacts the nucleic acid to protect it from enzymatic degradation. As disclosed in more detail elsewhere in this application, the carrier can comprise positively charged lipids and / or polymers. Certain embodiments utilize poly(β-amino esters).
[0017] In certain embodiments, the nucleic acid is encapsulated inside the carrier and, after cellular uptake by the selected cells, expresses a gene editing agent and / or a protein that permanently changes the phenotype of the cells. As disclosed in more detail elsewhere in this application, the nucleic acid can include synthetic mRNA expressing a megaTAL or a transcription factor. Certain embodiments utilize in vitro transcribed mRNA (see, e.g., Grudzien-Nogalska et al., Methods Mol. Biol. 969, 55-72 (2013)) expressing (i) the transcription factor FOXO1, which induces memory CD8 T cells, or (ii) a rare-cleaving megaTAL nuclease (see, e.g., Boissel & Scharenberg, Methods Mol. Biol. 1239, 171-196 (2015)) to disrupt T cell receptor expression by lymphocytes.
[0018] In certain embodiments, the nanocarriers disclosed herein include a coating that protects the encapsulated nucleic acid to reduce or prevent off-target binding. Off-target binding is reduced or prevented by reducing the surface charge of the nanocarriers to neutral or negative. As disclosed in more detail elsewhere in this application, the coating may include neutral or negatively charged polymeric and / or liposome-based coatings. Certain embodiments utilize polyglutamic acid (PGA) as the nanocarrier coating. If a coating is used, it does not necessarily have to cover the entire nanocarrier, but should be sufficient to reduce off-target binding by the nanocarrier.
[0019] When the nanocarriers disclosed herein are added to a heterogeneous cell mixture (e.g., ex vivo cell culture or in vivo environment), the engineered nanocarriers bind to the selected cell population and stimulate receptor-mediated endocytosis, a process that introduces the nucleic acid (e.g., synthetic mRNA) carried by the carrier, and the selected cells begin to express the encoded molecule (Figure 1A). Because no transgene nuclear transport and transcription is required, the process is rapid and efficient. If necessary, additional additions of nanocarriers can be performed until the desired result is achieved. In certain embodiments, the nanocarriers are biodegradable and biocompatible, and in ex vivo cell production, the engineered cells can be easily separated from unbound nanoparticles by centrifugation before being injected into a subject for therapy.
[0020] In certain embodiments, rapid means that expression of the encoded nucleic acid begins inside the selected cell type within 24 hours or 12 hours after exposure of a heterogeneous cell sample to the nanocarriers disclosed herein. This timeline is possible by utilizing nucleic acids, such as mRNA, that begin to be transcribed almost immediately (e.g., within minutes) after release into the cytoplasm of the target cell.
[0021] In certain embodiments, efficient means that the gene transfer rate into target cells (e.g., human primary T cells) is >80%, and at least 80% of the cells, at least 90% of the cells, or 100% of the cells undergo phenotypic modification. In certain embodiments, efficient means that the gene transfer rate into target cells is >80%, and at least 25% of the cells, at least 33% of the cells, or at least 50% of the cells undergo phenotypic modification. In certain embodiments, phenotypic modification can occur in one-third of selected cells that take up the nanocarrier, and the delivered nucleic acid encodes a nuclease.
[0022] Other options and embodiments of the disclosure are described in more detail below.
[0023] Selected cell targeting ligands. The selected cell targeting ligands of the nanocarriers disclosed herein selectively bind to immune cells of interest within a heterogeneous cell population. In certain embodiments, the immune cells of interest are lymphocytes. Lymphocytes include T cells, B cells, natural killer (NK) cells, monocytes / macrophages, and HSCs.
[0024] Several different subsets of T cells, each with different functions, have been discovered. In certain embodiments, the selected cell targeting ligand achieves selective targeting to specific lymphocyte populations by receptor-mediated endocytosis. For example, most T cells have a T cell receptor (TCR) that exists as a complex of several proteins. The actual T cell receptor is composed of two separate peptide chains, called α- and β-TCR chains, which are generated from independent T cell receptor α and β (TCRα and TCRβ) genes. The selected cell targeting ligands disclosed herein can bind to the α- and / or β-TCR chains to selectively deliver nucleic acids to these T cells.
[0025] γδ T cells are a small subset of T cells that have distinct T cell receptors (TCRs) on their surface. In γδ T cells, the TCR is composed of one γ chain and one δ chain. This group of T cells is significantly less abundant than αβ T cells (2% of all T cells). Nevertheless, selected cell targeting ligands disclosed herein can bind to the γ and / or δ-TCR chains to selectively deliver nucleic acids to these T cells.
[0026] CD3 is expressed on all mature T cells. Thus, the selected cell targeting ligands disclosed herein can bind to CD3 for selective delivery of nucleic acids to all mature T cells. Activated T cells express 4-1BB (CD137), CD69, and CD25. Thus, the selected cell targeting ligands disclosed herein can bind to 4-1BB, CD69, or CD25 for selective delivery of nucleic acids to activated T cells. CD5 and transferrin receptor are also expressed on T cells and can be used for selective delivery of nucleic acids to T cells.
[0027] T cells can be further classified into helper cells (CD4+ T cells) and cytotoxic T cells (CTL, CD8+ T cells), including cytolytic T cells. Helper T cells assist other white blood cells in immune processes, such as maturation of B cells into plasma cells and activation of cytotoxic T cells and macrophages. These cells are also called CD4+ T cells because they express the CD4 protein on their surface. Helper T cells are activated when presented with peptide antigens by MHC class II molecules expressed on the surface of antigen-presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist active immune responses. Selected cell targeting ligands disclosed herein can bind to CD4 to selectively deliver nucleic acids to helper T cells.
[0028] Cytotoxic T cells destroy virus-infected cells and tumor cells and are also involved in transplant rejection. These cells are also called CD8+ T cells because they express the CD8 glycoprotein on their surface. These cells recognize their targets by binding to antigens associated with MHC class I, which is present on the surface of almost all cells in the body. Selected cell targeting ligands disclosed herein can bind to CD8 to selectively deliver nucleic acids to CTLs.
[0029] As used herein, "central memory" T cells (or "TCM") refer to CTLs that have been exposed to an antigen and express CD62L or CCR7 and CD45RO on their surface, and do not express or have reduced expression of CD45RA compared to naive cells. In certain embodiments, central memory cells are positive for expression of CD62L, CCR7, CD25, CD127, CD45RO, and CD95, and have reduced expression of CD45RA compared to naive cells. Selected cell targeting ligands disclosed herein can bind to CD62L, CCR7, CD25, CD127, CD45RO, and / or CD95 to selectively deliver nucleic acids to TCMs.
[0030] As used herein, "effector memory" T cells (or "TEMs") refer to T cells that have been exposed to an antigen and that do not express or have reduced expression of CD62L on their surface compared to central memory cells, and do not express or have reduced expression of CD45RA compared to naive cells. In certain embodiments, effector memory cells are negative for CD62L and CCR7 compared to naive or central memory cells, and have variable expression of CD28 and CD45RA. Effector T cells are positive for granzyme B and perforin compared to memory or naive T cells. Selected cell targeting ligands disclosed herein can bind to granzyme B and / or perforin to selectively deliver nucleic acids to TEMs.
[0031] Regulatory T cells ("TREGs") are a subpopulation of T cells that regulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune diseases. TREGs express CD25, CTLA-4, GITR, GARP, and LAP. Selected cell targeting ligands disclosed herein can bind to CD25, CTLA-4, GITR, GARP, and / or LAP to selectively deliver nucleic acids to naive TREGs.
[0032] As used herein, "naive" T cells refer to T cells that have not been exposed to an antigen and that express CD62L and CD45RA, but not CD45RO, relative to central memory cells or effector memory cells. In certain embodiments, naive CD8+ T lymphocytes are characterized by expressing phenotypic markers of naive T cells, including CD62L, CCR7, CD28, CD127, and CD45RA. Selected cell targeting ligands disclosed herein can bind to CD62L, CCR7, CD28, CD127, and / or CD45RA to selectively deliver nucleic acids to naive T cells.
[0033] Natural killer cells (also known as NK cells, K cells and killer cells) are activated in response to interferon or macrophage-derived cytokines. These cells function to suppress viral infections while the adaptive immune response generates antigen-specific cytotoxic T cells that can eliminate viral infections. NK cells express CD8, CD16 and CD56, but not CD3. Selected cell targeting ligands disclosed herein can bind to CD8, CD16 and / or CD56 for selective delivery of nucleic acids to NK cells.
[0034] Macrophages (and their precursors, monocytes) are present in all tissues of the body (possibly as microglia, Kupffer cells and osteoclasts) and engulf apoptotic cells, pathogens and other non-self components. Because monocytes / macrophages engulf non-self components, selective uptake by these cells does not require the addition of special macrophage or monocyte directing agents to the nanocarriers described herein. Alternatively, selected cell targeting ligands disclosed herein can bind to CD11b, F4 / 80, CD68, CD11c, IL-4Rα and / or CD163 for selective delivery of nucleic acids to monocytes / macrophages.
[0035] Immature dendritic cells (i.e., before activation) engulf antigens and other non-self components in the periphery, then migrate in an activated state to the T cell area of lymphoid tissues to present antigens to T cells. Thus, like macrophages, targeting of dendritic cells does not have to rely on a selected cell targeting ligand. When using a selected cell targeting ligand to selectively target dendritic cells, it can bind to the following CD antigens: CD1a, CD1b, CD1c, CD1d, CD21, CD35, CD39, CD40, CD86, CD101, CD148, CD209, and DEC-205.
[0036] B cells can be distinguished from other lymphocytes by the presence of the B cell receptor (BCR). The primary function of B cells is the production of antibodies. B cells express CD5, CD19, CD20, CD21, CD22, CD35, CD40, CD52, and CD80. Selected cell targeting ligands disclosed herein can bind to CD5, CD19, CD20, CD21, CD22, CD35, CD40, CD52, and / or CD80 for selective delivery of nucleic acids to B cells. Antibodies targeting the B cell receptor isotype constant regions (IgM, IgG, IgA, IgE) can also be used to target B cell subtypes.
[0037] Lymphocyte function-associated antigen 1 (LFA-1) is expressed on all T cells, B cells and monocytes / macrophages, and therefore selected cell targeting ligands disclosed herein can bind to LFA-1 for selective delivery of nucleic acids to T cells, B cells and monocytes / macrophages.
[0038] HSCs can also be targeted for selective delivery of the nanocarriers disclosed herein. HSCs express CD34, CD46, CD133, Sca-1, and CD117. Selected cell targeting ligands disclosed herein can bind to CD34, CD46, CD133, Sca-1, and / or CD117 for selective delivery of nucleic acids to hematopoietic stem cells.
[0039] "Selective delivery" means that the nucleic acid is delivered and expressed in one or more selected lymphocyte populations. In certain embodiments, selective delivery is limited to selected lymphocyte populations. In certain embodiments, at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% of the administered nucleic acid is delivered and / or expressed in the selected lymphocyte population. In certain embodiments, selective delivery ensures that the delivered nucleic acid is not expressed in cells other than lymphocytes. For example, when the targeting agent is a T cell receptor (TCR) gene, selectivity is ensured because only T cells have the zeta chain required for TCR expression. Selective delivery can also be achieved based on lack of nucleic acid uptake in unselected cells or the presence of a particular promoter within the nucleic acid sequence. For example, the transiently expressed nucleic acid can include a T cell specific CD3δ promoter. Other promoters capable of selective delivery include the murine stem cell virus promoter or the distal lck promoter for T cells or HSCs; the CD45 promoter, the WASP promoter or the IFNβ promoter for HSCs; the B29 promoter for B cells; or the CD14 promoter or the CD11b promoter for monocytes / macrophages.
[0040] As described, the selected cell targeting ligand can include a binding domain with a motif present on lymphocyte cells. The selected cell targeting ligand can further include any selective binding mechanism that allows selective uptake into lymphocytes. In certain embodiments, the selected cell targeting ligand is a T cell receptor motif, T cell alpha chain, T cell beta chain, T cell gamma chain, T cell delta chain, CCR7, CD1a, CD1b, CD1c, CD1d, CD3, CD4, CD5, CD7, CD8, CD11b, CD11c, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD34, CD35, CD39, CD40, CD45R A, CD45RO, CD46, CD52, CD56, CD62L, CD68, CD80, CD86, CD95, CD101, CD117, CD127, CD133, CD137(4-1BB), CD148, CD163, F4 / 80, IL-4Rα, Sca-1, CTLA-4, GITR, GARP, LAP, granzyme B, LFA-1, transferrin receptor, and combinations thereof.
[0041] In certain embodiments, the binding domain comprises a cell marker ligand, a receptor ligand, an antibody, a peptide, a peptide aptamer, a nucleic acid, a nucleic acid aptamer, a spiegelmer, or a combination thereof. Within the context of a selected cell targeting ligand, a binding domain includes any substance that binds to another substance to form a complex capable of mediating endocytosis.
[0042] An "antibody" is an example of a binding domain and includes full length antibodies or binding fragments of antibodies (e.g., Fv, Fab, Fab', F(ab')2, Fc and single chain Fv fragments (scFv) or any biologically effective fragment of an immunoglobulin that specifically binds to a motif expressed by lymphocytes). Antibodies or antigen-binding fragments include all or a portion of polyclonal antibodies, monoclonal antibodies, human antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, bispecific antibodies, minibodies and linear antibodies.
[0043] Human-derived or humanized antibodies have reduced or eliminated immunogenicity in humans and have a reduced number of non-immunogenic epitopes compared to non-human antibodies. Antibodies and fragments thereof will generally be selected to have reduced or no antigenicity levels in human subjects.
[0044] Antibodies that specifically bind to motifs expressed by lymphocytes can be produced using methods known to those skilled in the art, such as obtaining monoclonal antibodies, phage display methods, producing human or humanized antibodies, or using transgenic animals or plants engineered to produce antibodies (see, for example, U.S. Patent Nos. 6,291,161 and 6,291,158). Phage display libraries of partially or fully synthetic antibodies are available and can be screened for antibodies or fragments thereof that can bind to lymphocyte motifs. For example, binding domains can be identified by screening Fab phage libraries for Fab fragments that specifically bind to the target of interest (see Hoet et al., Nat. Biotechnol. 23:344, 2005). Phage display libraries of human antibodies are also available. Additionally, traditional hybridoma generation strategies using the target of interest as an immunogen in a conventional system (e.g., mouse, HuMAb Mouse®, TC Mouse™, KM Mouse®, llama, chicken, rat, hamster, rabbit, etc.) can also be used to generate binding domains. In certain embodiments, the antibody specifically binds to a motif expressed by a selected lymphocyte and does not cross-react with non-specific components or unrelated targets. The amino acid or nucleic acid sequence encoding the antibody, once identified, can be isolated and / or determined.
[0045] In certain embodiments, the binding domain of the selected cell targeting ligand is selected from the group consisting of a T cell receptor motif antibody, a T cell alpha chain antibody, a T cell beta chain antibody, a T cell gamma chain antibody, a T cell delta chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD11b antibody, a CD11c antibody, a CD16 antibody, a CD19 antibody, a CD20 antibody, a CD21 antibody, a CD22 antibody, a CD25 antibody, a CD28 antibody, a CD34 antibody, a CD35 antibody, a CD39 antibody, These include CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, CD56 antibody, CD62L antibody, CD68 antibody, CD80 antibody, CD86 antibody, CD95 antibody, CD101 antibody, CD117 antibody, CD127 antibody, CD133 antibody, CD137 (4-1BB) antibody, CD148 antibody, CD163 antibody, F4 / 80 antibody, IL-4Rα antibody, Sca-1 antibody, CTLA-4 antibody, GITR antibody, GARP antibody, LAP antibody, granzyme B antibody, LFA-1 antibody, or transferrin receptor antibody. These binding domains may also be composed of scFv fragments of the above antibodies.
[0046] Peptide aptamers contain peptide loops (specific for the target protein) attached to both ends of a protein scaffold. This double structural constraint makes the binding affinity of peptide aptamers significantly higher, reaching levels comparable to antibodies. The variable loop length is typically 8-20 amino acids (e.g., 8-12 amino acids), and the scaffold can be any small, stable, soluble, non-toxic protein (e.g., thioredoxin A, stefin A triple mutant, green fluorescent protein, eglin C, and cellular transcription factor Spl). Peptide aptamer selection can be performed using various systems, such as the yeast two-hybrid system (e.g., the Gal4 yeast two-hybrid system) or the LexA interaction trap system.
[0047] Nucleic acid aptamers are single-stranded nucleic acid (DNA or RNA) ligands that function by folding into specific globular structures, thus binding target proteins or other molecules with high affinity and specificity, as described by Osborne et al., Curr. Opin. Chem. Biol. 1:5-9, 1997 and Cerchia et al., FEBS Letters 528:12-16, 2002. In certain embodiments, the aptamers are small (15 KD or 15-80 nucleotides or 20-50 nucleotides). Aptamers have been isolated from 100,000 nucleotides by a method commonly referred to as SELEX (systematic evolution of ligands by exponential enrichment; see, e.g., Tuerk et al., Science, 249:505-510, 1990; Green et al., Methods Enzymology. 75-86, 1991; and Gold et al., Annu. Rev. Biochem., 64:763-797, 1995). 14 ~10 15 The aptamers are isolated from a library composed of random oligonucleotide sequences. Other methods for producing aptamers are described, for example, in U.S. Patent Nos. 6,344,318, 6,331,398, 6,110,900, 5,817,785, 5,756,291, 5,696,249, 5,670,637, 5,637,461, 5,595,877, 5,527,894, 5,496,938, 5,475,096 and 5,270,16. Spiegelmers are similar to nucleic acid aptamers, except that at least one β-ribose unit is replaced with β-D-deoxyribose or a sugar unit isomer selected from, for example, β-D-ribose, α-D-ribose, β-L-ribose.
[0048] Other substances that can facilitate internalization by and / or transfection of lymphocytes, such as poly(ethyleneimine) / DNA (PEI / DNA) complexes, can also be used.
[0049] Carriers. As noted, the carriers of the nanocarriers disclosed herein function to compact the nucleic acid and protect it from enzymatic degradation. Particularly useful materials for use as carriers include positively charged lipids and / or polymers, such as poly(β-amino esters).
[0050] Other examples of positively charged lipids include esters of phosphatidic acid with amino alcohols, such as esters of dipalmitoylphosphatidic acid or distearoylphosphatidic acid with hydroxyethylenediamine. More specific examples of positively charged lipids include 3β-[N-(N',N'-dimethylaminoethyl)carbamoyl]cholesterol (DC-chol), N,N'-dimethyl-N,N'-dioctadecyl ammonium bromide (DDAB), N,N'-dimethyl-N,N'-dioctadecyl ammonium chloride (DDAC), 1,2-dioleoyloxypropyl-3-dimethylhydroxyethyl ammonium chloride (DORI), 1,2-dioleoyloxy-3-[trimethylammonio]propane (DOTAP), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), dipalmitoylphosphatidylcholine (DPPC), 1,2-dioctadecyloxy-3-[trimethylammonio]propane (DSTAP), and, for example, Martin et al., Current Pharmaceutical Design 2005, 11, 375-394.
[0051] Examples of positively charged polymers that can be used as carriers within the present disclosure include polyamines, organic polyamines (e.g., polyethyleneimine (PEI), polyethyleneimine cellulose), poly(amidoamines) (PAMAM), polyamino acids (e.g., polylysine (PLL), polyarginine), polysaccharides (e.g., cellulose, dextran, DEAE dextran, starch), spermine, spermidine, poly(vinylbenzyltrialkylammonium), poly(4-vinyl-N-alkylpyridinium), poly(acryloyltrialkylammonium), and Tat protein.
[0052] Lipid and polymer blends can also be used in any ratio at any concentration. Different polymer types can be blended in different ratios using different grades to obtain the characteristics of each of the component polymers. Different end group chemistries can also be incorporated.
[0053] In addition to the above, certain embodiments disclosed herein may utilize porous nanoparticles composed of any material capable of forming a porous network. Exemplary materials include metals, transition metals, and metalloids. Exemplary metals, transition metals, and metalloids include lithium, magnesium, zinc, aluminum, and silica. In certain embodiments, the porous nanocarrier comprises silica. Mesoporous silica has a very large surface area (>1,000 m2 / g), allowing it to carry nucleic acids at levels that exceed those of conventional DNA carriers such as liposomes.
[0054] Carriers can be formed into a variety of different shapes, including spherical, cubic, pyramidal, oblong, cylindrical, donut-shaped, and the like. Nucleic acids can be encapsulated in the pores of the carrier in a variety of ways. For example, nucleic acids can be encapsulated in porous nanocarriers. In other aspects, nucleic acids can be associated (e.g., covalently and / or non-covalently) with the surface or just below the surface of the porous nanocarrier. In certain embodiments, nucleic acids can be incorporated into the porous nanocarrier, e.g., integrated into the material of the porous nanocarrier. For example, nucleic acids can be incorporated into the polymer matrix of a polymeric nanocarrier.
[0055] Coating. In certain embodiments, the nanocarriers disclosed herein include a coating that protects the encapsulated nucleic acid to reduce or prevent off-target binding. Off-target binding is reduced or prevented by reducing the surface charge of the nanocarrier to neutral or negative. As disclosed in more detail elsewhere in this application, the coating can include neutral or negatively charged polymer and / or liposome-based coatings. In certain embodiments, the coating is a dense surface coating of hydrophilic polymers and / or neutrally charged hydrophilic polymers sufficient to prevent the encapsulated nucleic acid from being exposed to the environment before being released into the selected cells. In certain embodiments, the coating covers at least 80% or at least 90% of the surface of the nanocarrier. In certain embodiments, the coating includes polyglutamic acid (PGA).
[0056] Examples of neutrally charged polymers that can be used as coatings within the scope of embodiments of the present disclosure include polyethylene glycol (PEG), poly(propylene glycol), and polyalkylene oxide copolymers (PLURONIC®, BASF Corp., Mount Olive, NJ).
[0057] Neutrally charged polymers also include zwitterionic polymers, which means that they have both positive and negative charges, but an overall neutral charge. Zwitterionic polymers can behave like cell membrane regions that prevent cell and protein adhesion.
[0058] Zwitterionic polymers include zwitterionic building blocks that include pendant groups (i.e., groups pendant from the polymer backbone) bearing zwitterionic groups. Exemplary zwitterionic pendant groups include carboxybetaine groups (e.g., -Ra-N+(Rb)(Rc)-Rd-CO2-, where Ra is a linker group that covalently bonds the polymer backbone to the nitrogen cationic center of the carboxybetaine group, Rb and Rc are nitrogen substituents, and Rd is a linker group that covalently bonds the nitrogen cationic center to the carboxy group of the carboxybetaine group).
[0059] Examples of negatively charged polymers include alginic acid, carboxylic polysaccharides, carboxymethylcellulose, carboxymethylcellulose-cysteine, carrageenan (e.g., Gelcarin® 209, Gelcarin® 379), chondroitin sulfate, glycosaminoglycans, mucopolysaccharides, negatively charged polysaccharides (e.g., dextran sulfate), poly(acrylic acid), poly(D-aspartic acid), poly(L-aspartic acid), poly(L-aspartic acid) sodium salt, poly(D-glutamic acid), poly(L-glutamic acid), poly(L-glutamic acid) sodium salt, poly(methacrylic acid), sodium alginate (e.g., Protanal® LF 120M, Protanal® LF 200M, Protanal® LF 200D), sodium carboxymethylcellulose (CMC), sulfated polysaccharides (heparin, agaropectin), pectin, gelatin and hyaluronic acid.
[0060] In certain embodiments, the polymers disclosed herein may include "star polymers," which refers to branched polymers having two or more polymeric branches extending from a central core, which is a group of atoms having two or more functional groups that can be polymerized to extend the branches.
[0061] In certain embodiments, the branch is a zwitterionic or negatively charged polymer branch. In star polymers, the branch precursor can be converted to a zwitterionic or negatively charged polymer by hydrolysis, UV irradiation, or heat. The polymer can be obtained by any polymerization method effective for the polymerization of unsaturated monomers, including atom transfer radical polymerization (ATRP), reversible addition-fragmentation chain transfer polymerization (RAFT), photopolymerization, ring-opening polymerization (ROP), condensation, Michael addition reaction, branch generation / propagation reaction, or other reactions.
[0062] Liposomes are microvesicles that contain at least one concentric lipid bilayer. The lipids that form the vesicles are selected to provide a desired degree of fluidity or rigidity to the final complex. In certain embodiments, liposomes provide a lipid composition that is an outer layer that surrounds a porous nanoparticle.
[0063] Liposomes can be neutral (cholesterol) or bipolar and include phospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI) and sphingomyelin (SM) and other types of bipolar lipids with hydrocarbon chain lengths of 14-22, either saturated or containing one or more C=C double bonds, such as dioleoylphosphatidylethanolamine (DOPE). Examples of lipids capable of forming stable liposomes alone or together with other lipid components are phospholipids such as hydrogenated soy phosphatidylcholine (HSPC), lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cephalin, cardiolipin, phosphatidic acid, cerebrosides, distearoylphosphatidylethanolamine (DSPE), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), and dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (DOPE-mal). Other non-phospholipids that can be incorporated into liposomes include stearylamine, dodecylamine, hexadecylamine, isopropyl myristate, triethanolamine lauryl sulfate, alkylaryl sulfates, acetyl palmitate, glycerol ricinoleate, hexadecyl stearate, amphoteric acrylic polymers, polyethoxylated fatty acid amides, DDAB, dioctadecyldimethylammonium chloride (DODAC), 1,2-dimyristoyl-3-trimethylammonium propane (DMTAP), DOTAP, DOTMA, DC-Chol, phosphatidic acid (PA), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylglycerol, DOPG, and dicetyl phosphate.In certain embodiments, lipids used to make the liposomes disclosed herein include cholesterol, hydrogenated soybean phosphatidylcholine (HSPC) and the derivatized vesicle-forming lipid PEG-DSPE.
[0064] Methods for forming liposomes are described in, for example, U.S. Pat. Nos. 4,229,360, 4,224,179, 4,241,046, 4,737,323, 4,078,052, 4,235,871, 4,501,728, and 4,837,028, Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), and Hope et al., Chem. Phys. Lip. 40:89 (1986).
[0065] Nucleic Acids. The nucleic acids used in the nanocarriers disclosed herein can transiently express gene editing agents that modulate cell fate, differentiation, viability and / or trafficking and / or phenotype-altering proteins (see, e.g., Figures 1B, 1C).
[0066] In certain embodiments, the nucleic acid comprises a synthetic mRNA. In certain embodiments, 5'-capping is used to artificially create synthetic mRNA with increased intracellular stability. A number of different 5'-cap structures can be used to create a 5'-cap for a synthetic mRNA molecule. For example, an anti-reverse cap analog (ARCA) cap can include a 5'-5' triphosphate guanine-guanine bond, where one guanine contains an N7 methyl group and a 3'-O-methyl group. Synthetic mRNA molecules can be post-transcriptionally capped using an enzyme that results in the formation of a 5'-cap structure. For example, recombinant vaccinia virus capping enzyme and recombinant 2'-O-methyltransferase enzyme can form a standard 5'-5' triphosphate bond between the 5'-most nucleotide of an mRNA and a guanine nucleotide, where the guanine is N7 methylated and the most terminal 5'-nucleotide contains a 2'-O-methyl, forming a Cap1 structure. This results in a cap with increased translation initiation ability, increased intracellular stability, and reduced activation of intracellular inflammatory cytokines.
[0067] Synthetic mRNA or other nucleic acids may be circularized. Synthetic mRNA may be circularized or concatemerized to generate molecules with high translation initiation potential to facilitate interaction between polyA binding protein and 5' end binding protein. The mechanism of circularization or concatemerization can occur by at least three different pathways: 1) chemical pathway, 2) enzymatic pathway, and 3) ribozyme catalytic pathway. The newly formed 5'-3' bond may be intramolecular or intermolecular.
[0068] In the first route, chemically reactive groups can be introduced at the 5' and 3' ends of the nucleic acid that form a new covalent bond between the 5' and 3' ends of the molecule when they are in close proximity to each other. A reactive NHS ester group can be introduced at the 5' end and a 3' amino terminal nucleotide can be introduced at the 3' end of the synthetic mRNA molecule such that the 3' amino terminal nucleotide at the 3' end will nucleophilically attack the 5'-NHS ester moiety and form a new 5'-3' amide bond in organic solvent.
[0069] In the second pathway, T4 RNA ligase can be used to enzymatically ligate a 5' phosphorylated nucleic acid molecule to the 3' hydroxyl group of a nucleic acid, forming a new phosphodiester bond. In one example reaction, 1 μg of nucleic acid molecule can be incubated for 1 hour at 37° C. with 1-10 units of T4 RNA ligase (New England Biolabs, Ipswich, Mass.) according to the manufacturer's protocol. The ligation reaction can be performed in the presence of a splint oligonucleotide that can juxtapose and base-pair the 5' and 3' regions to facilitate the enzymatic ligation reaction.
[0070] In the third pathway, a ligase ribozyme sequence is encoded at the 5' or 3' end of the cDNA template such that the nucleic acid molecule obtained during in vitro transcription can contain an active ribozyme sequence capable of ligating the 5' end of a nucleic acid molecule to the 3' end of a nucleic acid molecule. The ligase ribozyme can be derived from group I introns, group I introns, hepatitis delta virus, hairpin ribozymes, or selected by SELEX (Systematic Evolution of Ligands by Exponential Enrichment). The ribozyme ligase reaction can be carried out at temperatures between 0 and 37°C for 1 to 24 hours.
[0071] In certain embodiments, the nucleic acid comprises a plasmid, cDNA or mRNA, which may comprise sequences (e.g., genes) for expressing, for example, gene editing agents or phenotype-altering proteins. Suitable plasmids include standard plasmid vectors and minicircle plasmids that can be used to introduce genes into lymphocytes. The nucleic acid (e.g., minicircle plasmid) may further comprise any other sequence information to facilitate transient expression in the selectively modified cells. For example, the nucleic acid may comprise a promoter, such as a general-purpose promoter, a tissue-specific promoter, a cell-specific promoter and / or a cytoplasm-specific promoter. As noted, promoters and plasmids (e.g., minicircle plasmids) are generally well known in the art and can be made using conventional techniques.
[0072] The term "gene" as used herein refers to a nucleic acid sequence that codes for a gene editing agent or a phenotype-altering protein. This definition includes various sequence polymorphisms, mutations, and / or sequence variants, where such variants do not affect the function of the gene editing agent or the phenotype-altering protein. The term "gene" can include not only the coding sequence, but also regulatory regions such as promoters, enhancers, and termination regions. The term can further include all introns and other DNA sequences spliced from the mRNA transcript, and variants resulting from alternative splice sites. The nucleic acid sequence that codes for the gene editing agent or the phenotype-altering protein can be an RNA that directs the expression of the gene editing agent or the phenotype-altering protein. These nucleic acid sequences include RNA sequences that are translated into proteins in certain embodiments. These nucleic acid sequences include both full-length nucleic acid sequences and non-full-length sequences derived from full-length proteins. These sequences can also include degenerate codons of the native sequence or sequences that can be introduced to ensure codon preference in a particular lymphocyte. Gene sequences for encoding the gene editing agents or phenotype-altering proteins disclosed herein are available in public databases and publications. As used herein, the term "encode" refers to the property of a nucleic acid sequence, such as a plasmid, gene, cDNA, mRNA, etc., to serve as a template for the synthesis of a gene editing agent or a phenotype-altering protein.
[0073] Gene editing agents. As used herein, gene editing agents include expression products of transient nucleic acid expression as described herein that modify or change a specific sequence of the endogenous genome of a selected cell. In certain embodiments, the modification includes removal or disruption of the endogenous gene, resulting in the protein encoded by the endogenous gene being not expressed, being expressed at a reduced level, or being expressed as an incomplete, unstable, misfolded and / or non-functional protein. In certain embodiments, the result is reduced protein expression by an interfering RNA type mechanism. Thus, gene editing agents are useful for genome editing, for example, gene disruption, gene editing by homologous recombination, and gene therapy to insert therapeutic genes into appropriate chromosomal target locations, including the human genome.
[0074] Certain embodiments utilize transcription activator-like effector nucleases (TALENs) as gene editing agents. TALENs refer to fusion proteins that include a transcription activator-like effector (TALE) DNA binding protein and a DNA cleavage domain. TALENs are used to edit genes and genomes by inducing double-strand breaks (DSBs) in DNA to induce repair mechanisms in cells. In general, two types of TALENs must bind to and sandwich both sides of the target DNA site in order for the DNA cleavage domain to dimerize and induce a DSB. DSBs are repaired in cells by non-homologous end joining (NHEJ) or homologous recombination (HR) with an exogenous double-stranded donor DNA fragment.
[0075] As described, TALENs are artificially engineered to bind to target sequences, for example in endogenous genomes, and cleave DNA at the location of the target sequence. TALEN TALEs are DNA-binding proteins secreted by Xanthomonas bacteria. The DNA-binding domain of TALEs contains highly conserved 33 or 34 amino acid repeats, but the 12th and 13th residues of each repeat are variable. These two positions are called Repeat Variable Diresidues (RVDs) and show a strong correlation with specific nucleotide recognition. Therefore, targeting specificity can be improved by substituting amino acids in the RVDs and incorporating unusual RVD amino acids.
[0076] Examples of DNA cleavage domains that can be used in TALEN fusions are wild-type and mutant FokI endonucleases. FokI domains function as dimers, requiring two constructs with unique DNA binding domains for sites on the target sequence. FokI cleavage domains cleave within a 5 or 6 base pair spacer sequence that separates the two inverted half-sites.
[0077] Certain embodiments utilize MegaTAL as a gene editing agent. MegaTAL has a single-stranded nuclease structure with low cleavage frequency, and TALE is fused with the DNA cleavage domain of meganuclease. Meganuclease, also called homing endonuclease, is a single peptide chain that combines DNA recognition and nuclease functions in the same domain. In contrast to TALEN, megaTAL only requires the delivery of a single peptide chain for functional activity. A representative megaTAL protein specific for TCRα is shown in FIG. 11 as SEQ ID NO:1.
[0078] Certain embodiments utilize zinc finger nucleases (ZFNs) as gene editing agents. ZFNs are a class of site-specific nucleases engineered to bind and cleave DNA at specific locations. ZFNs are used to introduce DSBs at specific sites in DNA sequences, allowing ZFNs to target unique sequences in the genome of a variety of different cells. Furthermore, after double-strand breaks, homologous recombination or non-homologous end joining can be performed to repair the DSB, thus enabling genome editing.
[0079] ZFNs are synthesized by fusing a zinc finger DNA binding domain with a DNA cleavage domain. The DNA binding domain includes three to six zinc finger proteins that are transcription factors. The DNA cleavage domain includes, for example, the catalytic domain of FokI endonuclease.
[0080] Guide RNAs can be used in conjunction with gene editing agents, such as the CRISPR-Cas system, which contains CRISPR repeats and a set of CRISPR-associated genes (Cas).
[0081] CRISPR repeats (clustered regularly interspaced short palindromic repeats) contain clusters of short direct repeats separated by spacers of short variable sequence of size comparable to the repeats. The repeats are 24-48 base pairs in size and have some degree of dyad symmetry, with the formation of secondary structures such as hairpins, but the repeats are not truly palindromic. The spacers separating the repeats closely match sequences derived from prokaryotic viruses, plasmids and transposons. Cas genes code for nucleases, helicases, RNA-binding proteins and polymerases that unwind and cleave DNA. Examples of Cas genes are Cas1, Cas2 and Cas9.
[0082] Considering the origin of the CRISPR spacer, the CRISPR-Cas system is thought to participate in adaptive immunity in bacteria. There are at least three types of CRISPR-Cas immune system responses, and the Cas1 and Cas2 genes are involved in spacer acquisition in all three types. The first stage of adaptive immunity is spacer acquisition, which captures the invading viral DNA and inserts it into the CRISPR locus. More specifically, spacer acquisition begins when Cas1 and Cas2 recognize the invading DNA, cleave the protospacer, and the cleaved protospacer is linked to the direct repeat adjacent to the leader sequence. Then, single-strand extension repair is performed, and the direct repeat is replicated.
[0083] The next step in CRISPR-associated adaptive immunity is CRISPR RNA (crRNA) biogenesis, which is carried out differently in each type of CRISPR-Cas system. Generally, during this step, the CRISPR transcript is cleaved by Cas genes to produce crRNA. In type I systems, Cas6e / Cas6f cleave the transcript. Type II systems utilize trans-activating (tracr)RNA to form dsRNA, which is cleaved by Cas9 and RNase III. Type III systems use a Cas6 homolog for cleavage.
[0084] In the final step of CRISPR-associated adaptive immunity, the processed crRNA associates with Cas proteins to form an interference complex. In type I and type II systems, Cas proteins interact with a protospacer adjacent motif (PAM), a short 3-5 bp DNA sequence, to degrade the invading DNA, whereas type III systems do not require interaction with a PAM for degradation. In type III-B systems, the crRNA base pairs with mRNA rather than the target DNA for degradation.
[0085] Therefore, the CRISPR-Cas system functions as an RNAi-like immune system in prokaryotes. CRISPR-Cas technology has been used to inactivate genes in human cell lines and cells. As an example, the CRISPR-Cas9 system based on the type II system is used as a genome editing agent.
[0086] Type II systems require three components: Cas9, crRNA, and tracrRNA. The system can be simplified by linking tracrRNA and crRNA to a single synthetic single guide RNA (sgRNA).
[0087] At least three different Cas9 nucleases have been developed for genome editing. The first category is wild-type Cas9, which introduces DSBs at specific DNA sites and activates DSB repair mechanisms. DSBs can be repaired by the NHEJ or homology-directed repair (HDR) pathways. The second category is mutant Cas9, called Cas9D10A, which only has nickase activity and therefore only cleaves single strands of DNA and does not activate NHEJ. Thus, DNA repair proceeds exclusively via the HDR pathway. The third category is nuclease-deficient Cas9 (dCas9), which does not have cleavage activity but can bind to DNA. Thus, dCas9 can target specific sequences in the genome without cleaving them. By fusing dCas9 with various effector domains, dCas9 can be used as a gene silencing or activation tool.
[0088] The gene editing agents selectively delivered by the nanocarriers disclosed herein can target a number of genes, including, but not limited to, targeting the Shp1 phosphatase gene (e.g., SEQ ID NO:2), the PD1 receptor gene (e.g., SEQ ID NO:3), the TCR alpha gene (e.g., SEQ ID NO:4), the CCR5 gene (e.g., SEQ ID NO:5), and / or the CXCR4 gene (e.g., SEQ ID NO:6).
[0089] Shp-1 (src homology region 2 domain-containing phosphatase 1; also known as non-receptor protein tyrosine phosphatase 6 (PTPN6)) is encoded by the PTPN6 gene in humans. The N-terminal portion of Shp-1 contains two Src homology (SH2) domains that function as protein phosphotyrosine binding domains that interact with other cellular components to regulate its interaction with substrates. Shp-1 plays a major role as a regulator of multiple signaling pathways involved in hematopoiesis and interacts with various phosphoproteins involved in hematopoietic cell signaling. Shp-1 binds to growth factor receptors, such as receptors for EPO, IL-3, GM-CSF, and M-CSF, and other signaling proteins by protein tyrosine phosphorylation. Shp-1 also mediates inhibitory signals triggered by immunoglobulin gamma Fc domain (FcVRIIB1), NK cell inhibitory receptor, T cell receptor (TCR), B cell receptor (BCR), CD22, and CD72. There are alternative splice variants of the PTPN6 gene that encode different isoforms. For representative nucleic acid sequences encoding mammalian Shp-1, see GenBank Accession Nos. NM_080549, NM_053908.1, and NM_013545.
[0090] Certain embodiments disclosed herein include targeting the Shp1 phosphatase gene to alter T cell signaling. Shp1 phosphatase activity limits the functional activity of high affinity T cell receptors, thus posing an obstacle to the therapeutic use of these receptors to target rare or low affinity tumor antigens. (Hebeisen M, et al. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. JCI. 2013). Shp1 activity has also been implicated in reduced antitumor activity of T cell therapeutics in solid tumors. (Moon EK, et al. Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors, Clinical Cancer Research, 2014). For these reasons, downregulation of Shp1 can enhance the specific recognition and functional activity of T cells and therapeutic T cell products.
[0091] PD1 (programmed cell death protein 1; also known as cluster of differentiation 279 (CD279)) is a cell surface receptor belonging to the immunoglobulin superfamily. It is expressed on the surface of activated T cells, B cells, and macrophages, and in humans is encoded by the PDCD gene. Structurally, PD-1 contains an extracellular IgV domain, a transmembrane region, and an intracellular tail. The intracellular tail contains two phosphorylation sites located at an immunoreceptor tyrosine-dependent inhibitory motif and an immunoreceptor tyrosine-dependent switch motif, so PD-1 is thought to be involved in the negative regulation of TCR signals. PD-1 is an immune checkpoint. It negatively regulates the immune system by suppressing T cell activation, suppressing autoimmunity, and promoting autoimmune tolerance. PD-1 fulfills its function by promoting apoptosis of antigen-specific T cells and simultaneously suppressing apoptosis of regulatory T cells (suppressor T cells) in lymph nodes. PD-1 binds to the ligands PD-L1 and PD-L2. For representative nucleic acid sequences encoding mammalian PD-1, see Genbank Accession Nos. AY238517, NM_001106927, and KJ865858.
[0092] Certain embodiments disclosed herein include targeting of the PD1 receptor gene. PD1 antibody blockade has been demonstrated to enhance therapeutic efficacy, but may also potentially result in immune-related adverse events in the gastrointestinal, hepatic and endocrine systems, as well as other organs (Postow MA, Managing Immune Checkpoint-Blocking Antibody Side Effects, ASCO, 2015). By selectively blocking or suppressing PD1 receptor expression in infused therapeutic T cell products by gene editing, off-target inflammatory side effects can be minimized while maintaining high in vivo activity of the infused T cells.
[0093] As mentioned above, T cell receptors (TCRs) are expressed on the surface of T lymphocytes that are responsible for recognizing antigen fragments as peptides bound to major histocompatibility complex (MHC) molecules. For TCR α chain genes, see GenBank Accession Nos. X04954, X72904.1 and L21699.1.
[0094] Certain embodiments disclosed herein involve targeting of the TCR alpha chain gene. Expression of the endogenous TCR can interfere with expression of the artificial T cell receptor, potentially resulting in autoimmune or alloreactive responses. Targeting of the TCR alpha chain gene can improve expression of the artificial T cell receptor, allowing partial donor independence in T cell product manufacturing.
[0095] CCR5 (chemokine receptor type 5; also known as CD195) is expressed on the surface of T cells, macrophages, dendritic cells, eosinophils, and microglia. In humans, it is encoded by the CCR5 gene. CCR5 is a G protein-coupled receptor that belongs to the β-chemokine receptor family of endogenous proteins.
[0096] Many viruses, including HIV, use CCR5 as a coreceptor to enter host cells. CCR5 is called a coreceptor because HIV requires its glycoprotein (gp120) to bind to both CD4 and the coreceptor (CCR5) in order to enter a host cell.
[0097] Therefore, one way to prevent viral infection is to block or suppress the expression of CCR5. Several CCR5 receptor antagonists have been developed to disrupt the interaction between CCR5 and the HIV envelope glycoprotein gp120. Examples of such antagonists include PRO140 (Progenics), Vicriviroc (Schering Plough), Aplaviroc (GlaxoSmithKline) and Maraviroc (Pfizer). Examples of ligands for CCR5 include RANTES, MIP-1β and MIP-1α. These ligands can suppress HIV-1 infection in vitro. For representative nucleic acid sequences encoding mammalian CCR5, see Genbank accession numbers U66285, FJ573195 and AF022990.
[0098] Certain embodiments disclosed herein involve targeting of the CCR5 gene to inhibit viral entry, such as HIV intracellular entry.
[0099] CXCR4 (CXC chemokine receptor type 4; also known as fusin or CD184) is encoded by the CXCR4 gene in humans. Like CCR5, CXCR4 is a coreceptor for viral entry into cells, including HIV intracellular entry. CXCR4 is also expressed on many types of cancer cells. CXCR4 is also an alpha chemokine receptor specific for stromal cell-derived factor 1 (SDF-1 or CXCL12), a molecule with chemotactic activity for lymphocytes. SDF-1 inhibits the replication of T-cell tropic HIV-1 isolates. For representative nucleic acid sequences encoding mammalian CCR4, see Genbank accession numbers NM_001008540, NM_022205, and NM_009911.
[0100] Certain embodiments disclosed herein involve targeting of the CXCR4 gene to inhibit viral entry, such as HIV intracellular entry.
[0101] As noted, certain embodiments disclosed herein rely on the expression of a phenotype-altering protein. The phenotype-altering protein can, for example, regulate cell differentiation, viability, or trafficking. Examples of phenotype-altering proteins include, for example, FOXO1, LKB1, TERT, CCR2b, and CCR4.
[0102] FOXO1 (forkhead box protein O1, or forkhead in rhabdomyosarcoma) is a transcription factor that in humans is encoded by the FOXO1 gene (e.g., SEQ ID NO: 7). FOXO1 is selectively integrated into the genetic program that regulates memory CD8+ T cell responses to infection (Kim et al., Immunity, 2013, 39(2):286-97). Kim et al. reported that mice lacking FOXO1 in activated CD8+ T cells had a defective primary but secondary response to Listeria monocytogenes infection (ibid.). Memory T cell precursors expressed higher amounts of FOXO1 compared to short-lived effector T cells, which promoted the generation and maintenance of memory T cell precursors (ibid.). The transcription factor Tcf7 and the chemokine receptor CCR7 have also been shown to interact with FOXO1 (ibid.).
[0103] FOXO1 also plays a role in promoting the effector to memory transition and functional maturation of memory CD4 and CD8 T cells (Tejara et al. J. of Immunology, 2013, 191(1):187-199). Although FOXO1 is not required for effector cell differentiation, memory CD8 T cells exhibited characteristics of senescence in the absence of FOXO1, resulting in impaired recall responses and poor protective immunity (Ibid). For representative nucleic acid sequences encoding mammalian FOXO1, see GenBank Accession Nos. BC021981, NM_001191846, and NM_019739. Certain embodiments disclosed herein include expression of FOXO1.
[0104] LKB1 (liver kinase B1, also known as kidney cancer antigen NY-REN-19 or serine / threonine kinase 11 (STK11)) is a serine / threonine protein kinase encoded by the STK11 gene in humans. LKB1 is a key regulator of T cell development, survival, activation and metabolism (MacIver, J. Immunol. 2011, 187(8):4187-4198). T cells lacking LKB1 exhibit impaired cell proliferation and survival, and altered glycolysis and lipid metabolism (ibid.). LKB1 also activates a group of kinases, including AMPK and AMPK-related kinases, that suppress growth and proliferation when energy nutrients are scarce. AMPK, AMPK-related kinases and LKB1 play important roles in suppressing tumor cell growth by maintaining cell polarity. For representative nucleic acid sequences encoding mammalian LKB1, see GenBank Accession Nos. NM_000455, NM_001108069, and AB015801. Certain embodiments disclosed herein include expression of LKB1. A representative LKB1 sequence is SEQ ID NO:8.
[0105] T cell specific transcription factor 7 (TCF7) is a transcriptional activator that plays a key role in lymphocyte differentiation. The gene is expressed primarily in T cells. The encoded protein can bind to enhancer elements to activate the CD3E gene and further repress the CTNNB1 and TCF7L2 genes through a feedback mechanism. For a representative nucleic acid sequence encoding human TCF7, see NCBI Reference Sequence NC_000005.10. Certain embodiments disclosed herein include expression of TCF7.
[0106] Eomesodermin (EOMES) is a transcription factor important for embryonic development of the mesoderm and central nervous system in vertebrates. It is also involved in the differentiation of effector CD8+ T cells. For a representative nucleic acid sequence encoding human EOMES, see NCBI Reference Sequence NC_000003.12 and SEQ ID NO: 9. Certain embodiments disclosed herein include expression of EOMES.
[0107] The HLH protein DNA-binding inhibitor 2 (ID2) is a transcriptional regulator that contains a helix-loop-helix (HLH) domain but no basic domain. Members of this DNA-binding inhibitor family dominant-negatively inhibit the function of basic helix-loop-helix transcription factors by suppressing their heterodimerization partners via the HLH domain. ID2 plays a role in negatively regulating cell differentiation. See NCBI Reference Sequence NC_000002.12 and SEQ ID NO: 10 for a representative nucleic acid sequence encoding human ID2. Certain embodiments disclosed herein include expression of ID2.
[0108] Certain embodiments disclosed herein include altering the differentiation of T cells by expression of transcription factors and signaling molecules (e.g., FOXO1, LKB1, TCF7, EOMES, and / or ID2) to generate specific cell phenotypes such as TEM, TCM, or TREG cells depending on the need for therapeutic efficacy. TCM and TEM cells have shown high therapeutic efficacy in anti-tumor models.
[0109] Telomerase is an RNA-dependent polymerase that can elongate telomeres in DNA strands, making senescent cells potentially immortal rather than postmitotic and apoptotic. The human telomerase complex contains two molecules each of human telomerase reverse transcriptase (TERT), telomerase RNA (TR or TERC), and dyskerin (DKC1). TERT cooperates with TERC to catalyze the addition of nucleotides to the ends of telomeres as TTAGGG sequences. The addition of repetitive DNA sequences prevents degradation of chromosome ends after cell division by mitosis. Thus, telomerase repairs and elongates telomeres, allowing senescent cells to divide and surpass the Hayflick limit of 50-70 cell divisions. For representative nucleic acid sequences encoding mammalian TERT, see GenBank Accession Nos. NM_198253, NM_053423, NM_009354, and SEQ ID NO: 11.
[0110] Normal somatic cells have no detectable telomerase activity. Certain embodiments disclosed herein include expression of TERT. Research has shown that the in vivo persistence and antitumor effect of adoptively transferred T cells can be enhanced by delivery of TERT mRNA (using electroporation, Cell Discovery (2015) 1, 15040).
[0111] On the other hand, malignant tumor cells have been shown to have high telomerase activity, so gene editing tools such as those mentioned above can be used to target TERT in malignant cancers.
[0112] CCR2b (CC chemokine receptor type 2 or CD192 (cluster of differentiation 192)) is a G protein-coupled receptor. In humans, CCR2 is encoded by the CCR2 gene, which encodes two isoforms of the receptor, CCR2a and CCR2b, by alternative splicing of a single gene.
[0113] CCR2b is the receptor for monocyte chemoattractant protein-1 (MCP-1), a chemokine closely related to MIP-1 (RANTES receptor) and mediating monocyte chemotaxis. CCR2 also binds MCP-2, MCP-3, and MCP-4, but with lower affinity. CCR2a and CCR2b differ in their C-terminal tails. MCP-1 is a small molecule chemokine that belongs to the CC chemokine family. MCP-1 is involved in the recruitment of monocytes, memory T cells, and dendritic cells to sites of inflammation caused by tissue injury or infection. MCP-1 is involved in monocyte infiltration in inflammatory diseases such as psoriasis, rheumatoid arthritis, and atherosclerosis, and in the inflammatory response to tumors. For representative nucleic acid sequences encoding mammalian CCR2b, see GenBank Accession Nos. NM_001123396 and NM_009915, and SEQ ID NO: 12.
[0114] Certain embodiments disclosed herein include expression of CCR2b to enhance tumor trafficking of therapeutic T cells (J. Immunother. 2010 Oct;33(8):780-8).
[0115] CCR4 (CC chemokine receptor 4 or CD194 (cluster of differentiation 194)) belongs to the G protein-coupled receptor family. In humans, it is encoded by the CCR4 gene. CCR4 is the receptor for the CC chemokines MCP-1, MIP-1, RANTES, TARC and macrophage-derived chemokine. CC chemokines induce the migration of monocytes and other cells such as NK cells and dendritic cells. As an example, MCP-1 induces monocytes to leave the bloodstream and enter the surrounding tissues to become tissue macrophages. RANTES attracts T cells, eosinophils and basophils. Thus, CCR4 and its ligands, the CC chemokines, regulate the cell trafficking of various types of leukocytes. For representative nucleic acid sequences encoding mammalian CCR4, see GenBank Accession Nos. NM_005508, NM_133532, and NM_009916.2, and SEQ ID NO:13.
[0116] Certain embodiments disclosed herein include expression of CCR4 to improve tumor homing and anti-tumor activity of therapeutic T cells (Blood. 2009 Jun 18;113(25):6392-402).
[0117] Certain embodiments utilize the nanocarriers disclosed herein, either independently or in addition to the hit-and-run effect, to deliver nucleic acids for expression by selected cells. In certain embodiments, such embodiments can enhance the growth, survival, immune function and / or tumor cell targeting of selected cells. Examples of genetic modifications include modifications that allow expression of chimeric antigen receptors (CARs), αβ T cell receptors (or variants thereof) and / or inflammatory cytokines. CAR modifications and / or αβ T cell receptor modifications enable modified lymphocytes to specifically target cell types.
[0118] In one embodiment, the genetically modified lymphocytes can improve tumor recognition and induce increased natural T cell proliferation and / or cytokine production.
[0119] By "chimeric antigen receptor" or "CAR" is meant an artificially designed receptor that contains at least a binding domain and an effector domain, and optionally a spacer domain and / or a transmembrane domain.
[0120] The binding domain may comprise any peptide that specifically binds to a marker on a target cell. Sources of the binding domain include antibody variable regions from various species (which may be in the form of antibodies, sFv, scFv, Fab, scFv grababodies, or soluble VH domains or domain antibodies). These antibodies may use only the heavy chain variable regions to form the antigen-binding region, i.e., these functional antibodies are homodimers consisting of only heavy chains (referred to as "heavy chain antibodies") (Jespers et al., Nat. Biotechnol. 22:1161, 2004; Cortez-Retamozo et al., Cancer Res. 64:2853, 2004; Baral et al., Nature Med. 12:580, 2006; and Barthelemy et al., J. Biol. Chem. 283:3639, 2008).
[0121] Alternative sources of binding domains include sequences encoding random peptide libraries or scTCRs (see, e.g., Lake et al., Int. Immunol. 11:745, 1999; Maynard et al., J. Immunol. Methods 306:51, 2005; U.S. Patent No. 8,361,794), fibrinogen domains (see, e.g., Weisel et al., Science 230:1388, 1985), Kunitz-type domains (see, e.g., U.S. Patent No. 6,423,498), artificial ankyrin repeat proteins (DARPins) (Binz et al., J. Mol. Biol. 332:489, 2003 and Binz et al., Nat. Biotechnol. 22:575, 2004), fibronectin binding domains (adnectins or monobodies) (Richards et al. al., J. Mol. Biol. 326:1475, 2003; Parker et al., Protein Eng. Des. Selec. 18:435, 2005 and Hackel et al. (2008) J. Mol. Biol. 381:1238-1252), cysteine knot miniproteins (Vita et al. (1995) Proc. Nat'l. Acad. Sci. (USA) 92:6404-6408; Martin et al. (2002) Nat. Biotechnol. 21:71, 2002 and Huang et al. (2005) Structure 13:755, 2005), tetratricopeptide repeat domains (Main et al., Structure 11:497, 2003 and Cortajarena et al., ACS Chem. Biol. 3:161, 2008), leucine-rich repeat domains (Stumpp et al., J. Mol. Biol. 332:471, 2003), lipocalin domains (e.g. WO2006 / 095164, Beste et al., Proc. Nat'l. Acad. Sci. (USA) 96:1898, 1999 and Schonfeld et al., Proc. Nat'l. Acad. Sci.(USA) 106:8198, 2009), V-region-like domains (see, e.g., U.S. Patent Application Publication No. 2007 / 0065431), C-type lectin domains (Zelensky and Gready, FEBS J. 272:6179, 2005; Beavil et al., Proc. Nat'l. Acad. Sci. (USA) 89:753, 1992 and Sato et al., Proc. Nat'l. Acad. Sci. (USA) 100:7779, 2003), mAbs. 2 or Fcab(TM) (see, e.g., PCT Patent Application Publication Nos. WO2007 / 098934, WO2006 / 072620), armadillo repeat proteins (see, e.g., Madhurantakam et al., Protein Sci. 21:1015, 2012; PCT Patent Application Publication No. WO2009 / 040338), affilins (Ebersbach et al., J. Mol. Biol. 372:172, 2007), affibodies, avimers, knottins, fynomers, atrimers or cytotoxic T-lymphocyte-associated protein 4 (Weidle et al., Cancer Gen. Proteo. 10:155, 2013), and the like (Nord et al., Protein Eng. 8:601, 1995; Nord et al. al., Nat. Biotechnol. 15:772, 1997; Nord et al., Euro. J. Biochem. 268:4269, 2001; Binz et al., Nat. Biotechnol. 23:1257, 2005; Boersma and Pluckthun, Curr. Opin. Biotechnol. 22:849, 2011), which encode various artificial amino acids in the loop regions of alternative non-antibody scaffolds.
[0122] In certain embodiments, the binding domain comprises a V α / β Chain and C α / β Chain (e.g. V α -C α , V β -C β ,V α -V β ) or Vα -C α , V β -C β , V α -V β It is a single-chain T cell receptor (scTCR) that contains a pair.
[0123] Exemplary CARs express ligand binding domains that target, for example, mesothelin, Her2, WT-1, and / or EGRF. Exemplary T cell receptor variants target melanoma associated antigen (MAGE) A3 TCR.
[0124] Specific cancers can be targeted by including binding domains within the extracellular component of the TCR or CAR that bind to relevant cell markers.
[0125] [Table 1]
[0126] In addition to the above, cell markers include A33, BAGE, Bcl-2, β-catenin, B7H4, BTLA, CA125, CA19-9, CD3, CD5, CD19, CD20, CD21, CD22, CD25, CD28, CD30, CD33, CD37, CD40, CD52, CD44v6, CD45, CD56, CD79b, CD80, CD81, CD86, CD123, CD134, CD137, CD151, CD171, CD276, CEA, and CEAC. AM6, c-Met, CS-1, CTLA-4, Cyclin B1, DAGE, EBNA, EGFR, EGFRvIII, Ephrin B2, ErbB2, ErbB3, ErbB4, EphA2, Estrogen receptor, FAP, Ferritin, alpha-fetoprotein (AFP), FLT1, FLT4, Folate binding protein, Frizzled, GAGE, G250, GD-2, GHRHR, GHR, GITR, GM2, gp75, gp100 (Pmel 17), gp130, HLA, HER-2 / neu, HPV E6, HPV Also included are E7, hTERT, HVEM, IGF1R, IL6R, KDR, Ki-67, Lewis A, Lewis Y, LIFRβ, LRP, LRP5, LTβR, MAGE, MART, mesothelin, MUC, MUC1, MUM-1-B, myc, NYESO-1, O-acetyl GD-2, O-acetyl GD3, OSMRβ, p53, PD1, PD-L1, PD-L2, PRAME, progesterone receptor, PSA, PSMA, PTCH1, RANK, ras, Robo1, ROR1, survivin, TCRα, TCRβ, tenascin, TGFBR1, TGFBR2, TLR7, TLR9, TNFR1, TNFR2, TNFRSF4, TWEAK-R, TSTA tyrosinase, VEGF, and WT1.
[0127] Specific cancer cell markers include the following:
[0128] [Table 2] TIFF2024164142000003.tif167168
[0129] In certain embodiments, the binding domain can bind to PSMA. Numerous antibodies specific for PSMA are known to those of skill in the art and can be readily characterized for sequence, epitope binding and affinity. In certain embodiments, the binding domain can include anti-mesothelin ligand (relevant to the treatment of ovarian cancer, pancreatic cancer and mesothelioma), anti-WT-1 (relevant to the treatment of leukemia and ovarian cancer), anti-HIV-gag (relevant to the treatment of HIV infection), or anti-cytomegalovirus (relevant to the treatment of CMV diseases such as herpes viruses).
[0130] In certain embodiments, the binding domain is capable of binding to CD19. In certain embodiments, the binding domain is a single chain Fv fragment (scFv) comprising a VH region and a VL region specific for CD19. H Area and V L The domain is humans. H Area and V L Regions include segments of anti-CD19 specific monoclonal antibody FMC63. In certain embodiments, the scFV is a human or humanized scFV comprising a light chain variable region comprising a CDRL1 sequence of RASQDISKYLN (SEQ ID NO: 22), a CDRL2 sequence of SRLHSGV (SEQ ID NO: 23), and a CDRL3 sequence of GNTLPYTFG (SEQ ID NO: 24). In certain embodiments, the scFV is a human or humanized ScFv comprising a heavy chain variable region comprising a CDRHI sequence of DYGVS (SEQ ID NO: 25), a CDRH2 sequence of VTWGSETTYYNSALKS (SEQ ID NO: 26), and a CDRH3 sequence of YAMDYWG (SEQ ID NO: 27). Other CD19 targeting antibodies such as SJ25C1 and HD37 are also known (SJ25C1: Bejcek et al. Cancer Res 2005, PMID 7538901; HD37: Pezutto et al. JI 1987, PMID 2437199). SEQ ID NO: 28 shows the anti-CD19scFv(VH-VL)FMC63 DNA sequence, and SEQ ID NO: 29 shows the anti-CD19scFv(VH-VL)FMC63 amino acid sequence.
[0131] In certain embodiments, the binding domain is capable of binding to ROR1. In certain embodiments, the scFV is a human or humanized scFv comprising a light chain variable region comprising a CDRL1 sequence of ASGFDFSAYYM (SEQ ID NO: 30), a CDRL2 sequence of TIYPSSG (SEQ ID NO: 31), and a CDRL3 sequence of ADRATYFCA (SEQ ID NO: 32). In certain embodiments, the scFV is a human or humanized scFv comprising a heavy chain variable region comprising a CDRH1 sequence of DTIDWY (SEQ ID NO: 33), a CDRH2 sequence of VQSDGSYTKRPGVPDR (SEQ ID NO: 34), and a CDRH3 sequence of YIGGYVFG (SEQ ID NO: 35). Numerous antibodies specific for ROR1 are known to those of skill in the art and can be readily characterized for sequence, epitope binding, and affinity.
[0132] In certain embodiments, the binding domain comprises a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or 100% identical to the amino acid sequence of TCR Vα, Vβ, Cα or Cβ, and each CDR has zero or at most one, two or three mutations relative to the TCR or a fragment or derivative thereof that specifically binds to a target of interest.
[0133] In certain embodiments, the binding domain Vα, Vβ, Cα or Cβ region may be derived from or based on the Vα, Vβ, Cα or Cβ of a known TCR (e.g. a high affinity TCR) and comprises one or more (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (e.g. conservative or non-conservative amino acid substitutions) when compared to the Vα, Vβ, Cα or Cβ of the known TCR, or a combination of the above mutations. There may be zero or at most one, two or three mutations in each CDR and insertions, deletions or substitutions anywhere in these regions, including the amino or carboxy termini or both ends of the Vα, Vβ, Cα or Cβ regions, so long as a binding domain comprising the modified Vα, Vβ, Cα or Cβ region is capable of specifically binding to its target with affinity equivalent to that of the wild type.
[0134] In certain embodiments, the binding domain VH region of the present disclosure can be derived from or based on the VH of a known monoclonal antibody, H When compared to the modified V, the modified V may include one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (e.g., conservative amino acid substitutions or non-conservative amino acid substitutions), or a combination of the above mutations. H As long as a binding domain containing the region can specifically bind to its target with an affinity comparable to that of the wild-type binding domain, the V H Insertions, deletions or substitutions may occur anywhere within this region, including at the amino or carboxy termini or both ends of the region.
[0135] In certain embodiments, the VL region in the binding domain of the present disclosure is derived from or based on the VL of a known monoclonal antibody and comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (e.g., conservative amino acid substitutions) when compared to the VL of the known monoclonal antibody, or a combination of the above mutations. There may be zero or at most one, two or three mutations in each CDR and insertions, deletions or substitutions anywhere in this region, including the amino or carboxy termini or both, so long as the binding domain comprising the modified VL region is able to specifically bind to its target with an affinity comparable to that of the wild-type binding domain.
[0136] In certain embodiments, the binding domain comprises or is a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or 100% identical to the amino acid sequence of the light chain variable region (VL) or heavy chain variable region (VH) or both, and each CDR has zero or at most one, two or three mutations relative to a monoclonal antibody or a fragment or derivative thereof that specifically binds to a target of interest.
[0137] The effector domain can transmit a functional signal to the cell. In certain embodiments, the effector domain will directly promote a cellular response or indirectly promote a cellular response by associating with one or more other proteins that directly promote the cellular response. When a lymphocyte expressing a CAR is introduced, the effector domain can activate at least one function of the lymphocyte upon binding to a marker expressed on the target cell. Activation of the lymphocyte can include one or more of proliferation, differentiation, activation, or other effector functions. In certain embodiments, the polynucleotide delivered encodes the effector domain.
[0138] An effector domain can comprise one, two, three or more receptor signaling domains, intracellular signaling domains, costimulatory domains, or combinations thereof. Any intracellular effector domain, costimulatory domain, or both, derived from any of a variety of signaling molecules (e.g., signaling receptors) can be used in the CARs of the present disclosure.
[0139] Exemplary effector domains include those derived from 4-1BB, CD3ε, CD3δ, CD3ζ, CD27, CD28 (e.g., SEQ ID NO:36), CD79A, CD79B, CARD11, DAP10, FcRα, FcRβ, FcRγ, Fyn, HVEM, ICOS, Lck, LAG3, LAT, LRP, NOTCH1, Wnt, NKG2D, OX40, ROR2, Ryk, SLAMF1, Slp76, pTα, TCRα, TCRβ, TRIM, Zap70, PTCH2, or any combination thereof.
[0140] T cell activation can be said to be induced by two different types of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation and provide T cell receptor-like signals (primary cytoplasmic signaling sequences), and those that act antigen-independently and provide secondary or costimulatory signals (secondary cytoplasmic signaling sequences). Primary cytoplasmic signaling sequences that act to stimulate can contain signaling motifs called receptor tyrosine-based activation motifs or iTAMs. Examples of primary cytoplasmic signaling sequences that contain iTAMs include those derived from CD3zeta, FeRgamma, CD3gamma, CD3delta, CD3epsilon, CD5, CD22, CD79a, CD79b, and CD66d.
[0141] In certain embodiments, the effector domain comprises a cytoplasmic portion that associates with a cytoplasmic signaling protein, said cytoplasmic signaling protein being a lymphocyte receptor or signaling domain thereof, a protein containing multiple ITAMs, a costimulatory factor, or any combination thereof.
[0142] Examples of intracellular signaling domains include the cytoplasmic sequences of the CD3 zeta chain and / or co-receptors that act in concert to initiate signaling after CAR engagement, as well as any derivatives or variants of these sequences, as well as any synthetic sequences with the same function. In certain embodiments, the intracellular signaling domain of a CAR can be designed to include an intracellular signaling domain along with any other desired cytoplasmic domains. For example, the intracellular signaling domain of a CAR can include an intracellular signaling domain and a costimulatory signaling region. By costimulatory signaling region is meant the portion of a CAR that includes the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than a marker ligand that requires an expressed marker ligand for lymphocytes to respond to the marker. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, lymphocyte function associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83.
[0143] The spacer region can be customized for individual markers on the target to optimize target recognition. In certain embodiments, the spacer length can be selected based on the location of the marker epitope, the affinity of the antibody for the epitope, and / or the ability of lymphocytes expressing the CAR to proliferate in vitro and / or in vivo in response to marker recognition.
[0144] Typically, there is a spacer region between the binding domain and the transmembrane domain of the CAR. The spacer region can provide flexibility to the binding domain and can increase the level of expression in engineered cells. In certain embodiments, the spacer region can be at least 10-250 amino acids, at least 10-200 amino acids, at least 10-150 amino acids, at least 10-100 amino acids, at least 10-50 amino acids, or at least 10-25 amino acids, any of the above ranges including any integer between the endpoints. In certain embodiments, the spacer region is 250 amino acids or less, 200 amino acids or less, 150 amino acids or less, 100 amino acids or less, 50 amino acids or less, 40 amino acids or less, 30 amino acids or less, 20 amino acids or less, or 10 amino acids or less.
[0145] In certain embodiments, the spacer region can be derived from a hinge region of an immunoglobulin-like molecule, for example, all or part of a hinge region from human IgG1, human IgG2, human IgG3, or human IgG4. The hinge region can be modified to avoid undesirable structural interactions, such as dimerization. In certain embodiments, all or part of the hinge region can be linked to one or more domains of the constant region of an immunoglobulin. For example, a portion of the hinge region can be linked to all or part of a CH2 or CH3 domain or a variant thereof.
[0146] The CAR disclosed herein can further comprise a transmembrane domain. In certain embodiments, the CAR polynucleotide encodes the transmembrane domain. The transmembrane domain functions to anchor the CAR to the lymphocyte membrane. The transmembrane domain can be of natural or synthetic origin. When natural in origin, the domain can be derived from any membrane-bound or transmembrane protein. The transmembrane region includes at least the transmembrane regions of the α, β or ζ chains of the T cell receptor, CD28, CD3, CD45, CD4, CDS, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154. In certain embodiments, the synthetic or mutant transmembrane domain includes highly hydrophobic residues such as leucine and valine.
[0147] In certain embodiments, the CAR comprises a single chain antibody (scFv) specific for the extracellular domain of PSMA (J591) and a P28z fusion receptor composed of CD28 and CD3 zeta cytoplasmic signaling domains. In certain embodiments, the CAR comprises the P28zCAR of SEQ ID NO: 37. SEQ ID NO: 37 comprises a murine component. Amino acids 1-797 comprise the anti-PSMA scFv (J592) and positions 797-1477 comprise the murine CD8 transmembrane domain, the murine CD28 signaling domain, and the murine CD3 zeta signaling domain. Any of the P28z domains can be individually replaced with optimized domains. In certain embodiments, the transmembrane domain and the signaling domain at positions 797-1477 of SEQ ID NO: 37 can be replaced with domains optimized specifically for humans or other animals. In certain embodiments, all or part of the binding domain, all or part of the effector domain, all or part of the spacer domain, and / or all or part of the transmembrane domain can be optimized for humans or other animals. In certain embodiments, P28zCAR is optimized for humans. When optimized for humans, P28zCAR can be less immunogenic in humans and can have a reduced number of non-immunogenic epitopes compared to non-human antibodies.
[0148] In a particular embodiment, the VL and VH chain segments of 2A2, R12 and R11mAb (ROR1) and FMC63mAb (CD19) can be used to generate ROR1-specific and CD19-specific CARs. The variable region sequences of R11 and R12 are described in Yang et al, Plos One 6(6):e21018, June 15, 2011. Each scFV can be linked with a spacer domain derived from IgG4-Fc (UniProt database: P01861, SEQ ID NO: 39) containing the sequence "hinge-CH2-CH3" (229AA, SEQ ID NO: 40), "hinge-CH3" (119AA, SEQ ID NO: 41) or "hinge" alone (12AA, SEQ ID NO: 42) by the (Gly4Ser)3 (SEQ ID NO: 38) protein. The entire spacer can contain an S→P substitution in the "hinge" domain located at position 108 of the native IgG4-Fc protein and can be linked to an effector domain signaling module that contains the 27AA transmembrane domain of human CD28 (SEQ ID NO: 43, for a representative full length CD28 see UniProt: P10747) and either (i) the 41AA cytoplasmic domain of human CD28 containing an LL→GG substitution located at positions 186-187 of the native CD28 protein (SEQ ID NO: 44) or (ii) the 42AA cytoplasmic domain of human 4-1BB (UniProt: Q07011, SEQ ID NO: 45), each of which can be linked to the 112AA cytoplasmic domain of isoform 3 of human CD3ζ (UniProt: P20963, SEQ ID NO: 46). This construct encodes a T2A ribosomal skip element (SEQ ID NO: 47) and a tEGFR sequence (SEQ ID NO: 48) downstream of the chimeric receptor. tEGFR may be replaced or supplemented with a tag cassette linking sequences such as STREP TAG®II (SEQ ID NO:49), Myc tag (SEQ ID NO:50), V5 tag (SEQ ID NO:51), FLAG® tag (SEQ ID NO:52), His tag, or other peptides or molecules disclosed herein. Codon-optimized gene sequences encoding each transgene can be synthesized (Life Technologies) and cloned into the epHIV7 lentiviral vector using NheI and NotI restriction sites.The epHIV7 lentiviral vector is derived from the pHIV7 vector by replacing the cytomegalovirus promoter of pHIV7 with the EF-1 promoter. Using the packaging vectors pCHGP-2, pCMV-Rev2 and pCMV-G and CALPHOS® transfection reagent (Clontech), lentiviruses encoding ROR1 chimeric receptor, CD19 chimeric receptor, tEGFR or tag cassettes can be generated in 293T cells.
[0149] HER2-specific chimeric receptors can be generated using VL and VH chain segments of a HER2-specific mAb that recognizes a juxtamembrane epitope on HER2, and the scFV can be linked to the extracellular spacer domains of IgG4 hinge / CH2 / CH3, IgG4 hinge / CH3 and IgG4 hinge alone, as well as the CD28 transmembrane domain, 4-1BB and CD3ζ signaling domain.
[0150] The CD19 chimeric receptor can comprise a single chain variable fragment (scFv: VL-VH) corresponding to the sequence of the CD19-specific mAb FMC63, a spacer derived from IgG4-Fc containing the "hinge-CH2-CH3" domain (229AA, long spacer) or the "hinge" domain alone (12AA, short spacer), and a signaling module of CD3ζ with a juxtamembrane CD28 or 4-1BB costimulatory domain alone or in tandem. The transgene cassette can comprise a truncated EGFR (tEGFR) downstream of the chimeric receptor gene, separated by a cleavable T2A element to serve as a tag sequence for the introduction, selection and in vivo tracking of chimeric receptor modified cells. The tEGFR may be replaced or supplemented with a tag cassette that binds to an ExoCBM, such as STREP TAG® II (SEQ ID NO: 49), Myc tag (SEQ ID NO: 50), V5 tag (SEQ ID NO: 51), FLAG® tag (SEQ ID NO: 52), His tag, or other peptides or molecules as disclosed herein.
[0151] To identify CARs with improved function over non-genetically modified lymphocytes and / or other CARs, various potential CAR nucleic acid constructs encoding various ligand binding domains, various spacer region lengths, various intracellular binding domains and / or various transmembrane domains can be tested in vivo (in animal models) and / or in vitro. In certain embodiments, the CAR is expressed independently or in addition to the hit-and-run effect described herein.
[0152] The dimensions of the nanocarriers disclosed herein can vary widely and can be measured in a variety of ways. For example, the nanocarriers disclosed herein can have a minimum dimension of 100 nm. The nanocarriers disclosed herein can also have a minimum dimension of 500 nm or less, 150 nm or less, 100 nm or less, 90 nm or less, 80 nm or less, 70 nm or less, 60 nm or less, 50 nm or less, 40 nm or less, 30 nm or less, 20 nm or less, or 10 nm or less. In certain embodiments, the nanocarriers can have a minimum dimension of 5 nm to 500 nm, 10 nm to 100 nm, 20 nm to 90 nm, 30 nm to 80 nm, 40 nm to 70 nm, and 40 nm to 60 nm. In certain embodiments, the dimension is the diameter of the nanoparticle or coated nanoparticle. In certain embodiments, the nanocarrier population of the present disclosure can have an average smallest dimension of 500 nm or less, 100 nm or less, 90 nm or less, 80 nm or less, 70 nm or less, 60 nm or less, 50 nm or less, 40 nm or less, 30 nm or less, 20 nm or less, or 10 nm or less. In certain embodiments, the nanocarrier population in the composition of the present disclosure can have an average diameter of 5 nm to 500 nm, 10 nm to 100 nm, 20 nm to 90 nm, 30 nm to 80 nm, 40 nm to 70 nm, and 40 nm to 60 nm. The dimensions of the nanocarriers can be measured using conventional techniques, such as, for example, dynamic light scattering and / or electron microscopy.
[0153] Ex vivo method of use. The nanocarriers disclosed herein can be used in ex vivo cell production (see, for example, Figures 1A and 4C). For example, such a method can include harvesting lymphocytes from a subject. The lymphocytes can be harvested from a subject, for example, using any procedure commonly known in the art.
[0154] Sources of lymphocytes include umbilical cord blood, placental blood, and peripheral blood. Methods for blood sample collection, anticoagulation, processing, etc. are known. See, for example, Alsever et al., 1941, NYSt. J.Med. 41:126; De Gowin, et al., 1940, J. Am. Med. Ass. 114:850; Smith, et al., 1959, J. Thorac. Cardiovasc. Surg. 38:573; Rous and Turner, 1916, J. Exp. Med. 23:219; and Hum, 1968, Storage of Blood, Academic Press, New York, pp. 26-160. Sources of lymphocytes also include bone marrow (see Kodo et al., 1984, J. Clin Invest. 73:1377-1384), embryonic cells, aorta-gonad-mesonephros-derived cells, lymph, liver, thymus and spleen from donors of appropriate age. Collected total lymphocyte samples are screened for undesirable components and can be discarded, treated or used according to the then current accepted standards.
[0155] In certain embodiments, the nanocarriers disclosed herein selectively target selected cell types within a heterogeneous cell population, eliminating the need for further harvesting or isolation of lymphocytes prior to exposure to the nanocarriers.
[0156] In certain embodiments, some degree of further cell harvesting and isolation prior to exposure to the nanocarriers disclosed herein may be beneficial. Any suitable technique may be used to harvest and isolate lymphocytes from a sample. Suitable harvesting and isolation techniques include magnetic separation, fluorescence activated cell sorting (FACS; Williams et al., 1985, J. Immunol. 135:1004; Lu et al., 1986, Blood 68(1):126-133), affinity chromatography, methods using substances bound to or in combination with monoclonal antibodies, "panning" with antibodies immobilized on solid matrices (Broxmeyer et al., 1984, J. Clin. Invest. 73:939-953), selective agglutination using lectins such as soybean (Reisner et al., 1980, Proc. Natl. Acad. Sci. USA 77:1164), and the like. Certain embodiments may utilize limited separation, which refers to crude cell enrichment, for example by removal of red blood cells and / or adherent phagocytes.
[0157] In certain embodiments, anti-CD8 or anti-CD34 antibodies directly or indirectly bound to magnetic particles can be used in conjunction with a magnetic cell separation device (e.g., CliniMACS® Cell Separation System (Miltenyi Biotec, Bergisch Gladbach, Germany)) to process a subject sample (e.g., a blood sample) to select / enrich CD8+ T cells or CD34+ HSPCs. Similarly, the above markers (e.g., T cell alpha chain, T cell beta chain, T cell gamma chain, T cell delta chain, CCR7, CD1a, CD1b, CD1c, CD1d, CD3, CD4, CD5, CD7, CD8, CD11b, CD11c, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD34, CD35, CD40, CD39, CD45RA, CD45RO, CD46, CD52, CD56, CD62L, CD68, CD69, CD80, Lymphocytes expressing any of the following markers (CD86, CD95, CD101, CD117, CD127, CD133, CD137 (4-1BB), CD148, CD163, CD209, DEC-205, F4 / 80, IL-4Rα, Sca-1, CTLA-4, GITR, GARP, LAP, granzyme B, LFA-1, transferrin receptor) can be isolated and enriched for use with antibodies or other binding domains of these markers.
[0158] In certain embodiments, nanocarriers are coupled to lymphocytes prior to or at an early stage of the expansion process. This approach allows modification of a small number of cells, which spreads throughout the population as the cell population expands. In certain embodiments, the modified lymphocytes can be expanded after exposure to the nanocarriers disclosed herein, which creates a hit-and-run effect based on transient expression.
[0159] Expansion cultures have been shown to secrete a number of cytokines, including angiopoietin-like proteins (Angptls, e.g., Angptl2, Angptl3, Angptl7, Angptl5, and Mfap4), erythropoietin, fibroblast growth factor 1 (FGF-1), Flt-3 ligand (Flt-3L), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), insulin growth factor 2 (IFG-2), interleukin 3 (IL-3), interleukin 6 (IL-6), and erythropoietin. The method can be carried out in the presence of one or more growth factors, such as interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 11 (IL-11), stem cell factor (SCF; also known as c-kit ligand or mast cell growth factor), thrombopoietin (TPO) and analogs thereof (including any structural variant of a growth factor that has the biological activity of the native growth factor; see, e.g., WO 2007 / 1145227 and U.S. Patent Publication No. 2010 / 0183564).
[0160] In certain embodiments, the amount or concentration of growth factor suitable for expanding lymphocytes is an amount or concentration effective to promote proliferation. A sufficient number of cells for at least one infusion into a human subject, typically about 10 cells, is preferably about 10%. 4 pieces / kg~10 9 It is preferable to expand the lymphocyte population until cells / kg are obtained.
[0161] The amount or concentration of growth factor suitable for expanding lymphocytes depends on the activity of the growth factor preparation, and the biological species correspondence between the growth factor and lymphocytes. In general, when the growth factor and lymphocytes are derived from the same biological species, the total amount of growth factor in the culture medium is 1 ng / ml to 5 μg / ml, 5 ng / ml to 1 μg / ml, or 5 ng / ml to 250 ng / ml. In a specific embodiment, the amount of growth factor can be 5 to 1000 ng / ml or 50 to 100 ng / ml.
[0162] In a particular embodiment, the growth factors are present under expansion culture conditions at concentrations of 25-300ng / ml SCF, 25-300ng / ml Flt-3L, 25-100ng / ml TPO, 25-100ng / ml IL-6, and 10ng / ml IL-3. In a particular embodiment, 50ng / ml, 100ng / ml, or 200ng / ml SCF, 50ng / ml, 100ng / ml, or 200ng / ml Flt-3L, 50ng / ml, or 100ng / ml TPO, 50ng / ml, or 100ng / ml IL-6, and 10ng / ml IL-3 can be used.
[0163] Lymphocytes can be expanded in tissue culture dishes immobilized with extracellular matrix proteins such as fibronectin (FN) or fragments thereof (e.g., CH-296 (Dao et. al., 1998, Blood 92(12):4612-21) or RetroNectin® (recombinant human fibronectin fragment (Clontech Laboratories, Inc., Madison, WI))).
[0164] Notch agonists appear to be particularly useful for expanding HSCs. In certain embodiments, HSCs can be expanded by exposing them to immobilized Notch agonist and 50 ng / ml or 100 ng / ml SCF, immobilized Notch agonist and 50 ng / ml or 100 ng / ml each of Flt-3L, IL-6, TPO, and SCF, or immobilized Notch agonist and 50 ng / ml or 100 ng / ml each of Flt-3L, IL-6, TPO, and SCF, and 10 ng / ml IL-11 or IL-3.
[0165] Lymphocytes are obtained from a subject as described. In certain embodiments, the hit-and-run modified and expanded lymphocytes are reintroduced in a therapeutically effective amount to the same subject from which the original sample was obtained. In certain embodiments, the hit-and-run modified and expanded lymphocytes are administered in a therapeutically effective amount to another subject. Therapeutically effective amounts are described in more detail elsewhere in this application.
[0166] In these embodiments, the hit-and-run modified and expanded lymphocytes can be formulated as cell-based compositions for administration to a subject. By cell-based compositions, it is meant the expanded cells prepared in a pharma- ceutically acceptable vehicle for administration to a subject. In certain embodiments, the cell compositions are administered to a subject in need thereof as soon as reasonably possible after expansion and formulation for administration are completed.
[0167] In certain embodiments, it may be necessary or beneficial to cryoprotect the cells. The terms "frozen / freezing" and "cryoprotected / cryoprotecting" may be used interchangeably. Freezing includes lyophilization.
[0168] As will be appreciated by those of ordinary skill in the art, freezing of cells can be destructive (see Mazur, P., 1977, Cryobiology 14:251-272), but a number of procedures are available to prevent such damage, for example, by (a) use of cryoprotectants, (b) control of the rate of freezing, and / or (c) storage at temperatures low enough to minimize degradative reactions. Representative cryoprotectants include dimethyl sulfoxide (DMSO) (Lovelock and Bishop, 1959, Nature 183:1394-1395; Ashwood-Smith, 1961, Nature 190:1204-1205), glycerol, polyvinylpyrrolidone (Rinfret, 1960, Ann. NY Acad. Sci. 85:576), polyethylene glycol (Sloviter and Ravdin, 1962, Nature 196:548), albumin, dextran, sucrose, ethylene glycol, i-erythritol, D-ribitol, D-mannitol (Rowe et al., 1962, Fed. Proc. 21:157), D-sorbitol, i-inositol, D-lactose, and choline chloride (Bender et al., 1962, Fed. Proc. 21:157). al., 1960, J. Appl. Physiol. 15:520), amino acids (Phan The Tran and Bender, 1960, Exp. Cell Res. 20:651), methanol, acetamide, glycerol monoacetate (Lovelock, 1954, Biochem. J. 56:265), and inorganic salts (Phan The Tran and Bender, 1960, Proc. Soc. Exp. Biol. Med. 104:388; Phan The Tran and Bender, 1961, in Radiobiology, Proceedings of the Third Australian Conference on Radiobiology, Ilbery ed., Butterworth, London, p.59). In certain embodiments, DMSO can be used. The addition of plasma (e.g., up to 20-25% concentration) can enhance the protective effect of DMSO.Since DMSO at a concentration of 1% can be toxic at temperatures above 4°C, it is advisable to keep the cells at 0°C after addition of DMSO until freezing.
[0169] In cell cryoprotection, slow and controlled cooling rates are considered important, and the optimal cooling rates vary for different cryoprotectants (Rapatz et al., 1968, Cryobiology 5(1):18-25) and different cell types (see, for example, Rowe and Rinfret, 1962, Blood 20:636; Rowe, 1966, Cryobiology 3(1):12-18; Lewis, et al., 1967, Transfusion 7(1):17-32; and Mazur, 1970, Science 168:939-949 for the effect of cooling rate on stem cell survival and its engraftment potential). The heat of fusion, which is the phase transition of water to ice, must be minimized. The cooling procedure can be performed, for example, by using a programmable freezing device or a methanol bath method. A programmable freezing device allows the optimal cooling rate to be determined, facilitating standard and reproducible cooling.
[0170] In a particular embodiment, the DMSO-treated cells are transferred to a tray containing ice-cold, previously cooled, cold methanol and placed in an automated refrigerator (e.g., Harris or Revco) at -80°C. Based on the methanol bath and thermocouple measurements of the samples, a cooling rate of 1-3°C / min appears to be preferable. After at least 2 hours, the samples are allowed to reach a temperature of -80°C and can be introduced directly into liquid nitrogen (-196°C).
[0171] After complete freezing, the cells can be quickly transferred to a long-term cryopreservation container. In certain embodiments, samples can be frozen and stored in liquid nitrogen (-196°C) or vapor (-1°C). Such storage is facilitated by the availability of highly efficient liquid nitrogen cooling equipment.
[0172] For other considerations and procedures regarding cell manipulation, cryoprotection and long-term storage, see representative references: U.S. Pat. Nos. 4,199,022, 3,753,357 and 4,559,298; Gorin, 1986, Clinics In Haematology 15(1):19-48; Bone-Marrow Conservation, Culture and Transplantation, Proceedings of a Panel, Moscow, July 22-26, 1968, International Atomic Energy Agency, Vienna, pp. 107-186; Livesey and Linner, 1987, Nature 327:255; Linner et al. al., 1986, J. Histochem. Cytochem. 34(9):1123-1135; Simone, 1992, J. Parenter. Sci. Technol. 46(6):226-32).
[0173] After cryoprotection, the frozen cells can be thawed for use according to methods known to those of ordinary skill in the art. It is preferred that the frozen cells be thawed quickly and chilled immediately after thawing. In certain embodiments, the frozen cells can be placed in a vial and immersed in a warm water bath up to the neck of the vial, with gentle rotation to mix the cell suspension as it thaws and increase heat transfer from the warm water to the internal ice mass. Once the ice has completely melted, the vial can be immediately transferred to ice.
[0174] In certain embodiments, various methods can be used to prevent cell aggregation during thawing, representative methods include adding DNase before and / or after freezing (Spitzer et al., 1980, Cancer 45:3075-3085), low molecular weight dextrans and citrate, hydroxyethyl starch (Stiff et al., 1983, Cryobiology 20:17-24), etc.
[0175] As will be appreciated by those of ordinary skill in the art, cryoprotectants that are toxic to the human body must be removed prior to therapeutic use. DMSO does not have significant toxicity.
[0176] Representative carriers and modes of administration of cells are described in U.S. Patent Publication No. 2010 / 0183564, pages 14-15. Other pharmaceutical carriers are described in Remington: The Science and Practice of Pharmacy, 21st Edition, David B. Troy, ed., Lippicott Williams & Wilkins (2005).
[0177] In certain embodiments, the cells can be harvested from the culture medium, washed, concentrated, and suspended in a therapeutically effective amount in a medium, representative of which include saline, buffered saline, saline, water, Hank's solution, Ringer's solution, Nonnosol-R (Abbott Labs), Plasma-Lyte A® (Baxter Laboratories, Inc., Morton Grove, Ill.), glycerol, ethanol, and combinations thereof.
[0178] In certain embodiments, the base may be supplemented with human serum albumin (HSA) or other human serum components or fetal bovine serum. In certain embodiments, the infusion base comprises a buffered saline solution supplemented with 5% HSA or dextrose. Other tonicity agents include polyhydric sugar alcohols, such as trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, or mannitol.
[0179] The base may include a buffer such as a citrate buffer, a succinate buffer, a tartrate buffer, a fumarate buffer, a gluconate buffer, an oxalate buffer, a lactate buffer, an acetate buffer, a phosphate buffer, a histidine buffer, and / or a trimethylamine salt.
[0180] Stabilizers are a broad category of pharmaceutical additives that can serve a range of functions, from bulking agents to additives that help prevent cell adhesion to the container wall. Typical stabilizers include polyhydric sugar alcohols; amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, and threonine; organic sugars or sugar alcohols such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myo-inositol, galactitol, glycerol, and cyclitols (e.g., inositol); PEG; amino acid polymers; urea, glutathione; and the like. These include sulfur-containing reducing agents such as thione, thioctic acid, sodium thioglycolate, thioglycerol, α-monothioglycerol and sodium thiosulfate; small polypeptides (i.e. <10 residues); proteins such as HSA, bovine serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides such as xylose, mannose, fructose and glucose; disaccharides such as lactose, maltose and sucrose; trisaccharides such as raffinose; and polysaccharides such as dextran.
[0181] If necessary or beneficial, a local anesthetic such as lidocaine can be added to the cell composition to ease pain at the site of the injection.
[0182] Representative preservatives include phenol, benzyl alcohol, meta-cresol, methylparaben, propylparaben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexamethonium chloride, alkylparabens (e.g., methylparaben and propylparaben), catechol, resorcinol, cyclohexanol, and 3-pentanol.
[0183] The therapeutically effective amount of cells contained in the cell composition is 10 2 Over 10 pieces 3 Over 10 pieces 4 Over 10 pieces 5 Over 10 pieces 6 Over 10 pieces7 Over 10 pieces 8 Over 10 pieces 9 Over 10 pieces 10 More than 10 11 It can be more than one.
[0184] In the cell compositions disclosed herein, the cells are generally contained in a volume of 1 liter or less, 500 mL or less, 250 mL or less, or 100 mL or less. Thus, the density of cells administered is generally less than 10 4 >pcs / ml, 10 7 >10 / ml or 8 More than 100 / ml.
[0185] The cell compositions disclosed herein can be prepared for administration, for example, by injection, infusion, perfusion or lavage. The cell compositions can be further formulated for bone marrow, intravenous, intradermal, intraarterial, intralymphatic, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesical and / or subcutaneous injection.
[0186] Compositions for in vivo use. The nanocarriers disclosed herein can also be formulated as compositions that can be administered directly to a subject for selective targeting and hit-and-run modification in vivo. (As will be appreciated by those skilled in the art, the ex vivo and in vivo approaches described herein are not mutually exclusive and can be performed in combination.) These compositions are referred to herein as nanocarrier-based compositions.
[0187] In certain embodiments, the nanocarriers are provided as part of a nanocarrier composition, which may contain at least 0.1% w / v or w / w nanocarriers, at least 1% w / v or w / w nanocarriers, at least 10% w / v or w / w nanocarriers, at least 20% w / v or w / w nanocarriers, at least 30% w / v or w / w nanocarriers, at least 40% w / v or w / w nanocarriers, at least 50% w / v or w / w nanocarriers, at least 60% w / v or w / w nanocarriers, at least 70% w / v or w / w nanocarriers, at least 80% w / v or w / w nanocarriers, at least 90% w / v or w / w nanocarriers, at least 95% w / v or w / w nanocarriers, or at least 99% w / v or w / w nanocarriers.
[0188] The nanocarrier compositions disclosed herein can be formulated for administration, for example, by injection, inhalation, infusion, irrigation, or oral ingestion. The nanocarrier compositions disclosed herein can further be formulated for intravenous, intradermal, intra-arterial, intra-lymphatic, intra-lymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesical, oral, and / or subcutaneous administration, and more particularly for intravenous, intradermal, intra-arterial, intra-lymphatic, intra-lymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesical, oral, and / or subcutaneous injection.
[0189] For injection, the nanocarrier composition can be formulated as an aqueous solution, such as in a buffer solution including Hank's solution, Ringer's solution, or physiological saline. The aqueous solution can contain formulation additives such as suspending agents, stabilizers, and / or dispersing agents. Alternatively, the nanocarrier composition can be formulated in lyophilized and / or powder form, which is reconstituted with a suitable solvent (e.g., sterile pyrogen-free water) before use.
[0190] For oral administration, the nanocarrier composition can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc. Pharmaceutical additives suitable for oral solid formulations, such as powders, capsules, and tablets, include binders (gum tragacanth, gum arabic, corn starch, gelatin), excipients (sugars, such as lactose, sucrose, mannitol, and sorbitol; dicalcium phosphate, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate; cellulose preparations, such as corn starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidone (PVP)); granulating agents; and binding agents. Disintegrants, such as corn starch, potato starch, alginic acid, crosslinked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof (e.g., sodium alginate), may be added as necessary. If desired, solid dosage forms may be sugar-coated or enteric-coated using standard techniques. Flavoring agents such as peppermint, oil of wintergreen, cherry flavor, orange flavor, and the like may also be used.
[0191] For administration by inhalation, the nanocarrier compositions can be formulated as an aerosol spray from pressurized packs or nebulizers by using a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In the case of a pressurized aerosol, a dosage unit can be dispensed by providing a valve to deliver a metered amount. They can also be formulated as gelatin capsules and cartridges for inhalers or insufflators containing a powder mix of the therapeutic agent and a suitable powder base such as lactose or starch.
[0192] Formulations of all nanocarrier compositions disclosed herein may advantageously contain any other pharma- ceutically acceptable carrier, including those that do not produce significant adverse, allergic, or other untoward reactions that outweigh the benefits of administration, whether for research, prophylactic, and / or therapeutic treatment. Exemplary pharma-ceutically acceptable carriers and formulations are disclosed in Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990. Additionally, formulations may be manufactured to meet sterility, pyrogenicity, general safety, and purity standards as set forth by the U.S. FDA Office of Biological Standards and / or other applicable foreign regulatory agencies.
[0193] Representative commonly used pharma- ceutically acceptable carriers include any and all fillers or excipients, solvents or cosolvents, dispersion media, coatings, surfactants, antioxidants (e.g., ascorbic acid, methionine, and vitamin E), preservatives, isotonicity agents, absorption delaying agents, salts, stabilizers, buffers, chelating agents (e.g., EDTA), gels, binders, disintegrants, and / or lubricants.
[0194] Representative buffers include citrate buffer, succinate buffer, tartrate buffer, fumarate buffer, gluconate buffer, oxalate buffer, lactate buffer, acetate buffer, phosphate buffer, histidine buffer and / or trimethylamine salt.
[0195] Representative preservatives include phenol, benzyl alcohol, meta-cresol, methylparaben, propylparaben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexamethonium chloride, alkylparabens (e.g., methylparaben and propylparaben), catechol, resorcinol, cyclohexanol, and 3-pentanol.
[0196] Representative isotonicity agents include polyhydric sugar alcohols, such as trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, or mannitol.
[0197] Representative stabilizers include organic sugars, polyhydric sugar alcohols, polyethylene glycol, sulfur-containing reducing agents, amino acids, low molecular weight polypeptides, proteins, immunoglobulins, hydrophilic polymers, or polysaccharides.
[0198] The nanocarrier compositions can also be formulated as a depot preparation using suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly soluble salt).
[0199] The nanocarrier composition can also be formulated as a sustained release system using a semipermeable matrix of solid polymers loaded with at least one active ingredient. A variety of sustained release materials are established and known to those skilled in the art. Sustained release systems can release the active ingredient for periods ranging from a few weeks to more than 100 days after administration, depending on their chemical nature.
[0200] Methods of Use. The methods disclosed herein include administering to a subject (human, domestic animal, livestock, and research animal) the cell compositions and nanocarrier compositions disclosed herein. As noted, these compositions can treat a wide variety of conditions ranging from cancer to infectious diseases. These compositions can also be used as vaccine adjuvants.
[0201] Administering to a subject includes delivery of a therapeutically effective amount, which can provide effective, prophylactic and / or therapeutic treatment.
[0202] An "effective amount" is the amount of a compound required to produce a desired physiological change in a subject. For research purposes, an effective amount is often administered. The effective amount disclosed herein changes the phenotype of a cell as a result of gene editing effects or expression of a phenotype-altering protein.
[0203] "Prophylactic treatment" includes treatment administered to a subject who is not showing signs or symptoms of a disease or condition, or who is showing only early signs or symptoms of said disease or condition, for the purpose of suppressing, preventing, or reducing the risk of developing said disease or condition. Thus, prophylactic treatment serves to prevent the onset of a disease or disorder. A vaccine is one example of a prophylactic treatment.
[0204] In certain embodiments, prophylactic treatment is administered to treat a viral infection, such as HIV. For example, the composition can be administered prophylactically to a subject at risk of developing a viral infection or a subject that has been exposed to a virus to prevent, inhibit, or delay the onset of a viral infection or disease. For example, the composition can be administered to a subject that may have been exposed to a virus (e.g., HIV) or is at high risk of being exposed to a virus.
[0205] "Therapeutic treatment" includes treatment administered to a subject who exhibits a symptom or sign of a disease or condition, with the intent of reducing or eliminating said sign or symptom of said disease or condition.
[0206] Prophylactic and therapeutic treatments need not completely prevent or cure a disease or condition but may provide partial efficacy.
[0207] With respect to cancer, a therapeutically effective amount can reduce the number of tumor cells, reduce the number of metastases, reduce tumor volume, increase life expectancy, induce apoptosis in cancer cells, induce cancer cell death, induce drug or radiation sensitivity in cancer cells, inhibit angiogenesis in the vicinity of cancer cells, inhibit cancer cell proliferation, inhibit tumor growth, prevent metastasis, increase the life span of a subject, reduce cancer-related pain, inhibit the number of metastases, and / or inhibit the recurrence or relapse of cancer following treatment.
[0208] With respect to viruses, a therapeutically effective amount can reduce the number of virally infected cells and relieve one or more symptoms associated with viral infection, such as fever, chills, vomiting, joint pain, etc.
[0209] With respect to HIV, a therapeutically effective amount can reduce the number of HIV-infected cells, can increase the number of T cells in a subject, can reduce the incidence, frequency or severity of infections, can increase life expectancy, can extend the lifespan of a subject, and / or can reduce HIV-associated pain or cognitive impairment.
[0210] With respect to vaccine adjuvants, vaccines enhance a subject's immunity against a particular disease, and vaccine adjuvants enhance and / or prolong this enhancement. As will be appreciated by those skilled in the art, the immune system can generally produce innate and adaptive immune responses. Innate immune responses can generally be characterized as not being substantially antigen-specific and / or not producing immune memory. Adaptive immune responses can generally be characterized as being substantially antigen-specific, maturing over time (e.g., increasing affinity and / or avidity for antigen), and generally producing immune memory. Although these and other functional differences between innate and adaptive immunity can be appreciated by those skilled in the art, the innate and adaptive immune systems can be integrated and therefore can act in concert.
[0211] For administration, the therapeutically effective amount (also referred to herein as dose) can be estimated initially based on the results from in vitro assays and / or animal model studies. Such information can be used to more accurately determine useful doses in intended subjects.
[0212] The actual dosage to be administered to a particular subject can be determined by a physician, veterinarian, or researcher, taking into account such parameters as physical and physiological factors, including the target, body weight, severity of the condition, type of disease, previous or concurrent therapeutic interventions, any idiopathic disease of the subject, and the route of administration.
[0213] Useful doses of the cell compositions are described elsewhere in this application. Useful doses of the nanocarrier compositions can include 0.1-5 μg / kg or 0.5-1 μg / kg. In other examples, the nanocarrier composition dose can include, for example, 1 μg / kg, 10 μg / kg, 20 μg / kg, 30 μg / kg, 40 μg / kg, 50 μg / kg, 60 μg / kg, 70 μg / kg, 80 μg / kg, 90 μg / kg, 100 μg / kg, 150 μg / kg, 200 μg / kg, 250 μg / kg, 350 μg / kg, 400 μg / kg, 450 μg / kg, 500 μg / kg, 550 μg / kg, 600 μg / kg, 650 μg / kg, 700 μg / kg, 750 μg / kg, 800 μg / kg, 850 μg / kg, 900 μg / kg, 950 μg / kg, 1000 μg / kg, 0.1-5 mg / kg, or 0.5-1 mg / kg. In other non-limiting examples, doses can include 1 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, 40 mg / kg, 50 mg / kg, 60 mg / kg, 70 mg / kg, 80 mg / kg, 90 mg / kg, 100 mg / kg, 150 mg / kg, 200 mg / kg, 250 mg / kg, 350 mg / kg, 400 mg / kg, 450 mg / kg, 500 mg / kg, 550 mg / kg, 600 mg / kg, 650 mg / kg, 700 mg / kg, 750 mg / kg, 800 mg / kg, 850 mg / kg, 900 mg / kg, 950 mg / kg, 1000 mg / kg or more.
[0214] A therapeutically effective amount can be achieved by single or multiple administrations during the treatment regimen (e.g., once a day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, once a week, once every 2 weeks, once every 3 weeks, once a month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, once every 6 months, once every 7 months, once every 8 months, once every 9 months, once every 10 months, once every 11 months, or once a year).
[0215] Unless otherwise indicated, the practice of the present disclosure may employ conventional immunological, molecular biology, microbiological, cell biology, and recombinant DNA techniques. These methods are described in, for example, Sambrook, et al. Molecular Cloning: A Laboratory Manual, 2nd Edition (1989); FM Ausubel, et al. eds., Current Protocols in Molecular Biology, (1987); Methods IN Enzymology series (Academic Press, Inc.); M. MacPherson, et al., PCR: A Practical Approach, IRL Press at Oxford University Press (1991); MacPherson et al., eds. PCR 2: Practical Approach, (1995); Harlow and Lane, eds. Antibodies, A Laboratory Manual, (1988); and R. I. Freshney, ed. Animal Cell Culture (1987).
[0216] Sequence information provided by public databases can be used to identify target gene sequences and nucleic acid sequences that encode proteins that alter phenotypes as disclosed herein. Representative sequences are shown in FIG.
[0217] Variants of the sequences disclosed and referenced herein are also included. Protein variants can include those that contain one or more conservative amino acid substitutions. As used herein, "conservative substitutions" include substitutions that occur within one of the following conservative substitution groups: Group 1: Alanine (Ala), Glycine (Gly), Serine (Ser), Threonine (Thr); Group 2: Aspartic Acid (Asp), Glutamic Acid (Glu); Group 3: Asparagine (Asn), Glutamine (Gln); Group 4: Arginine (Arg), Lysine (Lys), Histidine (His); Group 5: Isoleucine (Ile), Leucine (Leu), Methionine (Met), Valine (Val); and Group 6: Phenylalanine (Phe), Tyrosine (Tyr), Tryptophan (Trp).
[0218] Amino acids can also be divided into conservative substitution groups according to similar function or chemical structure or composition (e.g., acidic, basic, aliphatic, aromatic, sulfur-containing). For example, the aliphatic group can include, for substitution purposes, Gly, Ala, Val, Leu, and Ile. Other groups containing amino acids that are considered to be conservative substitutions for one another include the sulfur-containing group: Met and cysteine (Cys); the acidic group: Asp, Glu, Asn, and Gln; the small aliphatic non-polar or slightly polar residues group: Ala, Ser, Thr, Pro, and Gly; the polar negatively charged residues and their amides group: Asp, Asn, Glu, and Gln; the polar positively charged residues group: His, Arg, and Lys; the large aliphatic non-polar residues group: Met, Leu, Ile, Val, and Cys; and the large aromatic residues group: Phe, Tyr, and Trp. For further information, see Creighton (1984) Proteins, WH Freeman and Company.
[0219] As noted elsewhere herein, variants of gene sequences include codon optimization variants, sequence polymorphisms, splice variants and / or mutations that do not affect the function of the encoded product to a statistically significant extent.
[0220] Variants of the protein, nucleic acid and gene sequences disclosed herein also include sequences that have at least 70% sequence identity, 80% sequence identity, 85% sequence identity, 90% sequence identity, 95% sequence identity, 96% sequence identity, 97% sequence identity, 98% sequence identity or 99% sequence identity to the protein, nucleic acid or gene sequences disclosed herein.
[0221] "Percent sequence identity" refers to the relationship between two or more sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between protein, nucleic acid, or gene sequences, as determined by the match between strings of such sequences. "Identity" (often referred to as "similarity") can be readily calculated by known methods, including but not limited to those described in Computational Molecular Biology (Lesk, AM, ed.) Oxford University Press, NY (1988); Biocomputing: Informatics and Genome Projects (Smith, DW, ed.) Academic Press, NY (1994); Computer Analysis of Sequence Data, Part I (Griffin, AM, and Griffin, HG, eds.) Humana Press, NJ (1994); Sequence Analysis in Molecular Biology (Von Heijne, G., ed.) Academic Press (1987); and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Oxford University Press, NY (1992). Preferred methods for determining identity are designed to obtain the best match between the sequences tested. Methods for determining identity and similarity are codified in publicly available computer programs. Sequence alignment and percent identity calculation can be performed using the Megalign program in the LASERGENE bioinformatics software package (DNASTAR, Inc., Madison, Wisconsin). Multiple alignment of sequences can also be performed using the Clustal alignment method (Higgins and Sharp CABIOS, 5, 151-153 (1989)) with default parameters (gap penalty=10, gap length penalty=10).Related programs include the GCG program package (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, Wisconsin); BLASTP, BLASTN, BLASTX (Altschul, et al., J. Mol. Biol. 215:403-410 (1990); DNASTAR (DNASTAR, Inc., Madison, Wisconsin); and the FASTA program implementing the Smith-Waterman algorithm (Pearson, Comput. Methods Genome Res., [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Publisher: Plenum, New York, 1999). Also included are the nucleotide sequences of the nucleotides in sequence (Seq. No. 10 / 093,331, published by the National Institute of Informatics, New York, NY). Within the context of this disclosure, it will be understood that when sequence analysis software is used for the analysis, the results of the analysis will be based on the "default values" of the program to which it refers. As used herein, "default values" refers to any set of values or parameters that are initially loaded by the software when it is first initialized.
[0222] Representative embodiment. 1. A method for preparing a selected population of cells derived from the hematopoietic system for administration to a subject, comprising: obtaining from said subject a sample comprising a heterogeneous mixture of cells comprising a selected population of cells derived from the hematopoietic system; (i) a synthetic nucleic acid encapsulated inside a positively charged carrier and encoding a gene editing agent or a phenotype-altering protein; (ii) a neutral or negatively charged coating disposed on the outer surface of the carrier; (iii) a selected cell-targeting ligand protruding from the surface of said coating. selectively delivering the nanocarriers to the selected cell population by exposing the sample to synthetic nanocarriers comprising: expanding cells in said sample; The method thereby prepares the selected cell population for administration to the subject. 2. The method of embodiment 1, wherein the expanded cells in the sample comprise modified cells of the selected cell population. 3. The method of embodiment 1 or 2, further comprising formulating the prepared selected cell population into a cell composition. 4. The method of embodiment 3, further comprising administering the cell composition to the subject. 5. The method of any one of embodiments 1 to 4, wherein the exposing step is preceded by no or limited isolation procedures to increase the percentage of the selected cell population in the heterogeneous cell mixture. 6. The method of any one of embodiments 1 to 5, wherein the synthetic nucleic acid encodes a gene editing agent selected from a Transcription Activator-Like Effector Nuclease (TALEN), a megaTAL, and / or a zinc finger nuclease. 7. The method of embodiment 6, wherein the synthetic nucleic acid encodes a megaTAL of SEQ ID NO:1. 8. The method of any one of embodiments 1-7, wherein the gene editing agent disrupts endogenous genes encoding Shp-1 phosphatase, PD1 receptor, T cell receptor (TCR), CCR5, and / or CXCR4. 9. The method of any one of embodiments 1 to 8, wherein the gene editing agent disrupts an endogenous gene encoding a TCR alpha chain. 10. The method of any one of the preceding embodiments, wherein the synthetic nucleic acid encodes a phenotype-altering protein selected from a transcription factor, a kinase and / or a cell surface receptor. 11. The method of embodiment 10, wherein the phenotype-altering protein is selected from FOXO1, LKB1, TCF7, EOMES, ID2, TERT, CCR2b and / or CCR4. 12. The method of any one of embodiments 1-11, wherein the selected cell targeting ligand selectively binds to lymphocytes within a heterogeneous cell population. 13. The method of embodiment 12, wherein said heterogeneous cell population is an ex vivo cell culture. 14. The method of embodiment 12, wherein the heterogeneous cell population is in vivo. 15. The method of any one of embodiments 1-14, wherein the selected cell targeting ligand selectively binds to T cells, NK cells, monocytes, macrophages, dendritic cells, B cells, hematopoietic stem cells, or a combination thereof. 16. The method of any one of embodiments 1-15, wherein the selected cell targeting ligand comprises a binding domain selected from a lymphocyte receptor ligand, a lymphocyte receptor antibody, a lymphocyte receptor peptide aptamer, a lymphocyte receptor nucleic acid aptamer, a lymphocyte receptor spiegelmer, or a combination thereof. 17. The selected cell targeting ligand is selected from the group consisting of T cell receptor motif, T cell alpha chain, T cell beta chain, T cell gamma chain, T cell delta chain, CCR7, CD1a, CD1b, CD1c, CD1d, CD3, CD4, CD5, CD7, CD8, CD11b, CD11c, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD34, CD35, CD39, CD40, CD45RA, CD45RO, CD46, CD52, The method of any one of embodiments 1 to 16, wherein the antibody selectively binds to CD56, CD62L, CD68, CD69, CD80, CD86, CD95, CD101, CD117, CD127, CD133, CD137(4-1BB), CD148, CD163, CD209, DEC-205, F4 / 80, IL-4Rα, Sca-1, CTLA-4, GITR, GARP, LAP, granzyme B, LFA-1, or transferrin receptor. 18. The method of any one of embodiments 1 to 17, wherein the selected cell targeting ligand selectively binds CD1a, CD1b, CD1c, CD1d, CCR7, CD3, CD4, CD5, CD8, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD35, CD40, CD45RA, CD45RO, CD46, CD52, CD69, CD62L, CD80, CD95, CD127, CD137, CD209 or DEC-205. 19. The selected cell targeting ligand is a T cell alpha chain antibody, a T cell beta chain antibody, a T cell gamma chain antibody, a T cell delta chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD1 antibody. 1b antibody, CD11c antibody, CD16 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, CD56 19. The method of any one of embodiments 1 to 18, comprising a binding domain selected from an antibody, a CD62L antibody, a CD68 antibody, a CD69 antibody, a CD80 antibody, a CD86 antibody, a CD95 antibody, a CD101 antibody, a CD117 antibody, a CD127 antibody, a CD133 antibody, a CD137(4-1BB) antibody, a CD148 antibody, a CD163 antibody, a CD209 antibody, a DEC-205 antibody, an F4 / 80 antibody, an IL-4Rα antibody, a Sca-1 antibody, a CTLA-4 antibody, a GITR antibody, a GARP antibody, a LAP antibody, a Granzyme B antibody, an LFA-1 antibody, or a Transferrin Receptor antibody. 20. The binding domain is a T cell α chain antibody, a T cell β chain antibody, a T cell γ chain antibody, a T cell δ chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD11b antibody, a CD11c antibody, a CD 16 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, CD56 antibody, CD62L antibody, CD68 antibody 20. The method according to any one of embodiments 1 to 19, wherein the scFv fragment of the antibody is a CD69 antibody, a CD80 antibody, a CD86 antibody, a CD95 antibody, a CD101 antibody, a CD117 antibody, a CD127 antibody, a CD133 antibody, a CD137(4-1BB) antibody, a CD148 antibody, a CD163 antibody, a CD209 antibody, a DEC-205 antibody, an F4 / 80 antibody, an IL-4Rα antibody, a Sca-1 antibody, a CTLA-4 antibody, a GITR antibody, a GARP antibody, a LAP antibody, a Granzyme B antibody, an LFA-1 antibody, or a Transferrin Receptor antibody. 21. The method of any one of the preceding embodiments, wherein the synthetic nucleic acid is a synthetic mRNA. 22. The method of any one of the preceding embodiments, wherein the carrier comprises a positively charged lipid or polymer. 23. The method of embodiment 22, wherein the positively charged polymer comprises poly(β-amino ester), poly(L-lysine), poly(ethyleneimine) (PEI), poly(amidoamine) dendrimer (PAMAM), amine-ester copolymer, poly(dimethylaminoethyl methacrylate) (PDMAEMA), chitosan, L-lactide-L-lysine copolymer, poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA) or poly(4-hydroxy-L-proline ester) (PHP). 24. The method of any one of the preceding embodiments, wherein the coating comprises a neutral or negatively charged lipid or polymer. 25. The method of embodiment 24, wherein the neutral or negatively charged coating comprises polyglutamic acid (PGA), poly(acrylic acid), alginic acid, or cholesteryl hemisuccinate / 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine. 26. The method of embodiment 24 or 25, wherein the neutral or negatively charged coating comprises a zwitterionic polymer. 27. The method of any one of embodiments 24 to 26, wherein the neutral or negatively charged coating comprises liposomes. 28. The method of embodiment 27, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammoniumpropane (DOTMA), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), dioctadecylamidoglycylspermine (DOGS), cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). 29. The method of any one of embodiments 1 to 28, wherein the selected cell targeting ligand selectively binds CD4 and / or CD8. 30. The method of any one of the preceding embodiments, wherein the selected cell targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody. 31. The method according to any one of the preceding embodiments, wherein the selected cell-targeting ligand comprises a binding domain selected from an scFv fragment of a CD4 antibody and / or a CD8 antibody. 32. The method of any one of the preceding embodiments, wherein the carrier comprises a poly(β-amino ester). 33. The method of any one of the preceding embodiments, wherein the coating comprises polyglutamic acid (PGA). 34. The method of any one of the preceding claims, wherein the selected cell-targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody, the carrier comprises a poly(β-amino ester), and the coating comprises polyglutamic acid (PGA). 35. A method for preparing cells for treating a subject, comprising: Recovering lymphocytes from a subject; and (i) a synthetic nucleic acid encapsulated inside a positively charged carrier and encoding a gene editing agent or a phenotype-altering protein; (ii) a neutral or negatively charged coating disposed on the outer surface of the carrier; (iii) a selected cell targeting ligand protruding from the surface of said coating; and binding said lymphocytes to a synthetic nanocarrier comprising: The method further comprising selectively endocytosing the nanocarriers into lymphocytes such that, after binding, the lymphocytes transiently express the nucleic acid. 36. The method of embodiment 35, further comprising the step of expanding the lymphocytes. 37. The method of embodiment 35 or 36, further comprising formulating the lymphocytes into a cell composition. 38. The method of any one of embodiments 35 to 37, wherein the exposing step is preceded by no or limited isolation procedures to increase the percentage of the selected cell population in the heterogeneous cell mixture. 39. The method of any one of embodiments 35 to 38, wherein the synthetic nucleic acid encodes a gene editing agent selected from a Transcription Activator-Like Effector Nuclease (TALEN), a megaTAL and / or a zinc finger nuclease. 40. The method of any one of embodiments 35 to 39, wherein the synthetic nucleic acid encodes a megaTAL of SEQ ID NO:1. 41. The method of any one of embodiments 35-40, wherein the gene editing agent disrupts endogenous genes encoding Shp-1 phosphatase, PD1 receptor, T cell receptor (TCR), CCR5 and / or CXCR4. 42. The method of any one of embodiments 35 to 41, wherein the gene editing agent disrupts an endogenous gene encoding a TCR alpha chain. 43. The method of any one of embodiments 35 to 42, wherein the synthetic nucleic acid encodes a phenotype-altering protein selected from a transcription factor, a kinase and / or a cell surface receptor. 44. The method of embodiment 43, wherein the phenotype-altering protein is selected from FOXO1, LKB1, TCF7, EOMES, ID2, TERT, CCR2b and / or CCR4. 45. The method of any one of embodiments 35-44, wherein the selected cell targeting ligand selectively binds to lymphocytes within a heterogeneous cell population. 46. The method of embodiment 45, wherein the heterogeneous cell population is an ex vivo cell culture. 47. The method of embodiment 45, wherein the heterogeneous cell population is in vivo. 48. The method of any one of embodiments 35-47, wherein the selected cell targeting ligand selectively binds to T cells, NK cells, monocytes, macrophages, dendritic cells, B cells, hematopoietic stem cells, or a combination thereof. 49. The method of any one of embodiments 35 to 48, wherein the selected cell targeting ligand comprises a binding domain selected from a lymphocyte receptor ligand, a lymphocyte receptor antibody, a lymphocyte receptor peptide aptamer, a lymphocyte receptor nucleic acid aptamer, a lymphocyte receptor spiegelmer, or a combination thereof. 50. The selected cell targeting ligand is selected from the group consisting of T cell receptor motif, T cell alpha chain, T cell beta chain, T cell gamma chain, T cell delta chain, CCR7, CD1a, CD1b, CD1c, CD1d, CD3, CD4, CD5, CD7, CD8, CD11b, CD11c, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD34, CD35, CD39, CD40, CD45RA, CD45RO, CD46, CD52, C The method of any one of embodiments 35 to 49, wherein the antibody selectively binds to D56, CD62L, CD68, CD69, CD80, CD86, CD95, CD101, CD117, CD127, CD133, CD137(4-1BB), CD148, CD163, CD209, DEC-205, F4 / 80, IL-4Rα, Sca-1, CTLA-4, GITR, GARP, LAP, granzyme B, LFA-1, or transferrin receptor. 51. The method of any one of embodiments 35 to 50, wherein the selected cell targeting ligand selectively binds to CD1a, CD1b, CD1c, CD1d, CCR7, CD3, CD4, CD5, CD8, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD35, CD40, CD45RA, CD45RO, CD46, CD52, CD62L, CD69, CD80, CD95, CD127, CD137, CD209 or DEC-205. 52. The selected cell targeting ligand is a T cell alpha chain antibody, a T cell beta chain antibody, a T cell gamma chain antibody, a T cell delta chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD11 antibody. b antibody, CD11c antibody, CD16 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, CD56 antibody 52. The method of any one of embodiments 35 to 51, comprising a binding domain selected from an antibody, a CD62L antibody, a CD68 antibody, a CD69 antibody, a CD80 antibody, a CD86 antibody, a CD95 antibody, a CD101 antibody, a CD117 antibody, a CD127 antibody, a CD133 antibody, a CD137(4-1BB) antibody, a CD148 antibody, a CD163 antibody, a CD209 antibody, a DEC-205 antibody, an F4 / 80 antibody, an IL-4Rα antibody, a Sca-1 antibody, a CTLA-4 antibody, a GITR antibody, a GARP antibody, a LAP antibody, a Granzyme B antibody, an LFA-1 antibody, or a Transferrin Receptor antibody. 53. The binding domain is a T cell α chain antibody, a T cell β chain antibody, a T cell γ chain antibody, a T cell δ chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD11b antibody, a CD11c antibody, a CD 16 antibodies, CD19 antibodies, CD20 antibodies, CD21 antibodies, CD22 antibodies, CD25 antibodies, CD28 antibodies, CD34 antibodies, CD35 antibodies, CD39 antibodies, CD40 antibodies, CD45RA antibodies, CD45RO antibodies, CD46 antibodies, CD52 antibodies, CD56 antibodies, CD62L antibodies, CD68 antibodies, The method according to any one of embodiments 35 to 52, which consists of or consists essentially of an scFv fragment of an antibody, such as a CD69 antibody, a CD80 antibody, a CD86 antibody, a CD95 antibody, a CD101 antibody, a CD117 antibody, a CD127 antibody, a CD133 antibody, a CD137(4-1BB) antibody, a CD148 antibody, a CD163 antibody, a CD209 antibody, a DEC-205 antibody, an F4 / 80 antibody, an IL-4Rα antibody, a Sca-1 antibody, a CTLA-4 antibody, a GITR antibody, a GARP antibody, an LAP antibody, a Granzyme B antibody, an LFA-1 antibody or a Transferrin Receptor antibody. 54. The method of any one of embodiments 35 to 53, wherein the synthetic nucleic acid is a synthetic mRNA. 55. The method of any one of embodiments 35 to 54, wherein the carrier comprises a positively charged lipid or polymer. 56. The method of embodiment 55, wherein the positively charged lipid or polymer comprises poly(β-amino ester), poly(L-lysine), poly(ethyleneimine) (PEI), poly(amidoamine) dendrimer (PAMAM), amine-ester copolymer, poly(dimethylaminoethyl methacrylate) (PDMAEMA), chitosan, L-lactide-L-lysine copolymer, poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA) or poly(4-hydroxy-L-proline ester) (PHP). 57. The method of any one of embodiments 35-56, wherein the coating comprises a neutral or negatively charged lipid or polymer. 58. The method of embodiment 57, wherein the neutral or negatively charged coating comprises polyglutamic acid (PGA), poly(acrylic acid), alginic acid, or cholesteryl hemisuccinate / 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine. 59. The method of embodiment 57 or 58, wherein the neutral or negatively charged coating comprises a zwitterionic polymer. 60. The method of any one of embodiments 57 to 59, wherein the neutral or negatively charged coating comprises liposomes. 61. The method of embodiment 60, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammoniumpropane (DOTMA), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), dioctadecylamidoglycylspermine (DOGS), cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). 62. The method of any one of embodiments 35-61, wherein the selected cell targeting ligand selectively binds CD4 and / or CD8. 63. The method of any one of embodiments 35 to 62, wherein the selected cell targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody. 64. The method of any one of embodiments 35 to 63, wherein the selected cell-targeting ligand comprises a binding domain selected from an scFv fragment of a CD4 antibody and / or a CD8 antibody. 65. The method of any one of embodiments 35-64, wherein the carrier comprises a poly(β-amino ester). 66. The method of any one of embodiments 35-65, wherein the coating comprises polyglutamic acid (PGA). 67. The method of any one of embodiments 35 to 66, wherein the selected cell-targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody, the carrier comprises a poly(β-amino ester), and the coating comprises polyglutamic acid (PGA). 68. A method of treating a subject in need of treatment, comprising: (i) a synthetic nucleic acid encapsulated inside a positively charged carrier and encoding a gene editing agent or a phenotype-altering protein; (ii) a neutral or negatively charged coating disposed on the outer surface of the carrier; (iii) a selected cell targeting ligand protruding from the surface of said coating; and administering a therapeutically effective amount of the cells modified by the transient expression of the nucleic acid selectively delivered to the cells by a nanocarrier comprising: The method of treating the subject in need thereof by selectively incorporating the nanocarrier into lymphocytes such that, after binding, the lymphocytes transiently express the nucleic acid. 69. A method for preparing a selected cell population for administration to a subject, comprising: obtaining a sample from said subject comprising a heterogeneous mixture of cells comprising a selected cell population; (i) a synthetic nucleic acid encapsulated inside a positively charged carrier and encoding a gene editing agent or a phenotype-altering protein; (ii) a neutral or negatively charged coating disposed on the outer surface of the carrier; (iii) a selected cell targeting ligand protruding from the surface of said coating; and selectively delivering the nanocarriers to the selected cell population by exposing the sample to a synthetic nanocarrier comprising: expanding cells in said sample; The method thereby prepares the selected cell population for administration to the subject. 70. (i) A synthetic nucleic acid that is encapsulated inside a positively charged carrier and that encodes a gene editing agent or a phenotype-altering protein; (ii) a neutral or negatively charged coating disposed on the outer surface of the carrier; (iii) a selected cell targeting ligand protruding from the surface of said coating; and A synthetic nanocarrier comprising: 71. The synthetic nanocarrier described in embodiment 70, wherein the synthetic nucleic acid encodes a gene editing agent selected from transcription activator-like effector nucleases (TALENs), megaTALs and / or zinc finger nucleases. 72. A synthetic nanocarrier described in embodiment 70 or 71, wherein the synthetic nucleic acid encodes a megaTAL of sequence number 1. 73. The synthetic nanocarrier of any one of embodiments 70 to 72, wherein the gene editing agent disrupts endogenous genes encoding Shp-1 phosphatase, PD1 receptor, T cell receptor (TCR), CCR5 and / or CXCR4. 74. A synthetic nanocarrier described in any one of embodiments 70 to 73, wherein the gene editing agent disrupts an endogenous gene encoding the TCR alpha chain. 75. A synthetic nanocarrier described in any one of embodiments 70 to 74, wherein the synthetic nucleic acid encodes a phenotype-altering protein selected from a transcription factor, a kinase and / or a cell surface receptor. 76. The synthetic nanocarrier of embodiment 75, wherein the phenotype-altering protein is selected from FOXO1, LKB1, TCF7, EOMES, ID2, TERT, CCR2b and / or CCR4. 77. A synthetic nanocarrier described in any one of embodiments 70 to 76, wherein the selected cell targeting ligand selectively binds to lymphocytes within a heterogeneous cell population. 78. The synthetic nanocarrier described in embodiment 77, wherein the heterogeneous cell population is an ex vivo cell culture. 79. The synthetic nanocarrier described in embodiment 77, wherein the heterogeneous cell population is in vivo. 80. The synthetic nanocarrier described in any one of embodiments 70 to 79, wherein the selected cell targeting ligand selectively binds to T cells, NK cells, monocytes, macrophages, dendritic cells, B cells, hematopoietic stem cells, or a combination thereof. 81. A synthetic nanocarrier described in any one of embodiments 70 to 80, wherein the selected cell targeting ligand comprises a binding domain selected from a lymphocyte receptor ligand, a lymphocyte receptor antibody, a lymphocyte receptor peptide aptamer, a lymphocyte receptor nucleic acid aptamer, a lymphocyte receptor spiegelmer or or a combination thereof. 82. The selected cell targeting ligand is selected from the group consisting of T cell receptor motif, T cell alpha chain, T cell beta chain, T cell gamma chain, T cell delta chain, CCR7, CD1a, CD1b, CD1c, CD1d, CD3, CD4, CD5, CD7, CD8, CD11b, CD11c, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD34, CD35, CD39, CD40, CD45RA, CD45RO, CD46, CD52, CD5 6. The synthetic nanocarrier according to any one of embodiments 70 to 81, which selectively binds to CD62L, CD68, CD69, CD80, CD86, CD95, CD101, CD117, CD127, CD133, CD137(4-1BB), CD148, CD163, CD209, DEC-205, F4 / 80, IL-4Rα, Sca-1, CTLA-4, GITR, GARP, LAP, granzyme B, LFA-1 or transferrin receptor. 83. The synthetic nanocarrier according to any one of embodiments 70 to 82, wherein the selected cell targeting ligand selectively binds to CD1a, CD1b, CD1c, CD1d, CCR7, CD3, CD4, CD5, CD8, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD35, CD40, CD45RA, CD45RO, CD46, CD52, CD62L, CD69, CD80, CD95, CD127, CD137, CD209 or DEC-205. 84. The selected cell targeting ligand is a T cell alpha chain antibody, a T cell beta chain antibody, a T cell gamma chain antibody, a T cell delta chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD11b antibody. Antibody, CD11c antibody, CD16 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, CD56 antibody, 84. The synthetic nanocarrier according to any one of embodiments 70 to 83, comprising a binding domain selected from a CD62L antibody, a CD68 antibody, a CD69 antibody, a CD80 antibody, a CD86 antibody, a CD95 antibody, a CD101 antibody, a CD117 antibody, a CD127 antibody, a CD133 antibody, a CD137(4-1BB) antibody, a CD148 antibody, a CD163 antibody, a CD209 antibody, a DEC-205 antibody, an F4 / 80 antibody, an IL-4Rα antibody, a Sca-1 antibody, a CTLA-4 antibody, a GITR antibody, a GARP antibody, an LAP antibody, a Granzyme B antibody, an LFA-1 antibody or a Transferrin Receptor antibody. 85. The binding domain is a T cell α chain antibody, a T cell β chain antibody, a T cell γ chain antibody, a T cell δ chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD11b antibody, a CD11c antibody, a CD1 6 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, CD56 antibody, CD62L antibody, CD68 antibody, CD 85. The synthetic nanocarrier according to any one of embodiments 70 to 84, which consists of or consists essentially of an scFv fragment of an antibody, such as a CD40 antibody, a CD80 antibody, a CD86 antibody, a CD95 antibody, a CD101 antibody, a CD117 antibody, a CD127 antibody, a CD133 antibody, a CD137(4-1BB) antibody, a CD148 antibody, a CD163 antibody, a CD209 antibody, a DEC-205 antibody, an F4 / 80 antibody, an IL-4Rα antibody, a Sca-1 antibody, a CTLA-4 antibody, a GITR antibody, a GARP antibody, an LAP antibody, a Granzyme B antibody, an LFA-1 antibody or a Transferrin Receptor antibody. 86. The synthetic nanocarrier of any one of embodiments 70 to 85, wherein the synthetic nucleic acid is a synthetic mRNA. 87. A synthetic nanocarrier described in any one of embodiments 70 to 86, wherein the carrier comprises a positively charged lipid or polymer. 88. The synthetic nanocarrier described in embodiment 87, wherein the positively charged lipid or polymer comprises poly(β-amino ester), poly(L-lysine), poly(ethyleneimine) (PEI), poly(amidoamine) dendrimer (PAMAM), amine-ester copolymer, poly(dimethylaminoethyl methacrylate) (PDMAEMA), chitosan, L-lactide-L-lysine copolymer, poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA) or poly(4-hydroxy-L-proline ester) (PHP). 89. A synthetic nanocarrier described in any one of embodiments 70 to 88, wherein the coating comprises a neutral or negatively charged lipid or polymer. 90. The synthetic nanocarrier of embodiment 89, wherein the neutral or negatively charged coating comprises polyglutamic acid (PGA), poly(acrylic acid), alginic acid or cholesteryl hemisuccinate / 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine. 91. The synthetic nanocarrier described in embodiment 89 or 90, wherein the neutral or negatively charged coating comprises a zwitterionic polymer. 92. A synthetic nanocarrier described in any one of embodiments 89 to 91, wherein the neutral or negatively charged coating comprises a liposome. 93. The synthetic nanocarrier of embodiment 92, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammoniumpropane (DOTMA), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), dioctadecylamidoglycylspermine (DOGS), cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). 94. A synthetic nanocarrier described in any one of embodiments 70 to 93, wherein the selected cell targeting ligand selectively binds to CD4 and / or CD8. 95. A synthetic nanocarrier described in any one of embodiments 70 to 94, wherein the selected cell-targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody. 96. A synthetic nanocarrier described in any one of embodiments 70 to 95, wherein the selected cell-targeting ligand comprises a binding domain selected from an scFv fragment of a CD4 antibody and / or a CD8 antibody. 97. The synthetic nanocarrier of any one of embodiments 70 to 96, wherein the carrier comprises a poly(β-amino ester). 98. The synthetic nanocarrier of any one of embodiments 70 to 97, wherein the coating comprises polyglutamic acid (PGA). 99. A synthetic nanocarrier described in any one of embodiments 70 to 98, wherein the selected cell targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody, the carrier comprises a poly(β-amino ester), and the coating comprises polyglutamic acid (PGA). 100. A composition comprising a synthetic nanocarrier described in any one of embodiments 70 to 99. 101. A method for treating a subject in need of treatment, comprising administering to the subject in need of treatment a therapeutically effective amount of a synthetic nanocarrier described in any one of embodiments 70 to 99 or a composition described in embodiment 100. 102. Use of the nanocarriers disclosed herein for selectively delivering a nucleic acid encoding a CAR or TCR to a selected cell type. EXAMPLES
[0223] [Example 1] Introduction. Inducing an immune response against cancer by genetically engineering T cells to express chimeric antigen receptors (CARs) or T cell receptors (TCRs) is a therapeutic approach that is beginning to show great promise and is about to enter major clinical trials. Bioengineering T cells into "living drugs" that can expand in numbers, sequentially destroy tumor cells, and ultimately differentiate into long-lived memory T cells requires stable integration of receptor transgenes into the genome of lymphocytes. Viral vectors, although time-consuming and expensive to generate and limited in the size and number of genes they can package, are currently the most effective means to program these cells with tailored tumor recognition capabilities (Zhang et al., Nat Commun 6, 7639 (2015); Cribbs et al., BMC Biotechnol 13, 98 (2013)).
[0224] Apart from these chronic gene expression systems, it is also possible to induce phenotypic changes in cells by transient expression of macromolecules targeted by a "hit-and-run" mechanism. In most of these transient applications, permanent expression of therapeutic transgenes is undesirable and potentially dangerous (Wurm et al., Exp Hematol 42, 114-125 e114 (2014)), such as the use of transcription factors to regulate cell differentiation (Themeli et al., Nat Biotechnol 31, 928-933 (2013); Costa et al., Development 142, 1948-1959 (2015)) or the expression of sequence-specific nucleases to manipulate the genome (Cox et al., Nat Med 21, 121-131 (2015)).
[0225] Although there are an increasing number of applications in which transient gene therapy can substantially improve the therapeutic potential of engineered T cells, currently available methods (which, like the chronic expression methods mentioned above, mainly rely on viral vectors) are made difficult by the complex protocols required to perform transduction and their expense (Nightingale et al., Mol Ther 13, 1121-1132 (2006)). Electroporation has been developed as an alternative transfection method, but these approaches are not suitable for large-scale applications because mechanical permeabilization of the plasma membrane reduces T cell viability. Moreover, like viral methods, electroporation does not allow selective transfection of specific cell types in a heterogeneous pool, so a prior cell purification step is required.
[0226] This example describes a nanoreagent that induces transient gene expression in cultured T cells without the need for complicated protocols or complex support equipment. Appropriately designed mRNA nanocarriers can deliver functional macromolecules to lymphocytes in a dose-controlled manner by simply mixing the reagent with the cells in vitro (Figure 1A).
[0227] These nanoparticles (NPs) can bind to target cell subtypes and stimulate receptor-mediated endocytosis, allowing the transfer of synthetic mRNA loaded onto these particles and the expression of the encoded molecules in lymphocytes. This method is rapid and efficient, as transgene nuclear transport and transcription are not required. At least two examples are presented to illustrate how this novel platform can be implemented to produce superior CAR-T cell products for clinical use. In the first application example, targeted mRNA nanocarriers were used as a genome editing tool in T cells. Delivery of mRNA encoding the infrequently cleaving megaTAL nuclease (Boissel et al., Methods Mol Biol 1239, 171-196 (2015)) can efficiently disrupt T cell receptor expression by lymphocytes. In the second application, we transiently expressed Foxo1, a key regulator that reprograms effector cells to functional memory cells (Tejera, et al., J Immunol 191, 187-199 (2013); Kim et al., Immunity 39, 286-297 (2013)), and found that exposure to engineered nanoparticles transformed T cells to a central memory phenotype.
[0228] The greatest advantage of this system is that genetic modification of therapeutic cells can be easily performed on a clinical scale, simply by mixing the appropriate nanoparticle reagent with lymphocytes. The present approach is in clear contrast to currently used approaches for transient delivery of genetic material, which are limited in availability due to their low efficacy and the requirement of many specialized and expensive steps that are under proprietary. In addition to T cell therapy, this transient gene delivery platform could be easily integrated into existing preparation methods for other therapeutic cell types (e.g. natural killer cells, dendritic cells, hematopoietic stem cells or mesenchymal stem cells) to substantially improve their healing potential without increasing the operation time, risk or complexity.
[0229] Materials and Methods. Study Design. The objective of this project was to develop nanomaterials for in vitro targeted mRNA delivery to primary T cells. Pilot experiments were performed using cells from individual donors to optimize nanocarrier delivery for specific applications, followed by iterative optimization protocols using samples from multiple donors.
[0230] PBAE447 synthesis. This polymer was synthesized using a method similar to that described by Mangraviti et al. (Mangraviti et al., ACS Nano 9, 1236-1249 (2015)). 1,4-butanediol diacrylate was mixed with 4-amino-1-butanol in a diacrylate to amine monomer molar ratio of 1.1:1. The mixture was heated to 90°C under stirring for 24 hours to obtain an acrylate-terminated copolymer of 4-amino-1-butanol and 1,4-butanediol diacrylate. 2.3 g of this polymer was dissolved in 2 ml of tetrahydrofuran (THF). To form the piperazine-capped 447 polymer, 786 mg of 1-(3-aminopropyl)-4-methylpiperazine was dissolved in 13 ml of THF and added to the polymer / THF solution. The resulting mixture was stirred at room temperature for 2 hours, after which the capped polymer was precipitated with 5 volumes of ethyl ether. After decanting the solvent, the polymer was washed with 2 volumes of fresh ether and then dried under vacuum for 2 days until use to form a 100 mg / ml DMSO stock and stored at -20°C.
[0231] PGA-Antibody Conjugation. 15 kD polyglutamic acid (Alamanda Polymers) was dissolved in water to 20 mg / ml and sonicated for 10 min. An equal volume of 4 mg / ml aqueous solution of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Thermo Fisher) was added and the solution was mixed at room temperature for 5 min. The resulting activated PGA was then added to the antibody in phosphate buffered saline (PBS) at a 4:1 molar ratio and mixed at room temperature for 6 h. To remove unbound PGA, the solution was dialyzed against a 50,000 NMWCO membrane (Millipore) with three changes of PBS. Antibody concentrations were measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific). Antibodies used for T cell experiments were anti-CD3 (clone OKT3), anti-CD4 (clone OKT4), anti-CD8 (clone OKT8) and anti-CD28 (clone 9.3, all BioXCell). Clone C1.18.4 was used as a control antibody. For HSC transfer, polyclonal goat anti-mouse IgG and polyclonal goat anti-mouse CD105 antibodies (Fisher) were used.
[0232] mRNA synthesis. Codon-optimized mRNAs for eGFP, Foxo1, Trex2, and TRAC-megaTAL were produced by TriLink Biotechnologies and were fully substituted with the modified ribonucleotides pseudouridine (Ψ) and 5-methylcytidine (m5C) and capped with ARCA. To track delivery of these transcripts, eGFP mRNA modified with Ψ and m5C was labeled with Cy5 (also by TriLink).
[0233] Nanoparticle fabrication. The mRNA stock was diluted to 100 μg / ml in sterile nuclease-free 25 mM sodium acetate buffer (NaOAc) at pH 5.2. A DMSO solution of PBAE-447 polymer was diluted to 6 mg / ml in NaOAc and added to the mRNA in a 60:1 (w:w) ratio. The resulting mixture was vortexed at medium speed for 15 seconds and then incubated at room temperature for 5 minutes to allow NP formation. To add targeting elements to the nanoparticles, the PGA-linked antibody was diluted to 250 μg / ml in NaOAc and added to the mRNA in a 2.5:1 (w:w) ratio. The resulting mixture was vortexed at medium speed for 15 seconds and then incubated at room temperature for 5 minutes to allow PGA-Ab to bind to the NPs.
[0234] The nanoparticles were mixed with 60 mg / ml D-sucrose as a cryoprotectant, flash frozen in liquid nitrogen, and then lyophilized by processing in a FreeZone 2.5 L freeze-drying system (Labconco). The lyophilized NPs were stored at -80°C until use. At the time of use, the lyophilized NPs were resuspended in a large amount of sterile water to restore the original concentration.
[0235] Nanoparticle characterization. The hydrodynamic radius of the prepared particles was measured with a Nanosite (Malvern) and their zeta potential was determined using dynamic light scattering detected with a Zetapals instrument (Brookhaven Instrument Corporation). For size measurements, the particles were diluted 1:400 (v / v) in PBS (pH 7.4) and for zeta potential measurements, they were diluted 1:40. For transmission electron microscopy examination, 25 μl samples of nanoparticles were each added to carbon / formvar coated 200 mesh copper grids activated by glow discharge. After 30 s, the grids were contacted sequentially with one drop of 1 / 2 Karnovsky fixative, one drop of 0.1 M cacodylate buffer, eight drops of dH2O, and one drop of 1% (w / v) filtered uranyl acetate. The samples were examined using a JEOL JEM-1400 transmission electron microscope (JEOL USA).
[0236] Cell lines and culture media. K562-CD19 and control K562 cells were provided by Dr. Stanley Riddell (Fred Hutchinson Cancer Research Center). TM-LCL is an EBV-transformed CD19+ lymphoblastoid cell line optimized for use as a feeder for T cell expansion cultures (36). Jurkat-E6 T cell line was obtained from the American Type Culture Collection. These cell lines were cultured in T cell medium (TCM) in RPMI-1640 supplemented with 10% fetal bovine serum, 0.8 mM L-glutamine, 25 mM HEPES buffer, and 1% penicillin-streptomycin.
[0237] Primary human peripheral blood mononuclear cells (PBMCs) and T cells were cultured in TCM or ImmunoCult-XF T cell expansion medium (XFSFM) (Stemcell) supplemented with 50 IU IL-2 / ml (Preprotech) as indicated individually.
[0238] T cell mRNA transfection. Cryoprotected PBMCs from normal donors were thawed by dropwise addition of warmed TCM and then centrifuged. Where indicated, CD8 T cells were isolated by negative selection (Stemcell). Cells were cultured at 10 6 Cells were cultured at 100x the number of cells / ml and stimulated with CD3 / CD28 beads (Dynabeads, Life Technologies) at a bead:cell ratio of 1:1. For experiments with CD3-targeted nanoparticle transduction, the beads were removed 24 h prior to NP addition.
[0239] For transfection with NP, T cells were cultured in XFSFM at 2 × 10 6 The cells were resuspended to a concentration of 10 cells / ml. 6Antibody-targeted NPs loaded with 2.5 μg of mRNA per NP were added to the suspension and exposed for 2 hours at 37°C, after which the cells were washed with 3 volumes of TCM+IL-2. Control NPs were loaded with eGFP mRNA. TCRα gene editing NPs were loaded with TRAC-megaTAL, Trex2 and eGFP mRNA in a ratio of 42:42:16 w:w:w. Foxo1 3A NP has Foxo1 3A and eGFP mRNA was carried at a ratio of 84:16 w:w.
[0240] For electroporation, 2 × 10 T cells were cultured in PBS supplemented with 0.5% bovine serum albumin (BSA). 6 Cells were washed twice, resuspended in 100 μl of T cell electroporation medium (Lonza) supplemented with 3 μg of eGFP mRNA, transferred to an electroporation cuvette, and processed with a Nucleofector (Lonza) device using program T-20. Electroporated cells were transferred to plates containing 2 ml of TCM+IL-2 without antibody.
[0241] NP transduction of CD34+ cells. CD34+ cells purified from PBSCs previously mobilized from normal donors were obtained from the Hematopoietic Cell Processing and Storage Core Facility at Fred Hutchinson Cancer Research Center. After thawing, cells were counted and then cultured in StemSpan SFEMII serum-free medium (Stemcell Technologies) supplemented with 50 ng / ml human stem cell factor (Scf), 50 ng / ml mouse Flt3 / Flk-2 ligand, and 25 ng / ml human thrombopoietin as HSC medium for 10 min. 6 The next day, cells were harvested, counted, and plated in 96-well tissue culture plates (Costar) at 2.5 × 10 cells per well in 100 μl of cytokine-free HSC. 4Cells were either left untreated or treated with CD105-targeted NPs or anti-mouse-targeted control NPs loaded with 1 μg eGFP mRNA per well. Cells were treated with NPs for 1 h and then washed twice with 1 ml of cytokine-free HSC medium. The washed cells were then transferred to 500 μl of complete HSC medium in 24-well tissue culture plates and after 48 h, cells were labeled for CD34 and CD105 (BioLegend) for analysis by flow cytometry.
[0242] PCR amplification and indel detection of TCRα. Indel detection was performed using the Geneart Genomic Cleavage Detection Kit (Invitrogen) according to the manufacturer's instructions. Briefly, T cells were lysed and genomic DNA flanking the TCRα MegaTAL target site was amplified by PCR using the TRAC forward primer CCCGTGTCATTCTCTGGACT (SEQ ID NO: 53) and the TRAC reverse primer ATCACGAGCAGCTGGTTTCT (SEQ ID NO: 54). PCR products were denatured, reannealed, and treated with detection enzymes so that indel formation could be assessed by comparing the gel band density of the specifically cleaved bands with that of the germline.
[0243] Lentiviral transduction and expansion of T cells with 19-41BBζ CAR. A human anti-CD19 CAR construct (19-41BBζ) containing 41BB and CD3ζ signaling domains was modified with a single StrepTag as previously described (Liu et al., Nat Biotechnol 34, 430-434 (2016)) and transduced into an epHIV7 lentiviral vector. VSVG pseudotyped lentivirus was generated by calcium phosphate transfection (Invitrogen) of Lenti-X293T cells (Clontech) using the epHIV7 lentiviral vector and viral packaging plasmids pCMVdR8.91 and pMD2.G. For lentiviral transduction, T cells were transferred to RetroNectin-coated plates (Takara) with 8 μg / ml polybrene and lentivirus encoding 19-41BBζ-CAR at an MOI of 5:1, followed by spin infection at 800 × g for 1 h at 34 °C. To selectively expand 19-41BBζ-transduced cells, lymphocytes were stimulated with irradiated (7000 rad) CD19+TM-LCL cells at a ratio of 1:7 in TCM+IL-2.
[0244] Cell sorting and flow cytometry. Data were acquired using a BD LSRFortessa or FacsCanto II cell analyzer running FACSDIVA software, sorted on a BD FACS ARIA-II, and analyzed with FlowJo v10.1. Antibodies used for flow cytometry are listed in Figure 2.
[0245] Intracellular cytokine staining. Cells were cultured for 6 h in TCM supplemented with Brefeldin A 3 μg / ml ± PMA 20 ng / ml and ionomycin (Sigma-Aldrich) 1 μg / ml. Before fixation, anti-CD8 and anti-CD3 staining were used to identify TCR+CD8+ and TCR-CD8+ cell subsets. Cells were then treated with a fixation and permeabilization kit (BD Biosciences) and labeled with anti-IFN-γ and IL-2 mAb (BioLegend).
[0246] Intracellular staining of Foxo1. Anti-CD3-targeted NPs carrying 3 μg of eGFP mRNA or 2.5 μg of Foxo13A and 0.5 μg of eGFP mRNA were injected into 10 Jurkat T cells. 6 After 24 hours, cells were fixed with 4% paraformaldehyde in PBS, washed once, and permeabilized with 90% ice-cold methanol for 30 minutes. The samples were blocked with 0.5% BSA in PBS at room temperature and then stained with rabbit anti-Foxo1 (clone C29H4) or isotype (clone DAE1), followed by anti-rabbit IgG F(aB')2 Alexa-647 (Cell Signaling).
[0247] CAR T cell killing assay. Specific cell lysis of CAR target cells was assayed by flow cytometry. Target K562-CD19 cells and control K562 were labeled with low (0.4 μM) and high (4.0 μM) concentrations of carboxyfluorescein succinimidyl ester (CFSE), respectively, for 15 min at 37°C. Both samples were washed with complete medium supplemented with serum, mixed in a 1:1 ratio, and then co-cultured with 19-41BBζ at the indicated effector:target ratio. To assess specific cell lysis, samples from each condition were stained with anti-CD8 mAb (BioLegend) to identify T cells and 7AAD to exclude dead cells, and analyzed by flow cytometry. Specific cell killing was assessed by measuring the ratio of live CD19+ target cells (low CFSE) to control CD19-K562 cells (high CFSE).
[0248] Microscopic examination. T cells 10 61 were added to 400 μl of XFSFM and treated with anti-CD3 targeted NPs carrying 3 μg of cy5-labeled eGFP mRNA for 1 h at 4° C. for surface binding and then incubated at 37° C. for 2 h for internalization. After these treatments, cells were washed three times with cold PBS and attached to poly-L-lysine (Sigma)-coated slides for 30 min at 4° C. Samples were fixed with 2% paraformaldehyde, mounted with ProLong Gold Antifade reagent (Invitrogen), and imaged on a Zeiss LSM780NLO confocal laser scanning microscope.
[0249] RNA purification, RT-PCR, sequencing, and bioinformatics analysis. After lysis of T cells with Trizol reagent (Ambion), total RNA was isolated using the DirectZol kit (Zymo) with on-column DNA digestion method according to the manufacturer's instructions. For real-time quantitative PCR (qPCR), cDNA was generated using a High Capacity cDNA Kit (Applied Biosystems). The relative expression levels of endogenous FOXO1 and codon-optimized FOXO13A to the housekeeping gene B2M were measured using the PrimeTime qPCR assay (Integrated DNA technology) and the QuantStudio5 system (Applied Biosystems). The primers used to detect codon-optimized Foxo13A were selected to avoid cross-detection of endogenous Foxo1 mRNA. Foxo13A forward: GGACAGCCTAGAAAGAGCAG (SEQ ID NO: 55) Foxo13A probe: AGGTCGGCGTAGCTCAGATTGC (SEQ ID NO: 56) Foxo13A reverse: CTCTTGACCATCCACTCGTAG (SEQ ID NO:57).
[0250] For RNAseq analysis, RNA samples were isolated from in vitro cultured control NP- and Foxo13ANP-treated CD8+ cells after 3 and 8 days and compared to sorted reference naïve (CD8+CD45RA+CD62L+CCR7+) and TCM (CD8+CD45RA-CD62L+CCR7+) cells derived from two independent donor-matched cryoprotected PBMC samples. RNAseq libraries were prepared using the TruSeq sample preparation kit (Illumina) according to the manufacturer's instructions. Libraries were sequenced (paired-end method) for 50 cycles using the HiSeq platform (Illumina). Results that passed Illumina's base call quality filter against the human hg38 genome were aligned using TopHat v2.1.0. Counts for each gene were obtained using htseq-count (v0.6.1p1) in "intersection-strict" overlap mode. Data normalization and expression variation analysis were performed using the GLM method in edgeR. The TCM signature gene set was defined as the top 500 genes with high (TCM up) and low (TCM down) expression in CD8+ TCMs compared to donor-matched control NP-treated CD8+ T cells on day 8, ranked by statistical significance. Gene set enrichment was analyzed by GSEAPreranked software using the gene list ranked by the sign of fold variation × 1 / (p-value) (37). Raw and analyzed data from RNAseq analysis have been deposited in NCBI's Gene Expression Omnibus, GEO series accession number GSE89134 (38).
[0251] Statistical analysis. Unless otherwise stated, graphs show the mean ± standard deviation of the mean. Statistical analysis was performed using Prism software (Graphpad).
[0252] Results. Design of mRNA nanocarriers to produce robust transgene expression in T cells. To create a reagent capable of genetically modifying primary T lymphocytes (commonly known to be refractory to non-viral transfection methods), we bioengineered polymeric nanoparticles (Figure 1B) that contain four functional components: (i) a surface-tethered targeting ligand that selectively binds the nanoparticles to T cells and initiates rapid receptor-induced endocytosis for internalization. Anti-CD3 and anti-CD8 antibodies were used in this experiment; (ii) a negatively charged coating that protects the nanoparticles to minimize off-target binding by reducing the nanoparticles' surface charge. Polyglutamic acid (PGA) was chosen for this purpose since it is already widely used in drug delivery platforms; and (iii) a carrier matrix that functions to compact the nucleic acid and protect it from enzymatic degradation when it is in the endosome, but releases the nucleic acid and allows transcription of the encoded protein once the particle is transported into the cytoplasm. For this purpose, we used biodegradable poly(β-amino ester) (PBAE) polymer formulations with half-lives of 1-7 hours under aqueous conditions. (iv) Nucleic acids encapsulated inside the carrier resulting in gene editing or transient expression of proteins capable of permanently altering the phenotype of T cells. Since mRNA does not pose a risk of genomic integration and does not require nuclear localization for expression, it is an ideal platform for the transient expression of therapeutic proteins. However, unmodified mRNA can activate intracellular toll-like receptors, thus limiting protein expression and leading to toxicity (Kariko et al., Immunity 23, 165-175 (2005)). To improve the stability and reduce immunogenicity of delivered mRNA, we used synthetic products incorporating modified nucleotides. For example, the replacement of uridine and cytidine with the artificial bases pseudouridine and 5-methylcytidine synergistically blocks recognition by natural pattern recognition receptors and favors mRNA translation.
[0253] A two-step charge-driven self-assembly method was used to fabricate the NPs. First, the positively charged PBAE polymer and synthetic mRNA were complexed to compact the mRNA into nanosized complexes (Figures 3A, 3B). Following this step, antibody-PGA conjugates were added to protect the positive charge of the PBAE-mRNA particles and confer lymphocyte targeting capabilities. The resulting mRNA nanocarriers had dimensions of 109.6 ± 26.6 nm and a nearly neutral surface charge (zeta potential 1.1 ± 5.3 mV, Figure 3C).
[0254] The mRNA nanocarriers achieve T cell transfection efficiency comparable to electroporation without compromising viability. As the goal is to streamline cell therapy production, we tested whether the addition of targeted mRNA nanocarriers to existing human lymphocyte cultures is sufficient to reliably transfect them. When CD3-targeted NPs loaded with mRNA encoding a reporter (enhanced green fluorescent protein, eGFP) were incubated with these cells, the NPs not only bind to these cells but are also able to stimulate receptor-mediated endocytosis and transfer the particle-loaded gene (Figure 4A). A single addition of NPs (NP:T cell ratio = 2 × 10 4 After 1:1), 85% of these primary T cells (Figure 4B) were stably transfected, with transgene expression observed as early as 5 h post-transfection (Figure 5A). Thus, this method is rapid and efficient. Importantly, it does not require fresh preparation of mRNA NPs for each addition, and they can be lyophilized until use without any change in their properties or efficacy (Figure 5B).
[0255] We next evaluated the effect of mRNA-loaded targeted NPs on T cell expansion. Because malignancies often progress rapidly, it is important to be able to rapidly expand engineered T cells to a clinically relevant scale. One approach that is widely used to expand polyclonal lymphocytes in clinical laboratories is to incubate beads coated with antibodies against the TCR / CD3 and costimulatory CD28 receptors. NPs targeting CD3 (NP:T cell ratio: 2 × 10 4 Repeated transfection with 100 μg / ml of ...
[0256] Nanoparticle transfection is integrally integrated into the CAR-T cell manufacturing workflow to perform efficient genome editing. By incorporating NP-mediated mRNA transfection into the manufacturing of leukemia-specific 19-41BBζ CAR T cells, this approach was tested in a clinically relevant application (Figure 7A). Receptors targeting CD19 are currently the most explored CAR-T cell products, with approximately 30 clinical trials ongoing both domestically and internationally (Sadelain et al., J Clin Invest 125, 3392-3400 (2015)). If genome engineering could be performed in addition to this, it would be possible to improve the safety and efficacy of CAR-T cells. For example, the expression of endogenous TCR could be eliminated to avoid graft-versus-host disease. Furthermore, immune checkpoint genes can be selectively deleted to enhance their activity in an immunosuppressive tumor environment (Menger et al., Cancer Res 76, 2087-2093 (2016); Torikai et al., Blood 119, 5697-5705 (2012)). However, the use of electroporation to deliver genome editing agents to cells makes the scale-up of T cell manufacturing substantially difficult. Therefore, we measured the ability of NPs to deliver gene editing agents by creating particles targeted to the constant region of the TCRα gene (TRAC) and loaded with mRNA encoding megaTAL nuclease. Taking advantage of the versatility offered by the NP formulation method, we loaded mRNA encoding the DNA repair endonuclease TREX2 to improve knockout efficiency and also loaded eGFP mRNA to track transfection. Control particles were loaded with eGFP mRNA only. In contrast to eGFP transfection (no change in TCR expression; Fig. 7B, top), addition of TCRα-megaTAL particles to T cell cultures efficiently disrupted TCR expression by day 5, an effect that persisted through day 12, even after loss of mRNA (Fig. 7B, bottom). The mean TCR concentration was 60.8% (± 17.7%; Fig. 7C) compared to control, consistent with the percentage indel frequency (a measure of targeting efficiency) determined using the Surveyor assay (Fig. 7D).Importantly, the presence of mRNA-loaded nanoparticles did not affect viral gene delivery of tumor-specific CAR, as evidenced by comparable transduction efficiency of lentiviral vectors encoding 19-41BBζ CAR in NP-transfected and non-transfected T cells (Figure 7E). After NP-mediated genome editing and lentiviral transduction, CAR-programmed T cells fully maintained their proliferation, cytokine secretion, and ability to kill leukemic target cells (Figures 7F-7H). Altogether, these results demonstrate that lymphocyte-targeted mRNA nanocarriers can achieve efficient genome editing of CAR-T cells without compromising their function.
[0257] NP delivery of mRNA encoding the transcription factor Foxo1 imprints memory CAR-T cells. We therefore investigated whether lymphocyte-targeted mRNA NPs could improve the therapeutic activity of CAR-T cells by delivering mRNA that programs these cells to a preferred phenotype. Clinical results have already demonstrated that T cell products derived from CD62L+ central memory T cells (TCM) show improved engraftment and function in animal models, and the success of CAR therapy is related to the proportion of CD62L+ TCM phenotype cells in the infused product (Louis et al., Blood 118, 6050-6056 (2011); Sommermeyer et al., Leukemia 30, 492-500 (2016)). However, to reach therapeutically adequate lymphocyte numbers, these cells must be subjected to several in vitro stimulation / expansion steps that drive cells from the TCM lineage toward terminal differentiation and senescence (Wang et al., Journal of immunotherapy 35, 689-701 (2012)). To address this issue, we engineered NPs to target T cells carrying mRNA encoding Foxo1, a forkhead family transcription factor that regulates effector-to-memory transition in CD8 T cells (Tejera, et al., J Immunol 191, 187-199 (2013); Kim et al., Immunity 39, 286-297 (2013)). During in vitro stimulation / expansion, TCR and cytokine signaling activate AKT kinase. This enzyme phosphorylates Foxo1, resulting in its cytoplasmic segregation and inhibition of transcriptional activity. To maintain Foxo1 in cultured T cells, we used an AKT-insensitive mutant of the factor in which three key phosphorylation residues were mutated to alanine (Foxo13A). We hypothesized that adding Foxo13A-loaded NPs to T cell culture medium during ex vivo expansion would promote the generation of CD62L+ TCM cells with improved therapeutic potential. The effect of transcription factors on reprogramming varies depending on the strength and duration of their expression.To determine these values after Foxo13A-NP addition, we measured Foxo1 protein and mRNA expression in nanoparticle-treated cells. In the Jurkat T cell line, endogenous expression of Foxo1 was low, and total expression of the factor, measured by intracellular labeling, was significantly increased after Foxo13A NP treatment (Figure 8A, left panel). In primary T cells, Foxo1 protein expression levels were high and only slightly increased by Foxo13A-NP. Thus, it is concluded that near-physiological levels of active Foxo13A transcription factor can be induced by NP treatment (Figure 8A, right panel). To investigate the mRNA dynamics after NP transfection in activated and proliferating T cells, we measured Foxo13A expression using real-time quantitative PCR specific for artificial mRNA. mRNA expression was maximal on day 1 and approached baseline by day 8 post-transfection (Figure 8B). In vitro treatment with Foxo13A NPs after T cell priming rapidly increased expression of CD62L (Sallusto et al., Nature 401, 708-712 (1999)), a primary surface marker that distinguishes TCMs from effector and effector memory populations (Figure 8C). To examine whether transient expression of Foxo13A can produce lasting changes in CD8+ T cell differentiation, cells from three separate donors were treated with CD8-targeting Foxo13A-eGFP NPs, sorted based on eGFP expression, and maintained in vitro. An increase in CD62L+ cell frequency was observed within 24 hours after transfection, which was maintained even 8–20 days after NP addition (Figure 8D).
[0258] To elucidate the gene regulatory network induced by Foxo13A and its relationship to the TCM lineage, we performed RNASeq on ex vivo isolated naive CD8 T cells, TCM CD8 T cells, and in vitro cultured CD8 T cells after treatment with NPs encoding Foxo13A or control particles. We identified a TCM signature (Figure 8E and Figure 9A) consisting of the top 500 genes with high and low TCM expression compared to the average CD8 T cells. The majority of these genes were synchronously regulated in naive CD8 T cells, consistent with the close transcriptional relationship between naive and TCM (Kaech & Cui, Immunol 12, 749-761 (2012)). Treatment with NPs encoding Foxo13A resulted in the differential expression of a large number of genes. As expected, these genes included those encoding KLF2, a major memory transcriptional effector, and those encoding the surface molecules SELL (CD62L), CD28, and S1PR1, all of which are important mediators of CD8 TCM trafficking and function (Figure 8F) (Skon et al., Nature immunology 14, 1285-1293 (2013); Boesteanu et al., Seminars in immunology 21, 69-77 (2009)). Overlaying the TCM gene signature onto a Foxo13A volcano plot reveals good transcript concordance. TCM signature genes were upregulated in Foxo13A-programmed CD8 cells. Gene set enrichment analysis confirmed a strong association between Foxo13A-regulated transcripts and TCM-related gene expression (Figure 9B). Taken together, these results demonstrate that NP encoding Foxo13A induces sustained changes in surface markers and transcriptional programming toward a TCM-like phenotype.
[0259] Discussion: This example demonstrates that appropriately designed mRNA nanocarriers can transiently program gene expression in primary lymphocytes. Specifically, we demonstrate memory phenotype induction and therapeutic genome editing, and show how the simple addition of bioengineered nanoparticles to T cell cultures can permanently reprogram cell function and / or differentiation. Because this nanotechnology platform does not require special cell manipulation, it can be easily integrated into existing therapeutic T cell manufacturing protocols without changing the workflow or process equipment. This would provide a significant manufacturing advantage over RNA electroporation, which is currently the method of choice for hit-and-run gene therapy in T cells (Schumann et al., Proc Natl Acad Sci USA 112, 10437-10442 (2015); Wang et al., Nucleic Acids Res 44, e30 (2016); Bai et al., Cell Discovery, (2015)). As shown in Figure 2, electroporation requires many medium changes, centrifugation steps, and washing cycles, in addition to the need for expensive equipment. Each of these steps is error-prone, increasing the risk of contamination and reducing the production of disease-fighting lymphocytes. Even state-of-the-art flow electroporation equipment reduces T cell viability and therefore product yield and quality (Koh et al., Mol Ther Nucleic Acids 2, e114 (2013); Liu et al., Cancer Res 75, 3596-3607 (2015)). Our approach does not rely on mechanical permeabilization of cell membranes to deliver transgenes. Instead, engineered nanoparticles bind to T cells and stimulate receptor-mediated endocytosis, a physiological process that achieves the introduction of RNA loaded on the particles without reducing cell viability (Figure 4C).
[0260] Cell-penetrating peptides (CPPs), small proteins that facilitate the cellular uptake of various molecular cargoes, have also been used to deliver therapeutic agents to primary T cells (Copolovici, ACS Nano 8, 1972-1994 (2014)). Using this approach, even large proteins can be delivered to the cytoplasm by adding a CPP domain. However, CPPs do not allow specific targeting of selected cell types, and protein delivery is relatively inefficient (Liu et al., PLoS One 9, e85755 (2014); Liu et al., Mol Ther Nucleic Acids 4, e232 (2015)). The duration of therapeutic effect also strongly depends on the half-life of the delivered protein. In comparison, nanocarriers loaded with synthetic mRNA can be targeted to specific cells, with every delivered RNA molecule serving as a translation template for multiple protein copies.
[0261] The CD3 and CD8 molecules targeted in these experiments are just two of many antigens that can be used to selectively shuttle mRNA into lymphocytes. To selectively modify only certain T cell subsets, such as lymphocytes exposed to antigens, activation markers (e.g., CD25, 4-1BB, OX40 or CD40L) can be targeted. Furthermore, there is flexibility in the choice of core polymer and charge-neutralizing coating materials, which will likely be optimized before clinical-scale manufacturing occurs. For the core polymer, various cationic polymers, including hyperbranched star polymers, polyethylene glycol-grafted polyethyleneimine, and mesoporous silica nanoparticles, were tested, and PBAE447 was selected due to its excellent transfection efficiency and low biomaterial-induced cytotoxicity in primary T cells. This formulation has a half-life of 1-7 hours under aqueous conditions and is highly biodegradable, resulting in low cytotoxicity (Mangraviti et al., ACS Nano 9, 1236-1249 (2015)). This half-life is ideal for gene therapy, as the polymer compacts while trapped within endosomes, effectively protecting the mRNA from degradation, but quickly releases it after delivery to the cytoplasm, allowing transcription of the encoded protein. Importantly, all nanoparticle designs tested required a negatively charged nanoparticle coating to counteract the positive charge of the RNA / PBAE polyplexes and prevent off-target binding.
[0262] In addition to T cell therapy, we have also explored using the approach described herein to generate more effective hematopoietic stem cell (HSC) products using CD105-targeted mRNA nanocarriers (Figure 10). In particular, strategies to improve the self-renewal capacity of HSCs or to modulate their fate decisions have great clinical appeal (Galeev et al., Cell Rep 14, 2988-3000 (2016); Rentas et al., Nature 532, 508-511 (2016)). In the field of adoptive T cell therapy, pharmacologically active compounds are being tested as adjuvants to produce lymphocytes with improved longevity and / or in vivo efficacy, but also small molecules capable of modifying stem cell expansion have been identified by high-throughput screening of libraries (Nikiforow & Ritz, Cell Stem Cell 18, 10-12 (2016)). However, many compounds can only inhibit protein function and their specificity for the desired target is often questionable (Schenone et al., Nat Chem Biol 18, 10-12 (2016)). 9, 232-240 (2013)). In addition, it is not possible to regulate various proteins using small molecules. In contrast, targeted mRNA nanocarriers can selectively induce the expression of almost any known protein (or protein combination). Furthermore, the nucleotides to be loaded onto the nanocarriers can be easily prepared based on published sequences.
[0263] In summary, Example 1 demonstrates that T cells can be efficiently reprogrammed for therapeutic purposes using "hit-and-run" genetic modification by simply adding a single nanoparticle reagent to white blood cell cultures. This platform does not require specialized equipment or training, thus reducing manufacturing complexity. Thus, it can substantially streamline the manufacturing of gene and cell therapy drugs at clinical scale, making treatment of patients with genetically engineered T cells more widely applicable at lower cost.
[0264] As will be apparent to those of ordinary skill in the art, each embodiment disclosed herein can comprise, consist essentially of, or consist of the particular elements, steps, ingredients, or components specified. As used herein, the transitional term "comprising" means including but not limited to, and allows for the inclusion of elements, steps, ingredients, or components not specifically recited, even in greater amounts. The transitional term "consisting of" excludes elements, steps, ingredients, or components not specifically recited. The transitional term "consisting essentially of" limits the scope of the embodiment to the elements, steps, ingredients, or components specifically recited and those elements, steps, ingredients, or components that do not have a significant effect on the embodiment. As used herein, a significant effect is one that results in a statistically significant decrease in the ability of the nanocarriers disclosed herein to alter the phenotype of the selected cell type after 48 hours of exposure of the selected cell type to the nanocarriers.
[0265] Unless otherwise indicated, all numerical values expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and the like used in the specification and claims are to be understood as being preceded by the term "about." Accordingly, unless otherwise indicated, the numerical parameters set forth in the specification and claims are approximations and may vary depending upon the desired properties sought to be obtained by the present invention. Without intending to limit the application of the doctrine of equivalents to the scope of the claims, at the very least, each numerical parameter should be construed in light of at least the reported significant digits and by applying ordinary rounding techniques. Where further clarity is required, the term "about" when used in conjunction with a stated numerical value or range is given the meaning reasonably assigned by one of ordinary skill in the art, i.e., to a numerical value or range somewhat greater or smaller than the stated value or range, up to within ±20% of the stated value, ±19% of the stated value, ±18% of the stated value, ±17% of the stated value, ±16% of the stated value, ±15% of the stated value, ±14% of the stated value, ±13% of the stated value, ±12% of the stated value, ±11% of the stated value, ±10% of the stated value, ±9% of the stated value, ±8% of the stated value, ±7% of the stated value, ±6% of the stated value, ±5% of the stated value, ±4% of the stated value, ±3% of the stated value, ±2% of the stated value, or ±1% of the stated value.
[0266] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible, with the proviso that any numerical value inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0267] In the context of describing the present invention (particularly in the context of the claims below), the indefinite articles, definite articles, and similar referents should be construed to cover both the singular and the plural, unless otherwise specified herein or the context clearly dictates otherwise. Numerical ranges described herein are merely intended to serve as a shorthand method of referring to each individual value falling within the range. Unless otherwise specified herein, each individual value is incorporated herein as if it were individually set forth herein. All methods described herein can be performed in any suitable order, unless otherwise specified herein or the context clearly dictates otherwise. The use of any and all examples or exemplary language (e.g., "such as") described herein is for the purpose of clarifying the invention only and does not limit the scope of the invention as otherwise claimed. No language in this specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0268] Groups of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements described herein. One or more members of a group may be incorporated into or deleted from a group for reasons of convenience and / or patentability. When such an incorporation or deletion is made, the specification is deemed to include the modified group and therefore satisfies the full Markush group language used in the appended claims.
[0269] Certain embodiments of the invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become readily apparent to those of ordinary skill in the art after reading the above description. The inventors anticipate that such variations will be utilized by those of ordinary skill in the art, and the inventors also anticipate that the invention may be practiced otherwise than as specifically described herein. Accordingly, the present invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto to the extent permitted by applicable law. Moreover, the present invention includes any combination of the above-described elements in all possible variations thereof unless otherwise specified herein or otherwise apparent from the context.
[0270] Additionally, various patents and publications are cited throughout this specification. Each of the above cited patents and publications is individually incorporated herein by reference for the specific teachings cited therein.
[0271] Finally, it should be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the invention. Other variations that may be utilized are within the scope of the invention. In short, for example and not by way of limitation, alternative configurations of the invention may be utilized in accordance with the teachings of the present application. Thus, the invention is not limited to that precisely as shown and described.
[0272] The details shown in this application are exemplary and are presented only for the purpose of illustrating the preferred embodiments of the present invention, and are presented merely to provide what is believed to be the most useful and easily understood explanation of the principles and conceptual aspects of various embodiments of the present invention. In this regard, it is not intended to show the configuration of the present invention in more detail than is necessary for a fundamental understanding of the present invention, and it will be readily understood by those skilled in the art by considering the description in conjunction with the drawings and / or examples how the various forms of the present invention can be actually embodied.
[0273] The definitions and explanations used in this disclosure shall apply to all subsequent sentences unless clearly or obviously changed in the following examples or if the application of the meaning would be syntactically or essentially meaningless. If the syntactically or essentially meaningless of a term is used, a definition should be found in a dictionary known to those of ordinary skill in the art, such as Webster's Dictionary, 3rd Edition or Oxford Dictionary of Biochemistry and Molecular Biology (Ed. Anthony Smith, Oxford University Press, Oxford, 2004).
Claims
1. 1. A method for preparing a selected population of cells derived from the hematopoietic system for administration to a subject, comprising: obtaining from said subject a sample comprising a heterogeneous mixture of cells comprising a selected population of cells derived from the hematopoietic system; (i) a synthetic nucleic acid encapsulated inside a positively charged carrier and encoding a gene editing agent or a phenotype-altering protein; (ii) a neutral or negatively charged coating provided on the outer surface of the carrier; (iii) a selected cell targeting ligand protruding from the surface of said coating; and selectively delivering the nanocarriers to the selected cell population by exposing the sample to a synthetic nanocarrier comprising: expanding cells in said sample; The method thereby prepares the selected cell population for administration to the subject.
2. The method of claim 1 , wherein the selected cell targeting ligand selectively binds to lymphocytes within a heterogeneous cell population and initiates receptor-induced endocytosis.
3. 2. The method of claim 1, wherein the expanded cells in the sample comprise modified cells of the selected cell population.
4. 10. The method of claim 1, further comprising formulating the prepared selected cell population into a cell composition.
5. The method of claim 4 , further comprising the step of administering the cell composition to the subject.
6. 2. The method of claim 1, wherein the exposing step is preceded by no or limited isolation procedures to increase the percentage of the selected cell population in the heterogeneous cell mixture.
7. 2. The method of claim 1, wherein the synthetic nucleic acid encodes a gene editing agent selected from a transcription activator-like effector nuclease (TALEN), a megaTAL and / or a zinc finger nuclease.
8. The method of claim 7, wherein the synthetic nucleic acid encodes the megaTAL of SEQ ID NO:
1.
9. 2. The method of claim 1, wherein the gene editing agent disrupts an endogenous gene encoding Shp-1 phosphatase, PD1 receptor, T cell receptor (TCR), CCR5, and / or CXCR4.
10. 2. The method of claim 1, wherein the gene editing agent disrupts an endogenous gene encoding a TCR alpha chain.
11. 2. The method of claim 1, wherein the synthetic nucleic acid encodes a phenotype-altering protein selected from a transcription factor, a kinase and / or a cell surface receptor.
12. 11. The method of claim 10, wherein the phenotype-altering protein is selected from FOXO1, LKB1, TCF7, EOMES, ID2, TERT, CCR2b and / or CCR4.
13. The method of claim 1 , wherein the selected cell targeting ligand selectively binds to lymphocytes within a heterogeneous cell population and initiates receptor-induced endocytosis.
14. 14. The method of claim 13, wherein the heterogeneous cell population is an ex vivo cell culture.
15. The method of claim 13, wherein the heterogeneous cell population is in vivo.
16. 2. The method of claim 1, wherein the selected cell targeting ligand selectively binds to T cells, NK cells, monocytes, macrophages, dendritic cells, B cells, hematopoietic stem cells, or a combination thereof.
17. 2. The method of claim 1, wherein the selected cell targeting ligand comprises a binding domain selected from a lymphocyte receptor ligand, a lymphocyte receptor antibody, a lymphocyte receptor peptide aptamer, a lymphocyte receptor nucleic acid aptamer, a lymphocyte receptor spiegelmer, or a combination thereof.
18. The selected cell targeting ligand may be a T cell receptor motif, a T cell alpha chain, a T cell beta chain, a T cell gamma chain, a T cell delta chain, CCR7, CD1a, CD1b, CD1c, CD1d, CD3, CD4, CD5, CD7, CD8, CD11b, CD11c, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD34, CD35, CD39, CD40, CD45RA, CD45RO, CD46, C The method of claim 1, wherein the antibody selectively binds to D52, CD56, CD62L, CD68, CD69, CD80, CD86, CD95, CD101, CD117, CD127, CD133, CD137 (4-1BB), CD148, CD163, CD209, DEC-205, F4 / 80, IL-4Rα, Sca-1, CTLA-4, GITR, GARP, LAP, granzyme B, LFA-1, or transferrin receptor.
19. 2. The method of claim 1, wherein the selected cell targeting ligand selectively binds to CD1a, CD1b, CD1c, CD1d, CCR7, CD3, CD4, CD5, CD8, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD35, CD40, CD45RA, CD45RO, CD46, CD52, CD69, CD62L, CD80, CD95, CD127, CD137, CD209 or DEC-205.
20. The selected cell targeting ligand is a T cell α chain antibody, a T cell β chain antibody, a T cell γ chain antibody, a T cell δ chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, and a CD1 antibody. 1b antibody, CD11c antibody, CD16 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, 2. The method of claim 1, comprising a binding domain selected from a CD56 antibody, a CD62L antibody, a CD68 antibody, a CD69 antibody, a CD80 antibody, a CD86 antibody, a CD95 antibody, a CD101 antibody, a CD117 antibody, a CD127 antibody, a CD133 antibody, a CD137 (4-1BB) antibody, a CD148 antibody, a CD163 antibody, a CD209 antibody, a DEC-205 antibody, an F4 / 80 antibody, an IL-4Rα antibody, a Sca-1 antibody, a CTLA-4 antibody, a GITR antibody, a GARP antibody, a LAP antibody, a granzyme B antibody, an LFA-1 antibody, or a transferrin receptor antibody.
21. The binding domain is a T cell α chain antibody, a T cell β chain antibody, a T cell γ chain antibody, a T cell δ chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD11b antibody, a CD11c antibody, a CD 16 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, CD56 antibody, CD62L antibody, CD6 2. The method of claim 1, wherein the scFv fragment of the scFv fragment is selected from the group consisting of an scFv fragment of a CD4 antibody, a CD5 antibody, a CD69 antibody, a CD80 antibody, a CD86 antibody, a CD95 antibody, a CD101 antibody, a CD117 antibody, a CD127 antibody, a CD133 antibody, a CD137 (4-1BB) antibody, a CD148 antibody, a CD163 antibody, a CD209 antibody, a DEC-205 antibody, an F4 / 80 antibody, an IL-4Rα antibody, a Sca-1 antibody, a CTLA-4 antibody, a GITR antibody, a GARP antibody, a LAP antibody, a granzyme B antibody, a LFA-1 antibody, or a transferrin receptor antibody.
22. The method of claim 1 , wherein the synthetic nucleic acid is a synthetic mRNA.
23. The method of claim 1 , wherein the carrier comprises a positively charged lipid or polymer.
24. 23. The method of claim 22, wherein the positively charged polymer comprises poly(β-amino ester), poly(L-lysine), poly(ethyleneimine) (PEI), poly(amidoamine) dendrimer (PAMAM), amine-ester copolymer, poly(dimethylaminoethyl methacrylate) (PDMAEMA), chitosan, L-lactide-L-lysine copolymer, poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA), or poly(4-hydroxy-L-proline ester) (PHP).
25. The method of claim 1 , wherein the coating comprises a neutral or negatively charged lipid or polymer.
26. 25. The method of claim 24, wherein the neutral or negatively charged coating comprises polyglutamic acid (PGA), poly(acrylic acid), alginic acid, or cholesteryl hemisuccinate / 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.
27. 25. The method of claim 24, wherein the neutral or negatively charged coating comprises a zwitterionic polymer.
28. 25. The method of claim 24, wherein the neutral or negatively charged coating comprises a liposome.
29. 28. The method of claim 27, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammoniumpropane (DOTMA), 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), dioctadecylamidoglycylspermine (DOGS), cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).
30. The method of claim 1 , wherein the selected cell targeting ligand selectively binds to CD4 and / or CD8.
31. The method of claim 1 , wherein the selected cell targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody.
32. The method of claim 1 , wherein the selected cell targeting ligand comprises a binding domain selected from an scFv fragment of a CD4 antibody and / or a CD8 antibody.
33. The method of claim 1 , wherein the carrier comprises a poly(β-amino ester).
34. The method of claim 1 , wherein the coating comprises polyglutamic acid (PGA).
35. 2. The method of claim 1, wherein the selected cell targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody, the carrier comprises a poly(β-amino ester), and the coating comprises polyglutamic acid (PGA).
36. 1. A method for preparing cells for treating a subject, comprising: Recovering lymphocytes from the subject; and (i) a synthetic nucleic acid encapsulated inside a positively charged carrier and encoding a gene editing agent or a phenotype-altering protein; (ii) a neutral or negatively charged coating provided on the outer surface of the carrier; (iii) a selected cell targeting ligand protruding from the surface of said coating; and binding said lymphocytes to a synthetic nanocarrier comprising: The method further comprising selectively endocytosing the nanocarriers into lymphocytes such that, after binding, the lymphocytes transiently express the nucleic acid.
37. 36. The method of claim 35, further comprising the step of expanding the lymphocytes.
38. 36. The method of claim 35, further comprising formulating the lymphocytes into a cell composition.
39. 36. The method of claim 35, wherein the exposing step is preceded by no or limited isolation procedures to increase the percentage of the selected cell population in the heterogeneous cell mixture.
40. 36. The method of claim 35, wherein the synthetic nucleic acid encodes a gene editing agent selected from a transcription activator-like effector nuclease (TALEN), a megaTAL and / or a zinc finger nuclease.
41. 36. The method of claim 35, wherein the synthetic nucleic acid encodes the megaTAL of SEQ ID NO:
1.
42. 36. The method of claim 35, wherein the gene editing agent disrupts an endogenous gene encoding Shp-1 phosphatase, PD1 receptor, T cell receptor (TCR), CCR5 and / or CXCR4.
43. The method of claim 35, wherein the gene editing agent disrupts an endogenous gene encoding a TCR alpha chain.
44. 36. The method of claim 35, wherein the synthetic nucleic acid encodes a phenotype-altering protein selected from a transcription factor, a kinase and / or a cell surface receptor.
45. 36. The method of claim 35, wherein the phenotype-altering protein is selected from FOXO1, LKB1, TCF7, EOMES, ID2, TERT, CCR2b and / or CCR4.
46. 36. The method of claim 35, wherein the selected cell targeting ligand selectively binds to lymphocytes within a heterogeneous cell population.
47. 46. The method of claim 45, wherein the heterogeneous cell population is an ex vivo cell culture.
48. 46. The method of claim 45, wherein the heterogeneous cell population is in vivo.
49. 36. The method of claim 35, wherein the selected cell targeting ligand selectively binds to T cells, NK cells, monocytes, macrophages, dendritic cells, B cells, hematopoietic stem cells, or a combination thereof.
50. 36. The method of claim 35, wherein the selected cell targeting ligand comprises a binding domain selected from a lymphocyte receptor ligand, a lymphocyte receptor antibody, a lymphocyte receptor peptide aptamer, a lymphocyte receptor nucleic acid aptamer, a lymphocyte receptor spiegelmer, or a combination thereof.
51. The selected cell targeting ligand may be a T cell receptor motif, a T cell alpha chain, a T cell beta chain, a T cell gamma chain, a T cell delta chain, CCR7, CD1a, CD1b, CD1c, CD1d, CD3, CD4, CD5, CD7, CD8, CD11b, CD11c, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD34, CD35, CD39, CD40, CD45RA, CD45RO, CD46, CD 52, CD56, CD62L, CD68, CD69, CD80, CD86, CD95, CD101, CD117, CD127, CD133, CD137 (4-1BB), CD148, CD163, CD209, DEC-205, F4 / 80, IL-4Rα, Sca-1, CTLA-4, GITR, GARP, LAP, granzyme B, LFA-1 or transferrin receptor.
52. 36. The method of claim 35, wherein the selected cell targeting ligand selectively binds to CD1a, CD1b, CD1c, CD1d, CCR7, CD3, CD4, CD5, CD8, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD35, CD40, CD45RA, CD45RO, CD46, CD52, CD62L, CD69, CD80, CD95, CD127, CD137, CD209 or DEC-205.
53. The selected cell targeting ligand is a T cell α chain antibody, a T cell β chain antibody, a T cell γ chain antibody, a T cell δ chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, and a CD1 antibody. 1b antibody, CD11c antibody, CD16 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, C 36. The method of claim 35, comprising a binding domain selected from D56 antibody, CD62L antibody, CD68 antibody, CD69 antibody, CD80 antibody, CD86 antibody, CD95 antibody, CD101 antibody, CD117 antibody, CD127 antibody, CD133 antibody, CD137 (4-1BB) antibody, CD148 antibody, CD163 antibody, CD209 antibody, DEC-205 antibody, F4 / 80 antibody, IL-4Rα antibody, Sca-1 antibody, CTLA-4 antibody, GITR antibody, GARP antibody, LAP antibody, granzyme B antibody, LFA-1 antibody, or transferrin receptor antibody.
54. The binding domain is a T cell α chain antibody, a T cell β chain antibody, a T cell γ chain antibody, a T cell δ chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD11b antibody, a CD11c antibody, a CD 16 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, CD56 antibody, CD62L antibody, CD6 36. The method of claim 35, wherein the scFv fragment comprises, or essentially consists of, an scFv fragment of an antibody selected from the group consisting of CD8, CD69, CD80, CD86, CD95, CD101, CD117, CD127, CD133, CD137 (4-1BB) antibody, CD148, CD163, CD209, DEC-205, F4 / 80, IL-4Rα, Sca-1, CTLA-4, GITR, GARP, LAP, granzyme B, LFA-1 or transferrin receptor antibody.
55. 36. The method of claim 35, wherein the synthetic nucleic acid is a synthetic mRNA.
56. 36. The method of claim 35, wherein the carrier comprises a positively charged lipid or polymer.
57. 56. The method of claim 55, wherein the positively charged lipid or polymer comprises poly(β-amino ester), poly(L-lysine), poly(ethyleneimine) (PEI), poly(amidoamine) dendrimer (PAMAM), amine-ester copolymer, poly(dimethylaminoethyl methacrylate) (PDMAEMA), chitosan, L-lactide-L-lysine copolymer, poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA) or poly(4-hydroxy-L-proline ester) (PHP).
58. 56. The method of claim 55, wherein the coating comprises a neutral or negatively charged lipid or polymer.
59. 58. The method of claim 57, wherein the neutral or negatively charged coating comprises polyglutamic acid (PGA), poly(acrylic acid), alginic acid, or cholesteryl hemisuccinate / 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.
60. 58. The method of claim 57, wherein the neutral or negatively charged coating comprises a zwitterionic polymer.
61. 58. The method of claim 57, wherein the neutral or negatively charged coating comprises a liposome.
62. 61. The method of claim 60, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammoniumpropane (DOTMA), 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), dioctadecylamidoglycylspermine (DOGS), cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).
63. 36. The method of claim 35, wherein the selected cell targeting ligand selectively binds CD4 and / or CD8.
64. 36. The method of claim 35, wherein the selected cell targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody.
65. 36. The method of claim 35, wherein the selected cell targeting ligand comprises a binding domain selected from an scFv fragment of a CD4 antibody and / or a CD8 antibody.
66. The method of claim 35, wherein the carrier comprises a poly(β-amino ester).
67. 36. The method of claim 35, wherein the coating comprises polyglutamic acid (PGA).
68. 36. The method of claim 35, wherein the selected cell targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody, the carrier comprises a poly(β-amino ester), and the coating comprises polyglutamic acid (PGA).
69. 1. A method of treating a subject in need thereof, comprising: (i) a synthetic nucleic acid encapsulated inside a positively charged carrier and encoding a gene editing agent or a phenotype-altering protein; (ii) a neutral or negatively charged coating provided on the outer surface of the carrier; (iii) a selected cell targeting ligand protruding from the surface of said coating; and administering a therapeutically effective amount of the cell that has been modified by the transient expression of the nucleic acid selectively delivered to the cell by a nanocarrier comprising: The method of treating the subject in need thereof by selectively incorporating the nanocarrier into lymphocytes such that, after binding, the lymphocytes transiently express the nucleic acid.
70. 1. A method for preparing a selected cell population for administration to a subject, comprising: obtaining a sample from said subject comprising a heterogeneous mixture of cells comprising a selected cell population; (i) a synthetic nucleic acid encapsulated inside a positively charged carrier and encoding a gene editing agent or a phenotype-altering protein; (ii) a neutral or negatively charged coating provided on the outer surface of the carrier; (iii) a selected cell targeting ligand protruding from the surface of said coating; and selectively delivering the nanocarriers to the selected cell population by exposing the sample to a synthetic nanocarrier comprising: expanding cells in said sample; The method thereby prepares the selected cell population for administration to the subject.
71. (i) a nucleic acid encoding a gene editing agent or a phenotype-altering protein, the nucleic acid being encapsulated inside a positively charged carrier; (ii) a neutral or negatively charged coating provided on the outer surface of the carrier; (iii) a selected cell targeting ligand protruding from the surface of said coating; and 1. A synthetic nanocarrier comprising:
72. The synthetic nanocarrier of claim 70, wherein the synthetic nucleic acid encodes a gene editing agent selected from a transcription activator-like effector nuclease (TALEN), a megaTAL and / or a zinc finger nuclease.
73. The synthetic nanocarrier of claim 70, wherein the synthetic nucleic acid encodes a megaTAL of SEQ ID NO:
1.
74. The synthetic nanocarrier of claim 70, wherein the gene editing agent disrupts endogenous genes encoding Shp-1 phosphatase, PD1 receptor, T cell receptor (TCR), CCR5 and / or CXCR4.
75. The synthetic nanocarrier of claim 70, wherein the gene editing agent disrupts an endogenous gene encoding a TCR alpha chain.
76. The synthetic nanocarrier of claim 70, wherein the synthetic nucleic acid encodes a phenotype-altering protein selected from a transcription factor, a kinase and / or a cell surface receptor.
77. The synthetic nanocarrier of claim 70, wherein the phenotype-altering protein is selected from FOXO1, LKB1, TCF7, EOMES, ID2, TERT, CCR2b and / or CCR4.
78. The synthetic nanocarrier of claim 70, wherein the selected cell targeting ligand selectively binds to lymphocytes within a heterogeneous cell population.
79. The synthetic nanocarrier of claim 77, wherein the heterogeneous cell population is an ex vivo cell culture.
80. The synthetic nanocarrier of claim 77, wherein the heterogeneous cell population is in vivo.
81. The synthetic nanocarrier of claim 70, wherein the selected cell targeting ligand selectively binds to T cells, NK cells, monocytes, macrophages, dendritic cells, B cells, hematopoietic stem cells, or a combination thereof.
82. The synthetic nanocarrier of claim 70, wherein the selected cell targeting ligand comprises a binding domain selected from a lymphocyte receptor ligand, a lymphocyte receptor antibody, a lymphocyte receptor peptide aptamer, a lymphocyte receptor nucleic acid aptamer, a lymphocyte receptor spiegelmer, or a combination thereof.
83. The selected cell targeting ligand is selected from the group consisting of T cell receptor motifs, T cell alpha chain, T cell beta chain, T cell gamma chain, T cell delta chain, CCR7, CD1a, CD1b, CD1c, CD1d, CD3, CD4, CD5, CD7, CD8, CD11b, CD11c, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD34, CD35, CD39, CD40, CD45RA, CD45RO, CD46, CD52 , CD56, CD62L, CD68, CD69, CD80, CD86, CD95, CD101, CD117, CD127, CD133, CD137 (4-1BB), CD148, CD163, CD209, DEC-205, F4 / 80, IL-4Rα, Sca-1, CTLA-4, GITR, GARP, LAP, granzyme B, LFA-1 or transferrin receptor.
84. The synthetic nanocarrier of claim 70, wherein the selected cell targeting ligand selectively binds to CD1a, CD1b, CD1c, CD1d, CCR7, CD3, CD4, CD5, CD8, CD16, CD19, CD20, CD21, CD22, CD25, CD28, CD35, CD40, CD45RA, CD45RO, CD46, CD52, CD62L, CD69, CD80, CD95, CD127, CD137, CD209 or DEC-205.
85. The selected cell targeting ligand is a T cell α chain antibody, a T cell β chain antibody, a T cell γ chain antibody, a T cell δ chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, and a CD11 antibody. b antibody, CD11c antibody, CD16 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, CD5 71. The synthetic nanocarrier of claim 70, comprising a binding domain selected from a CD4+ / -6 antibody, a CD62L antibody, a CD68 antibody, a CD69 antibody, a CD80 antibody, a CD86 antibody, a CD95 antibody, a CD101 antibody, a CD117 antibody, a CD127 antibody, a CD133 antibody, a CD137 (4-1BB) antibody, a CD148 antibody, a CD163 antibody, a CD209 antibody, a DEC-205 antibody, an F4 / 80 antibody, an IL-4Rα antibody, a Sca-1 antibody, a CTLA-4 antibody, a GITR antibody, a GARP antibody, a LAP antibody, a granzyme B antibody, a LFA-1 antibody, or a transferrin receptor antibody.
86. The binding domain is a T cell α chain antibody, a T cell β chain antibody, a T cell γ chain antibody, a T cell δ chain antibody, a CCR7 antibody, a CD1a antibody, a CD1b antibody, a CD1c antibody, a CD1d antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD11b antibody, a CD11c antibody, and a CD1 antibody. 6 antibody, CD19 antibody, CD20 antibody, CD21 antibody, CD22 antibody, CD25 antibody, CD28 antibody, CD34 antibody, CD35 antibody, CD39 antibody, CD40 antibody, CD45RA antibody, CD45RO antibody, CD46 antibody, CD52 antibody, CD56 antibody, CD62L antibody, CD68 antibody 71. The synthetic nanocarrier of claim 70, which consists of, or consists essentially of, an scFv fragment of an antibody, a CD69 antibody, a CD80 antibody, a CD86 antibody, a CD95 antibody, a CD101 antibody, a CD117 antibody, a CD127 antibody, a CD133 antibody, a CD137 (4-1BB) antibody, a CD148 antibody, a CD163 antibody, a CD209 antibody, a DEC-205 antibody, an F4 / 80 antibody, an IL-4Rα antibody, a Sca-1 antibody, a CTLA-4 antibody, a GITR antibody, a GARP antibody, an LAP antibody, a Granzyme B antibody, an LFA-1 antibody, or a transferrin receptor antibody.
87. The synthetic nanocarrier of claim 70, wherein the synthetic nucleic acid is a synthetic mRNA.
88. The synthetic nanocarrier of claim 70, wherein the carrier comprises a positively charged lipid or polymer.
89. 88. The synthetic nanocarrier of claim 87, wherein the positively charged lipid or polymer comprises poly(β-amino ester), poly(L-lysine), poly(ethyleneimine) (PEI), poly(amidoamine) dendrimer (PAMAM), amine-ester copolymer, poly(dimethylaminoethyl methacrylate) (PDMAEMA), chitosan, L-lactide-L-lysine copolymer, poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA) or poly(4-hydroxy-L-proline ester) (PHP).
90. The synthetic nanocarrier of claim 70, wherein the coating comprises a neutral or negatively charged lipid or polymer.
91. The synthetic nanocarrier of claim 89, wherein the neutral or negatively charged coating comprises polyglutamic acid (PGA), poly(acrylic acid), alginic acid, or cholesteryl hemisuccinate / 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.
92. The synthetic nanocarrier of claim 89, wherein the neutral or negatively charged coating comprises a zwitterionic polymer.
93. The synthetic nanocarrier described in claim 89, wherein the neutral or negatively charged coating comprises a liposome.
94. 93. The synthetic nanocarrier of claim 92, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammoniumpropane (DOTMA), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), dioctadecylamidoglycylspermine (DOGS), cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).
95. The synthetic nanocarrier of claim 70, wherein the selected cell targeting ligand selectively binds to CD4 and / or CD8.
96. The synthetic nanocarrier of claim 70, wherein the selected cell targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody.
97. The synthetic nanocarrier of claim 70, wherein the selected cell targeting ligand comprises a binding domain selected from an scFv fragment of a CD4 antibody and / or a CD8 antibody.
98. The synthetic nanocarrier of claim 70, wherein the carrier comprises a poly(β-amino ester).
99. The synthetic nanocarrier of claim 70, wherein the coating comprises polyglutamic acid (PGA).
100. The synthetic nanocarrier of claim 70, wherein the selected cell targeting ligand comprises a binding domain selected from a CD4 antibody and / or a CD8 antibody, the carrier comprises a poly(β-amino ester), and the coating comprises polyglutamic acid (PGA).
101. 71. A composition comprising the synthetic nanocarrier described in claim 70.
102. A method of treating a subject in need of treatment, comprising administering a therapeutically effective amount of the nanocarrier described in claim 70 or the composition described in claim 100 to treat the subject in need of treatment.
